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Foreword
Today, humanity faces grand challenges of a global nature, such as epidemics,
disease outbreaks, food security challenges, climate change and increasing energy
demands. Such challenges can only be resolved through cooperation between
countries, as no country acting alone could possibly tackle them effectively.
A main driver towards the resolution of these challenges is research and inno-
vation. International cooperation in research and innovation is particularly impor-
tant, as it promotes the sharing of knowledge, skills and resources; it raises
awareness and may contribute to the fair sharing of the beneﬁts of research and
innovation among partners. Undertaking international cooperation in research and
innovation responsibly requires equitable and respectful relationships between
countries and among research and innovation partners. Fair research relationships
are particularly important for Europe, given its leading roles in responsible research
and innovation and human rights compliance, in order to foster the building and
maintaining of equitable research partnerships with low- and middle-income
countries (LMICs).
When it comes to international cooperation with LMICs, the most fundamental
element of responsible research and innovation is adherence to high ethical stan-
dards, independently of where the research takes place. This is particularly the case
when we take into account the power imbalances and disparities in know-how
between high-income countries and LMICs, which may result in the former taking
advantage of the vulnerabilities of the latter. Participants and resources from LMICs
must not be exploited in international partnerships, even if local ethics compliance
structures are weak compared with compliance structures in Europe. In other words,
research and innovation partners should refrain from taking either active or passive
advantage of loopholes and weaknesses in the governance systems of another
country in order to perform research that would be legally or ethically unacceptable
in their own country.
Ensuring equitable and respectful partnerships and avoiding exploitation of
LMICs require mutual understanding. In order to reach such mutual understanding,
it is of particular importance to examine case studies, as they may elucidate ethical
issues relevant to real-life recent research and innovation activities involving
vii
LMICs, which may contribute to avoiding the duplication of past mistakes and
injustices.
This book aims to raise awareness of the topic of unethical research and
therefore presents case studies of exploitative research conducted in LMICs.
Funded by the European Commission, it brings together experts on this topic from
around the world. Adhering closely to an important feature of responsible research
and innovation, namely societal engagement, the book has directly involved highly
vulnerable populations in its outputs (LMIC sex workers and indigenous peoples).
In order to maximize outreach, this book is made available as gold open access.
This means that stakeholders from LMICs who have access to the Internet will not
be excluded from the learning outcomes of this work. Learning about the
exploitation of LMICs from open-access case studies will hopefully increase the
chances that those involved in research will be open to the world in an inclusive and
equitable manner. Presenting such case studies aims to contribute to the develop-
ment of fair and equitable research and innovation collaborations between countries
—collaborations that are mutually beneﬁcial for all participants, as well as for
scientiﬁc progress at large.
Louiza Kalokairinou is a Policy Ofﬁcer at the Ethics and Research Integrity Sector
of the Directorate General (DG) for Research and Innovation (European
Commission), and a Ph.D. candidate at the Centre for Biomedical Ethics and Law
(University of Leuven).
Isidoros Karatzas is Head of the Ethics and Research Integrity Sector, European
Commission (EC), DG Research & Innovation. A biochemist by training, he
established advanced training courses on research ethics and research integrity for
EC staff, the research ethics expert community, early career researchers and
National and European professional associations. He was the ﬁrst to set up a
European system of ethics checks and contributed to the publication of the new
European Code of Conduct for Research Integrity and the preparation of the
Horizon 2020 research integrity strategy.
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Chapter 1
Ethics Dumping: Introduction
Doris Schroeder, Julie Cook, François Hirsch, Solveig Fenet
and Vasantha Muthuswamy
Abstract Achieving equity in international research is a pressing concern.
Exploitation in any scenario, whether of human research participants, institutions,
local communities, animals or the environment, raises the overarching question of
how to avoid such exploitation. Agreed principles can be universally applied to
research in any discipline or geographical area, whatever methodologies are
employed. This chapter introduces a collection of case studies, presenting a range of
up-to-date examples of exploitation in North-South research collaborations, in order
to raise awareness of ethics dumping.
Keywords Research ethics  Responsible research and innovation
Ethics dumping  North South collaborations  Exploitation
Introduction
Achieving equity in international research is a pressing concern. Exploitative
North-South research collaborations often follow patterns established in colonial
times. Whether the objects of exploitation are human research participants, insti-
tutions, local communities, animals or the environment, this raises questions about
how such exploitation can be avoided.
“Dumping” is a term used in economics to describe predatory pricing policies in
international trade (Investopedia nd). Dumping usually involves substantial export
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volumes of a product and often has the effect of endangering the ﬁnancial viability
of manufacturers of the product in the importing nation.
“Ethics dumping”1 occurs mainly in two areas. First, when research participants
and/or resources in low- and middle-income countries (LMICs) are exploited in-
tentionally, for instance because research can be undertaken in an LMIC that would
be prohibited in a high-income country. Second, exploitation can occur due to
insufﬁcient ethics awareness on the part of the researcher, or low research gover-
nance capacity in the host nation.
This book provides 14 case studies of ethics dumping and one case of good
practice. Its purpose is to address the second cause of ethics dumping by reducing
researchers’ lack of awareness.
Background to Ethics Dumping
Jeffrey Sachs, one of the world’s leading experts on economic development, noted:
Technology has been the main force behind the long-term increases in income in the rich
world, not exploitation of the poor. That news is very good indeed because it suggests that
all of the world … has a reasonable hope of reaping the beneﬁts of technological advance
(Sachs 2005: 31).
It is essential that the progress of science and technology is not accompanied by
reasonable claims of exploitation of the poor and vulnerable. This is not easy to
achieve, as both moderate poverty2 and extreme3 poverty increase the likelihood
that communities and individuals will be exploited.
Unevenness in ethical and legal standards has led to the exploitation of human
research participants and resources in LMICs that could have been avoided. The
international debate on bioethics has noted the existence of “double standards”
(Macklin 2004).
Vulnerable populations and research participants worldwide have been protected
for decades by research ethics committees (ECs), but their success depends on three
conditions. First, a relevant EC must exist with the capability, resources and
independence to deal with ethics applications. Second, such committees must be
able to recognize culturally sensitive ethical issues in complex settings. Third, a
1The term was introduced by the Science with and for Society Unit of the European Commission:
“Due to the progressive globalisation of research activities, the risk is higher that research with
sensitive ethical issues is conducted by European organisations outside the EU in a way that would
not be accepted in Europe from an ethical point of view. This exportation of these non-compliant
research practices is called ethics dumping” (European Commission nd).
2Households can only just meet basic needs for survival, with little left for the education of their
children.
3Households cannot meet basic needs for survival (e.g. chronic hunger, no access to health care).
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compliance mechanism must be in place. As these conditions cannot be guaranteed
in LMICs, there is always the risk of an implementation gap.
The ﬁrst condition (a capable EC) cannot be taken for granted, as in this list of
constraints on African ECs:
• Insufﬁcient resources
• Lack of or insufﬁcient expertise on ethical review
• Pressure from researchers
• Lack of active or consistent participation of EC members
• Lack of recognition of the importance of EC functions
• No or poor support from the EC’s institution
• Lack of independence
• Pressure from sponsors
• Unequal treatment of applicants in review (Nyika et al. 2009: 193)
The importance of cultural sensitivity is demonstrated in Chap. 4, which
describes a study that was granted ethics approval in both a high-income and a
middle-income country, but failed to consider culturally relevant ethical concerns.
The third condition (a compliance mechanism) exceeds the remit of this book, but
will be considered further in the TRUST project.4
The Cases5
Cases of exploitation in research have been used to illustrate unacceptable practices
since the mid twentieth century. However, infamous medical experiments, as cited
in many textbooks—for example, diabolical Nazi experimentation and the
Tuskegee study (Emanuel et al. 2011)—are not always a suitable sole learning
source for twenty-ﬁrst-century researchers.
The case studies in this book will help researchers understand better how
exploitation can occur in the context of contemporary North-South collaborations.
These are genuine cases, assembled from four sources. TRUST experts contributed
case studies. Two non-governmental organizations (NGOs) each contributed a case
study. Indian bioethicists were invited to a workshop in Mumbai in 2016 to share
their ideas, and a case study competition launched through TRUST sourced addi-
tional material from LMICs.
4http://trust-project.eu/.
5Responsibility for the accuracy of each case study, the integrity of the information cited
and the legitimacy of its acquisition rests with the respective authors. This disclaimer is especially
relevant to those cases where the editors could not verify publicly available sources.
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The selected case studies have been grouped into six themes:
• Vulnerable populations
• Clinical trials
• Beneﬁt sharing
• Animal research
• New and emerging technologies
• Ethical governance and processes
Vulnerable Populations
“Social Science Research in a Humanitarian Emergency Context”, by Gwenaëlle
Luc and Chiara Altare, describes conflicts for an international NGO in an African
village. The community felt betrayed when unexpected ﬁndings about
health-seeking behaviours that revealed illegal female genital mutilation
(FGM) were shared publicly and contributed to cultural stigmatization. The NGO
performed a dual role as assistance provider and researcher, which endangered the
neutrality of the data collection and, in the end, the acceptability of its assistance.
Roger Chennells and Andries Steenkamp criticize an international research
project, which aimed to examine the genetic structure of “indigenous
hunter-gatherer peoples” from Namibia and compare the results with “Bantu from
southern Africa”. A supplementary document published with the study contained
conclusions and details that the San regarded as pejorative and discriminatory;
“International Genomics Research Involving the San People” details the perceived
exploitation and the San response.
In “Sex Workers Involved in HIV/AIDS Research”, Anthony Tukai tells the
personal story of supporting a vulnerable and stigmatized population in a Nairobi
slum. In a demonstration of good practice, the case outlines empowerment mech-
anisms that reduced the potential for exploitation.
In “Cervical Cancer Screening Trials on Poor and Illiterate Women in India”,
Sandhya Srinivasan, Veena Johari and Amar Jesani describe three internationally
funded clinical trials that took place between 1998 and 2015 to determine whether
primary healthcare workers could conduct cervical cancer screening using cheap
visual inspection. These non-drug trials did not require regulatory permission, and
the existing standard of care was misconstrued. According to the authors, known
and effective methods of cervical cancer screening (by Pap smear) were withheld
from 141,000 women even though they have represented the standard of care in
India since the 1970s. Two hundred and ﬁfty-four women in the no-screening arm
died from cervical cancer.
4 D. Schroeder et al.
Clinical Trials
Godfrey Tangwa questions clinical trials in “A Match to Local Health Needs?
Ebola Vaccine Trials”. The Ebola epidemic of 2013 in West Africa which affected
three countries had been brought under reasonable control by 2015. This case study
is about a phase I/II clinical trial (testing for safety and immunogenicity) of a
candidate Ebola virus vaccine in 2015 in a sub-Saharan country which had not
registered any cases of Ebola. The study was sponsored and funded by one of the
biggest northern multinational pharmaceutical companies and had government
support. But public concerns about the risk of a public health disaster meant the trial
was suspended. A commentary by Katharine Browne and Doris Schroeder dis-
cusses the importance of trust, highlighting differences from a 2014 phase I Ebola
vaccine trial in Canada.
In “Hepatitis B Study with Gender Inequities”, Olga Kubar explores why a
proposed internationally sponsored study in Russia was not approved by the local
EC. Indications of exploitation consisted of inadequacies in the study’s design
compared with its announced purpose and the indirect inclusion of women in the
trial without their informed consent. On the basis of non-compliance with national
and international regulatory and ethical requirements, this trial was not approved,
providing an example of successful research ethics governance.
In resource-limited settings, healthy volunteers are most often poor people with
low literacy levels who might not understand the risks they are taking, and are in no
position to refuse even small ﬁnancial incentives. Participation in clinical trials is a
critical source of income, and some volunteers covertly enrol in several studies
simultaneously. This exposes them to medical risks (e.g. drug-drug interactions)
and also potentially biases the study data; “Healthy Volunteers in Clinical Studies”,
by Klaus Leisinger, Karin Schmitt and Francois Bompart, provides a recommen-
dation to protect healthy volunteers from such exploitation.
Beneﬁt Sharing
In “An International Collaborative Genetic Research Project Conducted in China”,
Yandong Zhao and Wenxia Zhang describe how US university researchers col-
lected blood samples from villagers with the cooperation of local research institutes
and the government. The US team was later accused of violating research ethics
principles by not adequately informing participants and not sharing beneﬁts fairly.
Subsequent investigations by American and Chinese media and authorities showed
that the US research institute, its personnel and a pharmaceutical company were
beneﬁting substantially from the project, while the Chinese research participants
and the government were not.
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Animal Research
In “The Use of Non-human Primates in Research”, Kate Chatﬁeld and David
Morton show that since regulations on the use of non-human primates are tight in
the European Union the number used has declined. However, the increase in
numbers used elsewhere indicates that researchers from high-income countries are
taking advantage of variations in standards, legislation and humane practices to
conduct experiments through collaborative efforts in countries where regulation is
less strict.
New and Emerging Technologies
Jaci van Niekerk and Rachel Wynberg present concerns about research to develop a
genetically modiﬁed “vitamin-enriched” banana for cultivation in Uganda through a
proposed trial with North American university students. “Human Food Trial of a
Transgenic Fruit” explains how northern researchers and philanthropic organiza-
tions determine research priorities without necessarily involving affected LMICs.
The case highlights differences between the concepts of food security and food
sovereignty, illuminating different approaches to addressing poverty-induced hun-
ger and malnutrition.
“mHealth” is the application of mobile phones or other remote monitoring
devices to health care. Mobile phones that can run software applications are
increasingly used to improve diagnosis, personalize care and expand access to
information and services. But mobile phones also collect a wide range of personal
information from users. In “ICT and Mobile Data for Health Research”, David
Coles, Jane Wathuta and Pamela Andanda focus on the potential ethical issues as
researchers and clinicians attempt to minimize unintended harms in new digital
territory.
Johannes Rath describes “Safety and Security Risks of CRISPR/Cas9” and other
novel genome editing technologies. The case focuses on the unresolved ethical
issues related to safety and security in the proliferation of a new and very powerful
technology at a time when tailored ethical and legal frameworks at the international,
national and local levels are missing.
Ethical Governance and Processes
In “Seeking Retrospective Approval for a Study in Resource-Constrained Liberia”,
Jemee Tegli describes an attempt to seek ethics approval for an anthropological
study after it had been conducted. “Emergency research” was used as a cover to
6 D. Schroeder et al.
avoid the review process, although emergency research regulations stipulated full
disclosure of proposed research prior to implementation.
In “Legal and Ethical Issues of Justice: Global and Local Perspectives on
Compensation for Serious Adverse Events in Clinical Trials”, Yali Cong analyses a
situation in which a major international pharmaceutical company sponsored clinical
research in an LMIC and applied a double standard in dealing with serious adverse
events (SAEs). A 78-year-old Chinese woman joined a clinical trial, and the
sponsor paid the cost of medical care arising from an SAE, but refused the family’s
request for compensation. The family sued the company and the hospital in liti-
gation that continued for nine years.
The editors of this collection hope that it contributes to raising awareness about
the dangers of ethics dumping and unethical conduct in North-South research
collaborations and promotes ever higher ethical standards in research conducted
anywhere in the world.
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Chapter 2
Social Science Research in a Humanitarian
Emergency Context
Gwenaëlle Luc and Chiara Altare
Abstract This case study about research in an emergency setting depicts how
unexpected ﬁndings created conflicts of conscience for non-governmental organi-
zation (NGO) workers and exposed research participants and their community to
retribution and compromised the local social structure. The community felt betrayed
when unexpected ﬁndings from research about health seeking behaviours revealing
illegal female genital mutilation were shared publicly and contributed to stigma-
tizing their culture. In addition, the NGO involved performed a dual role – that of
assistance provider as well as researcher – which endangered the neutrality of the
data collection and, in the end, the acceptability of the NGO as assistance provider.
Keywords Ethics  Female genital mutilation  Unexpected ﬁndings in research
Cultural relativity
Area of Risk of Exploitation
This case study covers two potential areas of ethics risks or potential for
exploitation.
First, a potential for ethics risks can exist when the ethical standards developed
in one context (Western medical research) are applied in another context without
due attention to local social norms or communication with local communities.
A case can be particularly serious if a local practice violates the laws of the country
the research takes place in, as in this case.
Second, a conflict of interest can arise when an assistance provider also conducts
research. For instance, this could create expectations among participants, and
influence their consent to be enrolled in the study.
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Background
A major ethical dilemma when conducting research in a volatile emergency setting
including culturally heterogeneous groups is the need to balance the risks and
beneﬁts for the research participants. An example of such a setting is a refugee
camp. Acquiring a clear understanding of context-related risks is challenging:
unanticipated risks, if not properly understood or taken into account, could lead to
the exploitation of participants or communities.
Research in emergency settings is associated with a range of ethical challenges,
as both implementers and participants might be situated in a position of vulnera-
bility and insecurity. In addition, in an emergency setting there may be a need for a
rapid response, and it might be difﬁcult for local communities (or the aid providers)
to distinguish relief from research, among other things.
In research, the “do no harm” imperative requires that research participants not
be put at any additional risk (WMA 2013). This is particularly important in cases
where vulnerable participants in emergency settings may not get any direct beneﬁts
from the research themselves, but may contribute to producing evidence that will
improve interventions with similar populations or in similar settings in the future.
Here we describe a case where research activities did put participants at risk,
while simultaneously providing no direct (personal) beneﬁts to them, which led to
community complaints. The community felt betrayed because the research did not
respond to their needs and priorities, and contributed to stigmatizing their culture.
Speciﬁc Case and Analysis
A socio-anthropological research study on health-seeking behaviours was under-
taken by a humanitarian non-governmental organization (NGO) in a rural village in
an African country where the prevalence of child global acute malnutrition was
high. The study focused on health-seeking practices during diarrhoea episodes
among children under the age of ﬁve, as diarrhoea is one of the underlying causes of
child undernutrition. The research aimed to study access to and utilization of health
services. The country’s national ethics review committee approved the research.
Qualitative ﬁeldwork was conducted which aimed to better understand the
cultural values and practices related to the therapeutic path of children with diar-
rhoea. Interviews were conducted with parents and other key informants in the
village (e.g. community leaders, elders, traditional healers).
Consent forms were signed by the participants, but as the NGO was mostly
known in the area as an assistance provider, it was not always clear to the
researchers whether participants freely consented to take part in the research or
whether they assumed they had to participate in order to receive assistance, or out
of gratitude.
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During data collection, the investigator found that a traditional treatment for
diarrhoea among baby girls (from three months of age) was female genital muti-
lation (FGM) . This practice was intended to remove “impurity” that interfered with
a girl’s well-being. FGM was practised in the village by a traditional healer with a
razor blade and without hygienic precautions. “If the diarrhoea is caused by a
worm, we have to remove the impure part of a girl’s body; it will kill the worm and
cure the girl,” a traditional FGM practitioner said during an interview.
According to the testimonies gathered during the research, FGM is highly valued
in the local culture. In addition to being considered an effective traditional cure for
girls’ diarrhoea, FGM is part of the accepted and expected identity of a woman.
“Uncircumcised” girls are marginalized, are a source of shame for their family and
have difﬁculty ﬁnding a husband. FGM also has religious and social signiﬁcance.
This act is symbolically seen as a ritual of incorporation of the girl into the rest of
the community.
At the global level, FGM is considered a violation of human rights, and it is also
prohibited by law in the country where the research took place. “Female genital
mutilation and cutting is a violation of the basic rights of women and girls,” said
Carol Bellamy, then executive director of the UN’s Children’s Fund (UNICEF), on
the International Day of Zero Tolerance for FGM in 2005. “It is a dangerous and
irreversible procedure that negatively impacts the general health, child bearing
capabilities and educational opportunities of girls and women.”
In the research setting of this case study, most of the participants in the inter-
views had never been to primary school and were illiterate. For them, local habits
and regulations took precedence over national or international laws and codes of
conduct.
The national ethical review committee1 and the research team did not anticipate
this ﬁnding, as their members did not have a deep understanding of the local culture
and the norms of the speciﬁc community and individuals. Because this traditional
cure for diarrhoea was an unexpected ﬁnding, participants had not been previously
informed by the researchers of what they could be exposed to while they proudly
exhibited their traditional culture.
When a researcher from an NGO witnesses a human rights abuse, there is always
a risk of that organization, when managing the resulting conflicts, being accused of
complicity, and/or of violating the interests of both the individuals and international
ethical standards. In this case the researcher acted in accordance with his own
model of norms and values, and one based on national and international codes of
law and ethics, rather than with the way in which the causal model of illness was
understood locally, and the implications of this for the social construction of female
identity. The researcher and the NGO decided to report the practices in a public
report in order to protect baby girls from a recognized and illegal human rights
abuse.
1The committee did not include lay members or representatives of the targeted communities.
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However, this approach had serious consequences: it offended participants and
the wider community, and led to the social rejection of girls who had not received
FGM − they were stigmatized in the community − and intensiﬁed community
tensions. It also jeopardized the NGO’s capacity to operate in the area.
Communities felt betrayed by the NGO, as they were expecting humanitarian
relief from the organization. They felt that the research was not responsive to their
needs as they did not feel any beneﬁt. On the contrary, its ﬁndings had exposed
vulnerable communities and respondents to retribution from a coercive government,
and endangered the local social structure.
Lessons Learned
This case study highlights the risks of exploitation of participants when researchers
face conflicts of conscience and have to choose between abusing the trust of the
community and protecting vulnerable individuals from violations of their funda-
mental rights in accordance with national and/or international laws and ethical
codes. For the NGO involved, a lesson learned was that researchers need to
anticipate the identiﬁcation of potential ethical challenges by assessing the risks and
beneﬁts for potential participants with “due diligence” before a project commences.
Risk assessments should not be a vertical and unilateral process, but rather a par-
ticipatory exercise. This can facilitate the understanding of the context, as inter-
pretations of beneﬁts, risks and harm are speciﬁc to each setting.
In this context, it is important to engage in mediation with all stakeholders,
which may result in an agreement according to which no actor needs to disown his/
her values. The research could be ethically acceptable to all if the entire process and
all the consequences are favourable (or at least neutral) for everyone. It is worth
emphasizing that when opposing values are involved, it is crucial to engage in a
discussion before taking action in order to reach an agreement. If no agreement can
be reached before the research is commenced, then it is simply not possible to
undertake the research involving that community, as some value gaps have proved
impossible to overcome.
The NGO also learned that when the same organization is both conducting
research and delivering aid in an area, biases can affect the voluntary informed
consent of vulnerable participants, as well as the research design, data collection
and interpretation, or the reporting of results. While power differences may be
difﬁcult or impossible to eliminate completely, steps can be taken to identify and
minimize the most serious potential sources of bias, as long as thorough, transparent
and culturally appropriate information has been given to participants.
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Recommendations
• Carry out a thorough risk and beneﬁt assessment involving community and
participant representatives. Ethical approval should also be sought from the
community, and community representatives should participate in the formal
ethical review committee process.
• Beyond simply being asked for informed consent, communities should be
trained and involved in the ethical approval process. Participants should be
made aware of the limits of conﬁdentiality and any duties the researchers have to
report certain ﬁndings.
• Ensure effective ongoing communication (including with representatives of
vulnerable subgroups). Communication mechanisms should not be dismantled
after the departure of the research team from the data collection site, but must be
maintained by local partners of the international researchers.
• Monitor and evaluate the process through which consent is negotiated with the
community and obtained from participants.
• Participation in research should not be linked to receiving assistance, and
researchers should make this very clear to participants to avoid any misunder-
standings. In other words, if an assistance NGO operates in an area, it should be
made clear that the beneﬁts of assistance will be open to all, regardless of who,
if anyone, works with the NGO on research.
• Further work is needed on how to approach unexpected ﬁndings that lead to
fundamental conflicts of conscience for researchers. Data collection itself should
be neutral. There should be a protocol in place regarding the consideration of
and response to any unexpected ﬁndings.
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Chapter 3
International Genomics Research
Involving the San People
Roger Chennells and Andries Steenkamp
Abstract In 2010 an international genomic research project entitled “Complete
Khoisan and Bantu genomes from southern Africa” was published in Nature
amidst wide publicity (Schuster et al 2010). The research aimed to examine the
genetic structure of “indigenous hunter-gatherer peoples” selected from Namibia,
and to compare the results with “Bantu from southern Africa” , including Nobel
peace prize winner Archbishop Desmond Tutu. Four San individuals, the eldest in
their respective communities, were chosen for genome sequencing, and the pub-
lished article analysed many aspects of the correlations, differences and relation-
ships found in the single-nucleotide polymorphisms (SNPs) (A single-nucleotide
polymorphism is a variation in a single nucleotide that occurs at a speciﬁc position
in a genome, where each variation is present to some appreciable degree within a
population) within the sequenced genomes. A supplementary document published
with the paper contained numerous conclusions and details that the San regarded as
private, pejorative, discriminatory and inappropriate. The San leadership met with
the authors in Namibia soon after publication, asking why they as leaders had not
been approached for permission in advance, and enquiring about the informed
consent process. The authors refused to provide details about the informed consent
process, apart from stating that they had received video-recorded consents in each
case (Hayes 2011). They defended their denial of the right of the San leadership to
further information on the grounds that the research project had been fully approved
by ethics committees/institutional review boards in three countries, (names of
committees given to editors of this book) and that they had complied with all the
relevant requirements. The San leadership wrote to Nature, expressing their anger at
the inherent insult and lack of respect displayed by the process (Ngakaeaja 2011b).
This case study details the most serious aspects of the perceived exploitative nature
of the research, and the San response.
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Area of Risk of Exploitation
This case study is about the conducting of genomic research on a vulnerable
population, and it focuses on the enhanced need for respectful and authentic prior
informed consent. While the research itself is undoubtedly of potential beneﬁt to
humankind as well as the participant population, the particular risk of exploitation
lies in the fact that certain types of information gleaned from genomic research are
essentially of a sensitive and private nature, and their publication can result in
potential embarrassment, discrimination and collective psychological damage. The
informed consent allegedly gained for this complex research project from the
illiterate San participants was never disclosed to the San leadership, and, as is made
clear below, the nature and content of the research publication was indeed dam-
aging to the community on various levels.
Speciﬁc Case and Analysis
The general population of San peoples of southern Africa is known to carry the
oldest human DNA on earth, and is consequently much sought after for
population-wide genomic research aimed at understanding aspects of human evo-
lution. The San peoples, known to be the earliest “hunter-gatherer” populations of
southern Africa, number an estimated 100,000 individuals spread across at least ﬁve
countries, with the largest populations in Namibia, Botswana and South Africa.
Since 1986 the seven dominant linguistic groups have formed elected organizations
in each country aimed at representing and protecting the rights of their illiterate
rural populations. One of the most important roles of the San councils of Namibia,
Botswana and South Africa is to protect their people from unwanted, inappropriate
or exploitative research.
The stated purpose of the genomic research project under discussion was to
sequence the genomes of four selected San individuals, and to “characterise the
extent of whole-genome and exome diversity amongst them” – that is, the four San
and a man of Bantu extraction. In addition it set out to “compare the described
variants to known data-bases” in order to pinpoint genetic variations in
genome-wide data, and to “facilitate inclusion of southern Africans in medical
research efforts” (Schuster et al 2010).
In about 2009 researchers associated with the three universities began the pro-
cess of obtaining informed consent and taking DNA samples from four selected San
elders from three linguistic groupings, described as Tuu,!Kung and Ju/’hoansi. How
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the researchers communicated the methodology, aims and objectives of the com-
plex research project via translators to the four illiterate elders will perhaps never be
known: the San leadership later formally requested access to this information, but
were refused. According to the published research, “all participants consented …
via video-recorded verbal consent (Bushmen)”. In February 2010 the research was
published − to wide publicity in the popular media − in an academic paper enti-
tled, “Complete Khoisan and Bantu genomes from southern Africa”, which was
accompanied by a document containing supplementary information (Schuster et al
2010).
The acting regional coordinator of the Working Group of Indigenous Minorities
in Southern Africa (WIMSA), Ben Begbie-Clench, approached the paper’s authors
requesting details of the informed consent process, as set out below. Mathambo
Ngakaeaja, deputy director of WIMSA, subsequently wrote to Nature on 18
February 2011 objecting to the publication by Schuster et al., and describing how
central the concept of prior informed consent was to all research affecting indige-
nous peoples. After commenting critically on the persistent refusal of the
researchers to approach the ofﬁcial San leadership structures or engage meaning-
fully with them, Ngakaeaja stated that the purpose of his letter was “to draw
attention to the absolute arrogance, ignorance and cultural myopia that is present
here” (Ngakaeaja 2011a). He continued, “these researchers have basked in the glory
of their publication whilst claiming smugly that they complied fully with the ethical
requirements”.
From the perspective of the San leadership, many aspects of this research study
were deeply problematic, and would have been objected to if one of their organi-
zations (e.g. WIMSA, the South African San Council or the South African San
Institute) had been given an opportunity to consider the research before it began or
to approve the ﬁnal form of the document prior to publication.
The San leaders engaged respectfully with the researchers following publication,
requesting details of the informed consent process. Despite much correspondence,1
the authors persistently refused to acknowledge the need to consult with San
leadership or to provide details of the informed consent documentation or process.
We set out below some of the San leadership’s reasons for regarding the research
project as exploitative.
Terminology
The use of words such as “Khoisan” and “Bushmen” and “hunter-gatherers”
shows a lack of consultation with San leaders. All of these terms were freely used in
the publication, but all are considered sensitive and problematic for different
1The emails concerned are in the possession of the principal author of this case study, who is a
lawyer, but are not reproduced here in order to protect the privacy of personal data.
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reasons. For example, the San object to being referred to collectively as “Khoisan” ,
a descriptive term coined by anthropologist Leonard Shutze in 1928 as a way of
referring to Khoi pastoralist and San hunter-gatherer groups collectively
(Schlebusch 2010). The word “Bushman”, meaning “uncivilized people”, is widely
regarded as pejorative in certain contexts. The anthropologically loaded term
“hunter-gatherer”, frequently used in the paper and the supplementary information,
implies a generally acknowledged low social status (Wynberg et al 2009).
Consultation would have resulted in more acceptable uses of these and other terms.
Published Conclusions Far Removed from Genomic
Research
Much of the discussion in the supplementary information document related to terms
and concepts such as “hunter-gatherer”, the low status of “hunter-gatherers”, the
payment of lobola and dowry, and marriage practices, for example:
A feeling of inferiority associated with the “Bushmen” or “San” ethnic classiﬁcation
meant that many Bushmen women tried to uplift their status via marriage to Bantu men
(Schuster et al 2010: suppl 3).
These conclusions could not have been drawn from the results of the genomic
research, nor could they have been permitted by a process of informed consent to
the collection of genomic data. The publication thus draws on and publishes con-
clusions drawn from other sources and disciplines, which would not have been
permitted in a normal research consent process. The bad practice and injustice of
publishing information that could not have been envisaged by the participants at the
time of their giving consent would have been lessened had the authors returned to
the communities before publication and tried to explain the far-reaching and sen-
sitive nature of their ﬁndings. The San leadership, however, are unaware of any
attempt by the researchers to return to the communities and explain the complex
nature of the published conclusions.
Individual Versus Collective Consent
It is well known that indigenous, rural and illiterate people do not understand
individuality and individual rights in the manner of the West, their identity being
deeply collective and associated with their communities. This research project only
obtained informed consent from the indigenous individuals who participated, while
it is known and accepted that genomic research by its very nature speaks to col-
lective issues. There is no shortage of published research ethics guidelines (e.g.
NHMRC 2003, CIHR et al 2014) that set out absolute requirements for research on
indigenous peoples, one of which is that collective “permission” should be obtained
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from the leadership, in addition to normal informed consent obtained from indi-
viduals. Not to do so is perceived as an expression of lack of respect for the
community. However, one of the authors wrote to WIMSA saying, “As we are
dealing with individuals in a personal manner (via their DNA) the individual has a
right to participate or not as the information contained is of direct impact to that
person” (Hayes 2011). This response does not take into account that genetic
information also has a direct impact on family members of the participant.
Lack of Respect for or Reference to Indigenous Research
Protocols
The need for “respect” to be shown to the particular community is perhaps the most
important fundamental element in the indigenous research ethics guidelines referred
to above. The requirement takes many forms, but can be summarized as authentic
communication with the community leadership from the inception to the conclusion
of the research project. None of the established suggested methods for showing
respect to communities were employed in this case. The authors refused to consult
with the leadership afterwards, relying upon the fact that allegedly none of the
elderly and illiterate San participants had demanded to be represented by the San
leadership. For that reason, they concluded that the San leadership had no say in the
matter (Hayes 2011). This reliance on individual consent by an illiterate person who
could have no idea of how the implications of genomic research related to the
collective was and is regarded by the San (an abuse of power).
Failure of Research Ethics Committees/Institutional Review
Boards
The researchers defended their methodology regarding consent and other aspects of
the process by repeating that the project had been approved by no fewer than four
separate research ethics committees. Yet not one of these committees referred to the
published research guidelines on indigenous populations, which were readily
available and with which they ought to have been familiar, despite the fact that the
very purpose of the research was to examine the most famous of indigenous
“hunter-gatherer” communities. In the words of Prof. Vanessa Hayes, geneticist
and co-author of the Nature paper, these committees were formally designed to
“approve, monitor and review biomedical and behavioural research involving
humans with the aim to protect the rights and welfare of the research subjects”
(Hayes 2011). In addition she stated that it was their duty to respect the “culture,
dignity and wishes of subjects”. It is the San view that they failed dismally in this
duty.
3 International Genomics Research Involving … 19
Breaches of Privacy in the Findings
The paper and its supplementary information included a number of discussions and
conclusions that contained intimate, personal or pejorative information. The fol-
lowing are some examples discussed in the context of “Bushmen-speciﬁc pheno-
types” (Schuster et al 2010: suppl 8): namely, howdifferent genetic and environmental
influences come together to create an organism’s physical appearance and behaviour.
1. “Hunter-gatherer” associated with low social status: Commentary in the paper
on “traditional life-style” included the following, which contains far-reaching
and unsupported assumptions:
A feeling of inferiority associated with the “Bushmen” or “San” ethnic classiﬁcation meant
that many Bushmen women tried to uplift their status via marriage to Bantu men (Schuster
et al 2010: suppl. 3).
2. Lactase persistence: The following conclusion was drawn:
As expected for a foraging society, we found the Bushmen in our study all to be
homozygous for the C-allele, suggesting an inability to tolerate milk consumption as adults
(Schuster et al 2010: suppl 4).
3. Human pigmentation: Conclusions were drawn about levels of San melanin pig-
mentation, their susceptibility as a group to skin cancer, and their consequent
selective advantage for survival in the Kalahari desert (Schuster et al 2010: suppl 5).
4. Lipid metabolism and bitter taste alleles: Complex conclusions were drawn
relating to Bushmen digestive tracts, and also the ability to sense a bitter taste, a
trait which would potentially assist human survival in the wilds. The “taste
receptor gene” was also discussed in the context of human evolution from
Neanderthal to the present (Schuster et al 2010: suppl 7).
5. Genes related to hearing: Drawing on the ﬁndings, the paper indulged in
speculation that “Bushmen have better hearing than Europeans” (Schuster et al
2010: suppl 8).
Lessons Learned
The San leaders see the Schuster case as a telling example of the harm and dis-
respect that research can bring about, notwithstanding approval by ethics com-
mittees/institutional review bodies. It also highlights the need for San themselves to
create their own protection mechanisms.
With this in mind, the San held a consultative workshop in September 2014 com-
prising San leaders from Botswana, Namibia and South Africa, as well as genomic
researchers, ethicists and lawyers. The purpose of the workshop was to discuss the San’s
perception of the exploitation inherent in the approach followed by the Schuster research,
and to propose a San response to ensure that such research could never take place again.
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In 2016 the San held two further workshops under the auspices of the TRUST
project2 designed to take the earlier discussions further and to consolidate proposals
aimed at ensuring that the San could in future manage and control research being
done on their communities. These proposals are set out below.
Recommendations
The following recommendations emerged from the San workshop aimed at pre-
venting exploitation in research.
• Collective permission must be obtained for all research to be carried out on San
individuals or communities.
• The San Council is the elected organization in South Africa mandated to engage
in this process with researchers.
• The San have since developed a San Code of Research Ethics (San Council
2017) that has to be completed by all prospective researchers. This code con-
tains a number of requirements relating to the need for research to be both
respectful and useful to the San peoples, including:
– early identiﬁcation of research useful to the San
– joint development, where appropriate, of design, content and methodology
of all aspects of the research
– full details provided in advance of all aspects of the research, including
(potential) beneﬁts to the San
– commitment to pre-publication consultation, where appropriate, and
post-publication feedback to the community
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Chapter 4
Sex Workers Involved in HIV/AIDS
Research
Anthony Tukai
This case study shows that equitable relationships between
researchers and research participants are about a lot more
than informed consent. For instance, the higher level of
research literacy among the sex workers that was achieved in
the Majengo clinic is a model for others to follow.
Doris Schroeder.
Abstract This case study is written as a personal story by an outside support
worker starting to engage with sex workers, a vulnerable and stigmatized popula-
tion in a Nairobi slum. We hope the shared experiences will give better insight into
the difﬁculties faced by members of this key population as they eke out a living. It is
also a positive case study, not one of exploitation, despite sex work being illegal in
Kenya.
Keywords Clinical trials  Sex workers  Kenya  Women  Empowerment
My Experience Visiting Majengo
I took an assignment with the Sex Workers Outreach Programme (SWOP), a
leading sex workers’ health organization in Kenya that promotes the health, safety
and wellbeing of sex workers, as well as afﬁrming their rights as workers and as
people. The programme is funded by CDC-PEPFAR1 through the University of
Manitoba, Canada. I began my assignment by visiting the Majengo slum where
SWOP runs a health clinic targeting sex workers living in and working from these
informal settlements.
I am Kenyan with a background in social work and public health. My public
health interest is in HIV prevention, while my social work interest is in
A. Tukai (&)
Sex Workers Outreach Programme (SWOP), P. O. Box 30709, Nairobi 00100, Kenya
e-mail: tonytukai@gmail.com
1The US President’s Emergency Plan for AIDS Relief, as implemented by the Centers for Disease
Control and Prevention in the USA.
© The Author(s) 2018
D. Schroeder et al. (eds.), Ethics Dumping, SpringerBriefs in Research
and Innovation Governance, https://doi.org/10.1007/978-3-319-64731-9_4
23
interventions. My hope is to build a strong foundation to improve the health and
well-being of vulnerable and stigmatized communities such as LGBTs (lesbian,
gay, bisexual and transgender persons) and sex workers.
I have lived in Nairobi for the greater part of my life, but like most Kenyans I
had never visited a slum in Kenya. I was prepared for the unexpected, but it was
like going to a different world. What struck me ﬁrst were the overcrowding and the
variety of activities that the residents engaged in for survival. The area is densely
populated; it felt like being in a city within a city. The road we tried to drive along
to access the slum was full of people selling second-hand shoes, clothes and
household items. We had to stop and wait for close to ten minutes for the hawkers
to clear a path – like parting the Red Sea – so that we could get into the clinic
compound. I took a walk with a health worker from the Majengo sex workers clinic
to meet some of the sex workers who live and work in the area. We saw dirty alleys,
open sewers and lots of trash. There were women doing laundry on the sidewalks,
and some sitting beside their doorsteps. Men were going in and out of the houses or
just walking around, many looking as if they had been drinking heavily. I saw
hardly any children; those I did come across were playing outside unsupervised.
The more fortunate children were presumably attending school in other parts of the
city, while many of the rest were at the dumpsites, trying to earn money by
scavenging for recycling companies. The houses were small and squeezed together,
poorly built with rusted metal roofs.
The sex workers to whom I was introduced on the narrow pathways and by the
doorsteps were friendly, saying “Hello!” and “Karibu!” (welcome). One of them
ushered us into her tiny room. She had been doing sex work since she was a
teenager and now looked to be in her mid-50s. She was skinny; I think she weighed
no more than 40 kg. Her single room was small and cramped, with no space for a
kitchen area or a living room. But two beds were squeezed in. One of the beds, she
said, was her “ofﬁce … where I service my clients, and the other one is where I
sleep when not working”. Hanging on top of her bed was an assortment of
underwear in different styles and colours. She smiled and said, “Some of my clients
prefer me to wear different colours and shapes of underwear, so I keep this for
them.”
Seeing the Majengo slums and experiencing something of the life there was an
eye-opening experience that I will not forget for the rest of my life.
About Majengo
The Majengo slums are about three kilometres away from Nairobi’s central busi-
ness district. One of the oldest slums in the country, it is located between Gikomba
market (the biggest mitumba, or second-hand clothes market, in East Africa) and
Eastleigh, a commercial hub that is now known as Little Mogadishu due to the huge
number of Somali immigrants living in the area. Majengo can be traced back to
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colonial times in the 1920s, when it was occupied by East African railway builders
and those serving them.
In her book The Comforts of Home: Prostitution in Colonial Nairobi, White
(1990) describes how cattle epidemics, locusts, famine and drought swept through
Kenya in the 19th century. A lack of food and the spread of disease, including
smallpox, in central Kenya caused the death of an estimated 70% of the population.
After the famine, the Nairobi economy began to boom in the mid-1920s, with
men and women from neighbouring districts arriving to sell agricultural products.
Many ended up staying in Majengo. Sex workers became Kenyan’s “urban pio-
neers”, and were among the ﬁrst residents to live in Nairobi year-round. They
frequently came from strong families (White 1990:9). Many were able to send
money home to bolster rural family incomes, which were racked by upheavals.
Prostitution emerged as an identiﬁable category of women’s work, taking three
forms:
• Watembezi prostitutes (from the Swahili word kutembea, “to walk”) offered
brief sexual services along the streets.
• Malaya (the term means “prostitutes” in Swahili) offered more prolonged indoor
domestic and sexual services.
• Wazi wazi (“open”) prostitutes sat in front of their houses, calling out their
prices raucously and aggressively.
For some women, sex work was casual and intermittent: “He was hungry for sex
and I was hungry for money” (White 1990:85). For others, it was the only way to
survive: “[W]e were hungry, we had to go with men to get money, or have no
money” (White 1990:79).
Majengo, also known as Soﬁa Town, was once an entertainment spot for British
soldiers who frequented the village to watch cultural performances by mostly
female groups. During the colonial era, Majengo grew into quite a popular area, but
without the provision of adequate shelter. Its population today is estimated to be
more than 150,000 people of all ages and different ethnicities. It is divided into the
four smaller settlements of Soﬁa, Mashimoni, Kitanga and Digo. The women
continue to sell sex, ﬁlling a gap for men whose wives, girlfriends and families
remain back home in rural Kenya. In addition, men from other countries continue to
visit Majengo for sex.
The Majengo Clinic
The Majengo Clinic is a medical facility for low-income and medically underserved
communities. Within a larger compound there is a special clinic, also known as the
Special Treatment Centre (STC), that has offered sex workers a safe space since the
mid-1980s. For a long time it was the only public health centre in Kamukunji,
Nairobi, providing sex workers and their clients with treatment for sexually
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transmitted infections (STIs). With funding from the Canadian government and the
assistance of the public health authority of Nairobi City Council, researchers from
the universities of Oxford, Nairobi and Manitoba worked to improve existing
resources and provide basic outpatient medical services to the Majengo community
of female sex workers. In the mid-1980s, the World Health Organization (WHO)
designated their operations as a WHO collaborating centre for sexually transmitted
diseases (STDs). Among the common ailments treated were classic STDs, malaria
and typhoid. Currently, the clinic offers comprehensive HIV prevention and treat-
ment services, birth control methods, gynaecological examinations, and TB tests
and treatment, in addition to supporting the management of assorted HIV/AIDS-
related opportunistic infections. It also serves as a research facility for the collab-
orating researchers, who run two HIV-integrated activities: HIV research and HIV
care and treatment. More than 5,000 sex workers receive care at the clinic, 3,200 of
them enrolled in clinical research studies.
Majengo Research
The Majengo Observational Cohort Study (MOCS) started in the late 1980s, and is
a long-term cohort study of disadvantaged female sex workers in Nairobi. The
study, as expected, has contributed to the development of several candidate vac-
cines against HIV.
HIV research studies started when Dr Frank Plummer, a Canadian scientist who
was the principal investigator undertaking research on STIs in Majengo, discovered
that about two-thirds of women visiting the clinic had tested positive for the virus in
1985. This changed the focus of his research from general STIs to include the
epidemiology of HIV in Africa.
Plummer and his team later discovered that a small number of the women had
apparently developed immunity to the HIV virus despite long-term exposure
through sex with infected clients. This led to other studies aimed at understanding
the epidemiology and immunobiology of HIV and the risk factors associated with
its spread. Blood, cervical, vaginal and saliva samples were drawn from women in
this cohort, with their consent. One of the key ﬁndings was that when some of the
“HIV-resistant” women took breaks from sex work – for example, to visit family or
pursue alternative employment – temporarily stopping their exposure to HIV, they
rapidly lost their immunity and became signiﬁcantly at risk of HIV-infection on
resuming sex work.
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Majengo Research Participants
“Prostitutes” is what they called them in the past. Then they were known as
commercial sex workers, and now the term is sex workers. “I don’t know what they
will call them next,” said one of the Majengo clinic workers during my visit. “Sex
worker” is the term used by researchers and policymakers and includes female,
male and transgender adults aged over 18 years who sell consensual sexual services
in return for cash or payment in kind, and who may sell sex formally or informally,
regularly or occasionally. It’s a word used by people who think the word “prosti-
tute” is impolite or offensive.
Sex work is classiﬁed under Kenya’s Penal Code as illegal (Laws of Kenya
2014), and it entails a stiff penalty. It is seen as an “immoral activity” rather than a
form of labour, and many believe that sex workers deserve to be punished.
At ﬁrst sex workers were nervous to register with the SWOP clinic, because they
feared that their personal information would be shared with the Kenyan law
enforcement agencies. Once they were assured that the information gathered
through unique identiﬁers and biometric tools was for research purposes and would
not be shared with any third party, they registered in droves. They also signed
informed consent documents for the different research studies undertaken. In return,
the SWOP team provided and continues to offer free health care including HIV
management. One of the reasons why the clinic has a good record on research ethics
is its engagement work with the community that is involved in the research.
Research Literacy Among the Sex Workers
The research has built up long-term relationships between the researchers and the
women sex workers through peer leaders and educators who engage in dialogue and
negotiations with the scientiﬁc investigators about the terms and conditions for
participation in the research. Over time, these activities have helped to develop and
formalize a “community” among the sex workers that did not previously exist. The
partnership has enabled a wide range of beneﬁts in the research cohort and wider
community, such as health education, free distribution of condoms, and the pro-
vision of free treatment for a range of STIs. In addition, it has led to effective
referral for other health care requirements, such as non-communicable diseases,
cancers and surgical procedures including hysterectomy. Such services would
probably not otherwise have been available to these women.
These peer educators are themselves sex workers. They educate women about
their rights, promote behavioural change, distribute condoms and provide referrals
to health clinics. Peer educators also address workers’ concerns, whether about
personal issues, services offered, or the research they are a part of. They are the
gatekeepers of the sex workers’ community.
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Education about condom use has given sex workers the conﬁdence to negotiate
this with their clients. Over time, 100% condom use has been achieved with casual
clients, but regular clients still remain a challenge. Peer educators have also been
active in the provision of general information on the research consenting process.
Capacity building on the consent procedures undertaken over the years by the
SWOP team seems to have borne fruit. Sex workers currently involved in the
pre-exposure prophylaxis (PrEP) studies2 have stated that they are not subject to
any pressure in deciding whether to participate in any of the research projects. “We
are free to refuse to consent to any research, be it from SWOP or any other,” stated
one of the participants. “Consent is voluntary and has always been voluntary at the
Majengo clinic,” said a sex worker who was also a peer educator.
Ethical Concerns and Beneﬁts
The sex workers have long been collaborating with researchers from Kenya, South
Africa, Europe and Canada. The Majengo clinic has also been providing better
health care than is offered at other public health facilities. There are obvious issues
around informed consent and the possible exploitation of the sex workers in the
studies that constantly have to be dealt with. For example, do the sex workers really
understand what they are consenting to, or do they trade participation for access to
better and free health care? The peer educators, in my judgement, are influential. Do
they therefore play a big role in the willingness of sex workers to participate in the
studies? Does the collective opinion of the sex worker community on particular
studies have a major influence on individual willingness to participate, thus diluting
autonomy and self-determination?
These issues have been raised before – for example, in a newspaper article
headed “Sex slaves for science?” (Nolen 2006) and in Beneﬁt Sharing: From
Biodiversity to Human Genetics (Schroeder and Cook Lucas 2013) – and they
demand answers. In addition, Andanda and Cook Lucas (2007:9) have stated that:
In the Majengo case, the original, routine issues of negotiation and decision-making related
to the conduct of the research studies only involved researchers and administrators from the
relevant universities and institutions. … There was no formal inclusion of representatives
from the sex workers in any of these negotiations.
While writing this case study, I asked one of the peer educators about the
inclusion of sex workers in decision-making in the past. She conﬁrmed that
inclusion and genuine partnership had not been emphasized previously, but she
added: “Now we are enlightened, this would not happen at the moment without our
consent. We must be part of the decision-making”. The long-term engagement of
the clinic with research participants in the spirit of ethical research has therefore,
2Pre-exposure prophylaxis, or PrEP, is a way for people who do not have HIV but who are at
substantial risk of getting it to prevent HIV infection by taking a pill every day.
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over time, led to improvements in the positioning and negotiation skills among the
peer leaders/educators. This is easily noticeable on the ground. Other factors noted
include:
• The women’s health has improved because of their access to education and
high-quality care, which has reduced HIV incidence, the disease burden and
mortality.
• Important ﬁndings about HIV infections are shared with the sex workers’
community as they emerge. This has a great impact on the health of sex workers
generally, since both partners now practise evidence-based interventions and
programming. This will become even more prevalent as a greater understanding
of novel prevention strategies emerges, and as these strategies are adopted.
• Sex workers involved in the studies have increased their self-worth and agency
by becoming valued partners in the research and by developing a sense of
community among themselves. It is important not to romanticize this, because
the women’s lives are fraught with difﬁculty, but it has to be noted that sex
workers have been able to counter assaults on their self-worth due to the ille-
gality of sex work in Kenya by developing a new emphasis on their rights.
Bandewar et al. (2010) argue that participation in the MOCS has improved and
enriched sex workers’ lives, because community engagement activities have
helped create a community that did not exist independently. Majengo sex
workers – as part of the growing sex workers’ movement in Kenya – have
formed an association called the Kenya Sex Workers Alliance (KESWA). This
is a local chapter of the global sex worker alliance, whose mandate is to train sex
workers about their human rights. “Sex work is work!” is an everyday slogan
among the Nairobi sex workers.
Poor enrolment in the ongoing PrEP demonstration project, despite a huge
number of potential at-risk HIV-negative participants from the cohort, presents
some real food for thought. In my discussions with the sex workers’ representatives,
they pointed out that community education, demand creation and advocacy for
PrEP among the sex workers were done poorly. The researchers and policymakers
had not fully engaged the community in promoting the project. Therefore uptake of
the novel intervention, despite its potential, will remain poor so long as the sex
workers’ community is not educated and involved in the grass-roots advocacy
processes. Inclusion and the community buy-in and support are crucial to progress.
This ﬁnding also conﬁrms that the Majengo sex workers do indeed practice
self-determination in the consenting process.
4 Sex Workers Involved in HIV/AIDS Research 29
Conclusion and Looking Forward
At a recent TRUST3-sponsored high-level meeting in Nairobi, the peer educators’
demands for inclusion went a notch higher. They insisted on being part of the ethics
board that approved any research study involving sex workers. They also asked to
be included in the technical working group to advise on issues concerning sex
workers.
The ethics concerns for a group of sex workers from the Nairobi slums are
obvious. I would like to end with two observations. First, to be considered vul-
nerable in a research context does not mean to be weak or to need others always to
speak for one. Many of the sex workers I have met are very clear when expressing
their concerns and suggesting ways forward. Second and very important, sex
workers have increased their self-worth by participating in past and ongoing
studies. They are now more empowered to make their own choices, whether these
choices concern the way they receive their health services from SWOP or their
decisions about participating in research projects.
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Chapter 5
Cervical Cancer Screening in India
Sandhya Srinivasan, Veena Johari and Amar Jesani
Abstract Three clinical trials took place in India between 1998 and 2015 in urban
and rural areas of Mumbai, Osmanabad and Dindigul. The trials aimed to determine
whether trained health care workers could conduct cervical cancer screening in a
community using cheap methods of testing – primarily visual inspection with acetic
acid – to reduce the incidence and mortality rate of cervical cancer. The clinical
trials were conducted on approximately 374,000 women, of whom about 141,000
were placed in the control arm (no screening). Although the standard of care for
testing of the disease in India has been cytology screening (or Pap smear) since the
1970s, screening for cervical cancer was not available universally under a gov-
ernment programme, and for the study purposes the standard of care was therefore
misconstrued to be no screening. Known and effective methods of screening for
cervical cancer were therefore withheld from 141,000 women in areas where it was
known to be of high incidence and prevalence. This placed them at a known risk of
developing invasive cervical cancer, and dying from it, because it was not detected
and treated in time. Two hundred and ﬁfty-four women in the no-screening arm
died due to cervical cancer as per the latest published reports on the three trials.
A no-screening control arm would not have been allowed in the USA, but was
accepted by the US funders for clinical trials in India. It is imperative that ethical
standards for research be applied equally across nations to prevent “ethics dump-
ing” and protect the rights of human research participants in research, no matter
where they are located on the globe.
Keywords Clinical trials  India  Cervical cancer  Women  Standard of care
The date periods for deaths in the no-screening arms are taken from the dates quoted in the last
available publication on each trial. They are: 98 in Mumbai 1998–2011 (Shastri et al. 2014), 64
in Osmanabad 2000–2007 (Sankaranarayanan et al. 2009), 92 in Dindigul 2000–2006
(Sankaranarayanan et al. 2007). The Mumbai trial reported ﬁndings up to 2011, though the
trial would not have ended before 2015.
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Area of Risk of Exploitation
While the trials described in this case study showed a number of ethical short-
comings, the main area of risk of exploitation was a placebo arm – no screening for
cervical cancer despite high incidence and prevalence – instead of provision of an
accepted standard of care.
Context
Medical and public health research had crossed national boundaries during colonial
times; but controversies on ethical violations in research conducted by those from
high-income countries (HICs) in low- and middle-income countries (LMICs)
became a real focus once higher ethical standards were established in the HICs.
LMICs however have continued to lag far behind in bringing such standards into
their legal and ethical systems.
This unevenness in ethical and legal standards has been used by HICs to carry
out research at reduced ﬁnancial costs in LMICs. Many participants in such
research have suffered avoidable injuries and deaths. The international bioethics
debate has chastised researchers from HICs for practicing “double standards”
(Macklin 2004), taking advantage of vulnerable people in vulnerable nations and
thus “exploiting” them for their own scientiﬁc goals and proﬁt motives. Inequities
among researchers, and in ethics standards, have since become major issues of
concern in international collaborative research.
The globalization of neoliberal economic policies has pressured LMICs to open
their markets and deregulate their economies. The establishment of the World Trade
Organization in 1995 created an international trade regime favourable to HICs. One
major issue in international trade is the “dumping” of cheap and/or substandard
commodities by powerful nations into the economies of less powerful nations, with
a devastating negative impact on their economies (Howell and Ballantine 1998).
“Ethics dumping” follows the same pattern as dumping in trade, but in slightly
different ways. Ethics dumping takes place because doing such research is either not
possible at all in the HIC concerned or entails high costs due to the value attached to
the ethical standards it is required to follow. This is matched in the low- or
middle-income country (LMIC) by either a lack of adequate ethical standards in its
guidelines or a failure to convert such guidelines into law and mandatory
requirements and enforce them. At the same time, the suffering of many people
from a range of communicable and non-communicable diseases may render such
research relevant to the LMIC, and may also tempt local scientists to undertake it
with inadequate ethical standards, in order to ﬁnd well-intentioned solutions.
While research of this kind may or may not provide an early solution to a
medical problem suffered by people, the need for a solution invariably tends to
provide a justiﬁcation for using a lower ethical standard, according less importance
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to respect for participants, or to the avoidable injuries and deaths of vulnerable
subjects. Overall however, it causes irreparable harm to the nation’s desire to bring
ethical standards up to an international level.
We provide an example of ethics dumping in three trials conducted from 1998 to
2015 in urban and rural India on testing for cervical cancer. These were funded by
the USA’s National Institutes of Health (NIH) and the Bill and Melinda Gates
Foundation (BMGF), a private foundation that supports public-private partnerships
in the development of technological solutions and their inclusion in government
programmes, in collaboration with the International Agency for Research on Cancer
(IARC) in France, a specialized cancer agency of the World Health Organization
(WHO).
These trials have been condemned as unethical by public health experts and
ethicists because the participants were not offered the same level of protection and
consideration as participants in HICs would have been. Women in the no-screening
arm of the three trials were merely observed to determine how many would get
cervical cancer and how many would die, if they were never screened. Issues
relating to informed consent, the use of placebo or control arms of the trial (in this
case no screening) despite awareness of and the in-principle availability of
well-known effective methods of testing for cervical cancer (e.g. Pap smear), a lack
of proper supervision in the intervention arm of the trial, and irreversible harm to
the women participants have marred these trials and resulted in human rights
violations.
Background on Cervical Cancer Screening in India
Cervical cancer is the fourth most common cancer in women worldwide, with 85%
of the global burden of disease in LMICs (Ferlay et al. 2013). It is a leading cause
of cancer mortality in Indian women over the age of 15, and too often women die
because they do not get prompt diagnosis and treatment. Researchers note:
Nearly 70% of cervix cancer patients in India present at stages III and IV. Around 20% of
women who develop cervix cancer die within the ﬁrst year of diagnosis and the 5-year
survival rate is 50% (Mittra et al. 2010).
This cancer affects poor women the most, especially those living in rural areas,
because they are less likely to get screened and treated, and therefore more likely to
develop invasive cancer and die from it (Krishnan et al. 2013).
In HICs, regular screening programmes for the early detection of precancerous
lesions, and their prompt treatment before they progress to invasive cancer, have led
to a reduction in incidence of and deaths from cervical cancer (Sankaranarayanan
et al. 2001). The international standard of screening is cytology, or the Pap smear,
an examination of cells on the surface of the cervix for precancerous lesions.
Another test involves the DNA of the human papillomavirus (HPV), a viral
infection closely associated with the development of cervical cancer. The HPV test,
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which is manufactured by various companies, is being advocated for routine use in
HICs, where it costs substantially more than cytology.
Cytology screening has been used in Indian public health services since the
1970s and is available in all major hospitals in the country. Since at least 2001 it has
been advocated for inclusion in the government’s cancer control programme ser-
vices (Sankaranarayanan et al. 2001). In 2006, guidelines developed by the Indian
government and WHO advocated the use of the Pap smear at district level, along
with a cheaper, simpler screening method at the primary health centre level
(National Cancer Control Programme 2006). The HPV test is available in the
private sector in India, but it is very expensive. Though cytology is available all
over India, researchers have held that it is not feasible for population screening in a
country like India:
Cervical cancer prevention researchers and advocates have argued that the standard
approach in high-income countries, namely cytology-based screening, is difﬁcult to
establish in LMICs where laboratory infrastructure; trained personnel, such as
cyto-technicians and pathologists; and continuous quality assurance processes are largely
unavailable … Consequently, research has focused on evaluating screening approaches
requiring less training and fewer clinic visits and using existing (or minimal additional)
human resources (Krishnan et al. 2013).
An inexpensive cervical screening method is visual inspection of the cervix to
detect precancerous lesions. Since at least the 1990s, studies have been conducted
of various visual inspection methods, with or without magniﬁcation, and after
application of contrast chemicals such as acetic acid or iodine to highlight pre-
cancerous lesions. These methods do not need to be conducted by a medical pro-
fessional. By 1999, visual inspection of the cervix after application with acetic acid
(VIA) was considered a “promising approach in the detection of cervical neoplasia”
(Sankaranarayanan et al. 2003) for cancer prevention programmes. VIA was being
advocated for inclusion in the cancer screening programme as early as 2001, but it
was felt that deﬁnitive information on the value of VIA was still lacking.
Study Design
The value of a screening intervention as a public health measure is judged by
various criteria: sensitivity, speciﬁcity and positive predictive value of the test; the
feasibility of implementing it in a health programme, its cost-effectiveness, and its
impact on incidence and mortality. Such information is gathered through various
types of research, including cross-sectional studies, mathematical modelling,
implementation projects and cluster randomized controlled trials (CRCTs).
Within the scientiﬁc community, the CRCT is a classic trial design to evaluate an
intervention in the community. The CRCT provides the gold standard of evidence
necessary for making public policy decisions. CRCTs test an intervention (pre-
ventive or therapeutic) for a disease or condition by giving it to a “cluster” of
people, and comparing the results to a control group of clusters, who are given
36 S. Srinivasan et al.
another intervention. The clusters can be slums within a municipal ward, or villages
covered by a single primary health centre. The group or sample is chosen from a
larger community using a system of randomization that is meant to eliminate all
differences between the two groups (e.g. age or parity) other than the intervention
being studied.
When there is no existing effective intervention for the disease being studied,
then a trial may compare the intervention to a placebo (e.g. a “dummy pill”). When
a non-drug trial tests a preventive intervention such as screening, then the “placebo”
arm is a “no-screening” arm. However, ethical guidelines governing the use of
placebo in research severely restrict the use of placebo or “no intervention” if an
effective treatment or test already exists for the disease being studied. This is to
ensure that research participants in the control arm do not receive a lower standard
of care than is already known to be effective, and are not therefore disadvantaged by
their participation in the study. This had been asserted in a number of national and
international documents published prior to and during the three trials undertaken in
this case study (WMA 2008; ICMR 2000, 2006; CIOMS 2002). The World
Medical Association’s Declaration of Helsinki ﬁrst introduced strict guidelines on
the use of a placebo control in 2000 (WMA 2000).
Three Cluster Randomized Controlled Trials of VIA with “No
Screening” Controls in India
In a review of cervical cancer screening in LMICs, R. Sankaranarayanan et al.
described research on cervical cancer screening in India, which included studies of
the impact of awareness and health education, and cross-sectional studies of various
visual inspection-based approaches as well as HPV testing. They concluded by
mentioning three studies:
There are three large, ongoing cluster-randomized intervention trials in India – in Dindigul
district (Tamil Nadu), in Mumbai, and in Osmanabad district (Maharashtra) – to evaluate
the effectiveness of VIA in reducing cervical cancer incidence and mortality. The inter-
vention programme in Osmanabad district aims to address the comparative efﬁcacy and
cost-effectiveness of three different primary screening approaches in reducing the incidence
and mortality: VIA, conventional cervical cytology, and HPV testing. The results of these
studies are likely to provide valuable leads to the development of public health policies to
control cervical cancer in developing countries (Sankaranarayanan et al. 2001).
The trials were conducted on a total of 374,000 women. The 141,000 women in
the control arms of these trials received no screening for cervical cancer, but were
provided with the so-called “usual care” or “standard care”, consisting of health
education on cervical cancer symptoms, screening and treatment, and the avail-
ability of these facilities in their localities. According to the last published report on
each trial (Sankaranarayanan et al. 2007, 2009; Shastri et al. 2014), a total of 548
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women were recorded to have died in the trials, 254 of them in the no-screening
control arms.1
The use of no-screening control arms went against all established ethical prin-
ciples, as articulated in national and international guidelines: namely, that new
interventions must be tested against a proven effective method. In the case of the
VIA trials, cytology screening was a proven effective method, and it was available
in health services all over the country, including in the institutions which conducted
these trials.
When a controversy about these trials using a no-screening control broke out,
one of the investigators stated: “Whenever a new intervention is evaluated, it is
compared with the standard of care existing in the country”. In India, he wrote,
there “is no organised or large-scale opportunistic cervical cancer screening pro-
gramme” anywhere in the country. As a result, “[t]he standard of care for cervical
cancer control in India is clinical diagnosis and treatment of invasive cancer only
when symptomatic women seek medical attention” (Sankaranarayanan et al. 2011).
Another researcher stated: “Pap smear cannot be considered the standard of care in
India, not only because of the lack of infrastructure and trained manpower, but also
because it is not cost-effective” (Pramesh et al. 2013).
All the women recruited in these trials were poor and socially disadvantaged,
and thus highly vulnerable. The Mumbai study was conducted on women in slum
clusters living in tenements, shanties on open ground, or makeshift huts on the
pavements and along the railway lines. Osmanabad, Maharashtra, is “a predomi-
nantly rural and socio-economically backward district with a high incidence of
cervical cancer” (Sankaranarayanan et al. 2005). Between 25–30% women lived in
thatched roof houses. Dindigul, Tamil Nadu, is a rural district whose high incidence
of cervical cancer was a reason to choose it as the site of this VIA trial. Some 65–
75% of the women in Osmanabad and Dindigul and 40% in Mumbai had no formal
education. The average age of the women in these trials was 40–45 years (range
30–59). They would have had poor access to health care, whether because of cost or
the inconvenience of long waiting lines and ill-equipped public services or the low
priority given to self-care. Though it is known that the vast majority of women,
particularly after they have given birth, suffer from various gynaecological symp-
toms, 90% of women in the Mumbai trial had never visited a gynaecologist with
their complaints.
The Mumbai Trial
The ﬁrst study to start was in Mumbai, at the Tata Memorial Hospital and Centre
(TMC), a national centre of excellence for cancer research and policy. The study,
1The ﬁgures are based on the start and cut-off dates given in the study reports: Dindigul: 2000–
2006, Osmanabad: 2000–2007, Mumbai 1998–2011. The Mumbai trial concluded in 2015, but
reported results as of 2011.
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entitled “Early detection of common cancers in women in India”, was funded by the
US National Institutes of Health. The study initially sought to ﬁnd out if repeated
rounds of screening using inexpensive techniques would reduce mortality from
cervical cancer.
Women community health workers educated up to the tenth grade were trained
to conduct screening with VIA and also to do clinical breast examination for the
detection of breast cancer. They were required to be supervised, and about 10% of
women screened were also to be tested by the researchers for cross-checking of the
results. Women in both arms were given health education on the causes of cancer.
They were also told about the need for screening, and that the screening and
treatment were available. Then the women in intervention/experimental arms were
given screenings for cervical cancer, while women in the control arms were given
no screening at all.
The trial started in 1998 and concluded in December 2015. A total of 75,000
women in the intervention arm and 76,000 women in the no-screening arm were
recruited into this trial. Each woman was in the trial for 17 years. Women in the
intervention arm were given health education and screening four times, i.e. once
every two years. Those who tested positive were directed to TMC, where they were
given conﬁrmatory tests and treatment if needed. After the four rounds of screening
were over, the women were then contacted four times, once every two years, for
follow-up. Women in the control arm, on the other hand, received health education
only once, were not offered any preventive screening for carcinoma cervix, and
were observed through surveillance for 17 years. Every two years, through active
surveillance, data of women in the control arm were collected to ﬁnd out the
number that developed cervical cancer or died as a result of it. In 17 years, seven
rounds of active surveillance were carried out in both arms to document the
development of cervical cancer and deaths due to it.
Changes were made to the study protocol over a period of time. The intervention
was initially “direct visual inspection” without any magniﬁcation or contrast, a
technique that had been judged obsolete before this trial began, and was later
changed to VIA. The sample size increased from about 35,000 in each arm initially
to about 75,000 in each arm. The objectives were later amended to include
reduction in the incidence of cancers. These details do not appear in the published
reports of the study. Cross-checking of test results by the researchers was also
performed for fewer than 10% women in the intervention arm.
In 2011, an American physician ﬁled a complaint with the US government’s
Ofﬁce of Human Research Protections (OHRP), relating to the Mumbai and
Osmanabad trials. An application for documents was also ﬁled by a journalist under
the US Freedom of Information Act. The OHRP stated that its jurisdiction was
limited to trials funded by the US government and did not apply to research funded
by the Bill and Melinda Gates Foundation (BMGF) , a private party (Suba 2014).
The OHRP’s investigation found irregularities in the functioning of TMC’s
institutional review board: standard operating procedures had not been followed,
meeting minutes were not documented, and decisions were taken without a quorum.
The OHRP also found discrepancies in the informed consent document between the
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English and the local language translation (Marathi). The English form gave
information on cervical cancer, the tests required for its detection and where testing
was available, but the Marathi form did not.
The OHRP did not ﬁnd the no-screening arm of the trial to be unethical. By
2011, 98 women who had entered the control arm of the Mumbai trial and received
no screening, only health education, had died of cervical cancer. The results of the
Mumbai trial were announced at the 2013 meeting of the American Society of
Clinical Oncology. The researchers announced that a test for cervical cancer, using
just vinegar and conducted by trained health workers, could bring mortality from
cervical cancer down by 31% (ASCO Post 2013). The ﬁndings were reported
extensively in the press.
Osmanabad Trial
In October 1999, TMC with its Rural Extension Project and the Nargis Dutt
Memorial Cancer Hospital started a second trial, in the Osmanabad district in rural
Maharashtra. They were funded in this trial by BMGF.
This trial compared the impact of a single screening of VIA, HPV test or
cytology to a no-screening control arm in a CRCT. The primary outcomes were the
incidence of cervical cancer and the associated rates of death. The researchers stated
in their interim report:
Whether a screening program using VIA or HPV testing will be followed by a reduction in
disease burden and the cost–effectiveness of these alternate approaches based on real
program-based information remain to be established. These approaches need to be evalu-
ated in comparison with the established standard cytological screening, with respect to their
comparative efﬁcacy and cost–effectiveness, before recommendations can be made con-
cerning their introduction in a public health context (Sankaranarayanan et al. 2005).
Women in the intervention arm were identiﬁed through household surveys, and
those who consented to be in the trial were given information on cervical cancer and
its prevention, and invited to screening camps in each village where trained mid-
wives conducted the screening. Depending on which intervention arm the village
belonged in, the women received VIA, Pap smear or the DNA test for HPV.
Women with positive VIA tests were given immediate follow-up tests and
on-the-spot treatment if appropriate; or they were referred to the Nargis Dutt
Hospital for further treatment. Samples from the cervix were taken from women in
the cytology and HPV arms, and the results sent to them in two weeks. Those with
positive tests were given appointments at the hospital for follow-up. Women in the
control arm were given education on cancer and its prevention and information
about the services available at the Nargis Dutt Hospital. “Since there is little
screening for cervical cancer in India, women who did not undergo screening
(control group) were considered to receive the standard of care” (Sankaranarayanan
et al. 2009).
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All the women were contacted just once, at the time of the intervention, after
which they were surveyed and tracked through the cancer registries and death
registries, until the end of the eight-year follow-up period. The trial was conducted
in partnership with the IARC and the Association for Cervical Cancer Prevention
(ACCP). The ACCP is a member of the IARC and both receive some funding from
the BMGF. Screening was started in January 2000 and completed by April 2003
(Sankaranarayanan et al. 2005). The ﬁndings of the interim report of the
Osmanabad trial ran contrary to standard wisdom:
Our results show that a high level of participation and good-quality cytology can be
achieved in low-resource settings. VIA is a useful alternative but requires careful moni-
toring. Detection rates obtained by HPV testing were similar to cytology, despite higher
investments (Sankaranarayanan et al. 2005).
However, when the ﬁnal ﬁndings were reported in 2009, the researchers con-
cluded that while a single round of screening for HPV reduced both incidence and
mortality from cervical cancer, cytology and VIA were no better than no screening
at all. The researchers observed that while the test used in the trial, by Digene
Corporation, was effective, a cheaper HPV test had been developed, manufactured
by Qiagen, a Chinese company.
Our results, combined with those of the Chinese study of the new HPV test, indicate that
HPV testing is appropriate as a primary screening approach in low-resource settings for
women who are at least 30 years of age (Sankaranarayanan et al. 2009).
These comments gain signiﬁcance when one learns that in 2004, Digene had
entered into a partnership with the Program for Appropriate Technologies in Health
(PATH), an implementing agency for BMGF, to promote the use of HPV testing in
LMICs. In 2007, Qiagen Corporation bought Digene Corporation.
Dindigul Trial
The third trial started a few months after the Osmanabad trial. In May 2000, BMGF
with IARC initiated another trial of VIA, this one with the Christian Fellowship
Community Health Centre hospital in Ambilikkai, Dindigul District, Tamil Nadu.
The objective was to evaluate the efﬁcacy of a single round of VIA provided by
nurses, with appropriate treatment approaches, in reducing the incidence of and
mortality from cervical cancer.
The women in the intervention arm were screened with VIA by trained nurses.
Those found positive were offered cryotherapy on the spot, and those with larger
lesions were referred for treatment. Screening was completed by April 2003. The
control group received “existing care”. “No active intervention was provided for the
control group” (Sankaranarayanan et al. 2004). The researchers explained: “We
used an unscreened control group because there are no organised screening pro-
grammes in India” (Sankaranarayanan 2007).
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Information on incidence and mortality was collected from cancer and mortality
registries as well as through active follow-up. Follow-up started in September 2003
and was to continue until 2012. However, by December 2006 the researchers
concluded that a single round of VIA followed by appropriate treatment reduced
incidence and mortality signiﬁcantly. “Timely implementation of an affordable and
effective screening strategy in developing countries is thus crucial, while waiting for
further improvements in HPV testing, vaccine technology, costs, and its widespread
use” (Sankaranarayanan 2007).
Analysis
While ethics and human rights often offer universal frameworks for research, their
actual implementation differs from country to country. Basic ethical principles of
research such as those of informed consent, cautions on research on vulnerable
populations and the need for monitoring mechanisms to protect participants are laid
out in international guidelines. The three trials described in this case study are
evidence that principles of research ethics are not always translated into practice.
The VIA trials demonstrate ethics dumping, and the harm that it causes to
participants in host LMICs. These trials would never have been granted ethical
approval in the USA or France, the countries of the sponsors and collaborator. They
exploited local regulatory weaknesses and economic and social inequities. They
were pushed, approved and accepted by the sponsors (NIH and BMGF in the USA)
and collaborator (IARC in France) to be conducted in India on poor and vulnerable
women.
In these three trials, rights of the women participants in the no-screening control
arm were violated: the universal and fundamental right to life and the right of access
to the highest available standard of care. It was known that as poor women, they
were already at increased risk of developing cervical cancer, and denying them
known effective and potentially lifesaving screening put them at a predictable risk
of developing invasive cervical cancer and dying from it. The denial of screening
delayed not only the detection of the disease, but also access to appropriate and
timely treatment that could have saved their lives. The standard of care was wrongly
construed by the researchers as meaning the universal availability of tests under a
programme of the government in India, rather than the universal standard of care
used for testing of the disease, which was available in India.
For the purpose of public health policy, there was no need for a natural history
control arm with no screening. The researchers should have provided an active
control arm using one of the known methods of testing for cervical cancer, as they
would have had to if the trials had been conducted in the USA or France.
In addition, the trials ignored the importance of informed consent. Women in the
trials were not given adequate information. This violated their right to life, vitiated
their consent and rendered the trial highly unethical. A trial without the participants’
voluntary and informed consent would not have been permitted in an HIC.
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What made these unethical trials possible? What were the conditions that
enabled ethics dumping in the VIA trials? One needs to understand why host
countries seek international support for research, why sponsors fund this research,
and whether these reasons are justiﬁable. These reasons may include: a shortage of
locally available funds for research; the interest of organizations in HICs in con-
ducting research in LMICs as part of their international health agendas; and the
relationships between local institutions and international organizations, as well as
researchers’ own links with these organizations as part of their individual scientiﬁc
careers. All these create a web of relations that lies at the heart of the resulting
double standard.
Research ethics must also contend with the view (Prasad et al. 2016) that locally
relevant research justiﬁes lower ethical standards. The researchers in these studies
have argued that these studies are important because cervical cancer affects and kills
poor women in LMICs more than it does women in HICs, and this calls for a test
that is inexpensive, implementable and effective. They have also asserted that
double standards do not cause active harm, as there is no functional screening
system in the host country.
Finally, the women participants in both experimental and control arms of these
trials are poor, voiceless and invisible. They may view participation in such trials as
giving them access to some care. When faced with a powerful medical establish-
ment, they are reluctant to make their grievances public. For instance, the hospital
conducting the Osmanabad trial is the only such service in the area. In such a
situation, violations of research ethics are less likely to come into the public eye.
Ethical Implications of Research in Communities Without
Universal Access to Health Care
Researchers in the VIA trials did not provide the standard of care to participants in the
control arm, arguing that India did not have an effective universal screening programme
and its standard of care for cervical cancer prevention was therefore “no care”.
Most LMICs, barring a few honourable exceptions, do not have universal access to
health care. Even when the government is supposed to provide free access to health
care, individuals are frequently forced to seek care in the private sector and pay for it.
The care that people receive is therefore determined not by a universal standard but by
what they can afford, or what the government provides, and many people do not get
any care whatsoever. This situation has permitted researchers to interpret the standard
of care, and their own responsibilities as physician-researchers, in a way that is not in
the best interests of research participants.
The standard of care cannot depend on, or be deﬁned according to, whether or
not it is universally accessible. In the VIA trials, the Pap smear is the universal
standard of care because it is universally considered to be an effective screening test
for cervical cancer. Any woman who goes to a private or public hospital should
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expect to be offered it. It is part of the Indian government’s cancer prevention
programme.
Whether or not the community involved in research has universal access to the
standard of care, through the government or private or social insurance, researchers
and sponsors must be held responsible for providing this standard preventive,
diagnostic and curative care free of cost to participants in the control arm of a trial.
There is therefore a need to have an explicit provision in ethics guidelines and in the
law emphasizing researchers’ ethical obligation to provide standard care to par-
ticipants in the control arm, as they are under their direct care during the course of
research.
Regulatory Weaknesses
Guidance for ethics review of non-drug trials is included in the ethical guidelines of
the Indian Council of Medical Research (ICMR) for biomedical research on human
participants (ICMR 2006). The ICMR guidelines acknowledge that the denial of
available treatment to a control group is unethical. They also state that “proper
justiﬁcation should be provided for using the placebo” and that “[i]n keeping with
the Declaration of Helsinki as far as possible standard therapy should be used in
the control arm” (ICMR 2006) (emphasis added).
However, since the trials were non-drug related, prior permission from the Drugs
Controller General of India was not required. Thus the VIA trials did not have any
legal oversight. The regulatory roles were played by institutional committees – the
institutional ethics committees, scientiﬁc review committees and data safety mon-
itoring committees. In this case, their authority was limited to within the institution
and they were not accountable to a regulatory authority.
US regulatory bodies claimed inability to investigate and act on complaints of
unethical research in the Osmanabad and Dindigul trials as these were funded by a
private foundation. Hence, these trials were not accountable to the US regulator as
they were not government-funded. Private foundations in HICs fund a substantial
amount of collaborative research in low-income countries, and their lack of
accountability to any authority is a matter of concern.
In the case of the Mumbai trial, the US regulatory body applied double stan-
dards. The use of a retrospective waiver of written informed consent, or permission
to obtain consent after the intervention, goes against the very principle of prior
informed consent in research, and would not have been allowed in the US.
Likewise, the US OHRP did not conclude that the no-screening arm in the Mumbai
trial was ethical, although it would not have been possible in the US. The trial even
continued when the relevant local hospital ethics committee in Mumbai stated that
the use of a no-screening arm was unethical.
Information about the actual trials, apart from the published papers, was not
readily available. This prolonged the harm done to the participants, as it delayed the
response to claims about the unethical and illegal nature of the trials.
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Recommendations
The following steps are necessary to prevent ethics dumping between HICs and
LMICs.
• Ensure the regulation of collaborative research. Studies involving interna-
tional collaboration should only be allowed in LMICs if mechanisms are in
place which ensure that the rights of participants will be respected at all times,
and that sponsors, researchers, ethics committees or institutions, whether gov-
ernmental or private, operating both inside and from outside the host country,
are held accountable for their activities in the LMIC.
• Ensure a framework for transparency. Mechanisms must be put in place to
ensure that trials are conducted in an open and transparent manner, and infor-
mation about ongoing trials must be available and open to expert scrutiny, so as
to prevent harm at any stage of the trial. The anonymized data, ﬁndings and
conclusions of the researchers should be open to scrutiny, so that the ﬁndings
and decisions on whether they should be used in public health policy can be
properly evaluated.
• Provide compensation for research-related injury. Mariner (1997) writes:
Since most legitimate research is intended to beneﬁt society as a whole, the subject assumes
risk for society’s sake (some would say making a gift to society). Therefore, society has a
moral obligation to make the injured subject whole by compensating those who took the
risks and suffered thereby. In addition, it may be argued that where society conducts,
supports, or sponsors research, it voluntarily assumes an obligation to compensate those
who are injured in its enterprise.
Sponsors and researchers must compensate participants who suffer from
trial-related injuries, by offering diagnostics and treatment freely and by providing
monetary compensation for loss, injury, harm, mental and physical suffering, and
expenses incurred as a result of participating in the trial. The mechanism should be
simple, so that it causes minimal problems to the participants. In the above trials,
proper follow-up of the women in the control arms, testing them with the best known
methods, and providing treatment and compensation would be a step in the right
direction. Families of women who died due to the standard of care being withheld,
thereby preventing them from accessing timely treatment, must also be compensated.
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Chapter 6
Ebola Vaccine Trials
Godfrey B. Tangwa, Katharine Browne and Doris Schroeder
Abstract The Ebola epidemic that broke out in West Africa towards the end of
2013 had been brought under reasonable control by 2015. The epidemic had
severely affected three countries. This case study is about a phase I/II clinical trial
(testing for safety and immunogenicity) of a candidate Ebola virus vaccine in 2015
in a sub-Saharan African country which had not registered any cases of the Ebola
virus disease. The study was designed as a randomized double-blinded trial. It was
sponsored and funded by one of the biggest Northern multinational pharmaceutical
companies. The protocol received ethics clearance from the relevant national ethics
committee. The study was coordinated and managed at the local branch of a big
Northern diagnostic laboratory and a laboratory of a local regional hospital. The
overall study was a multi-country, multi-site trial aimed at recruiting a total of 3,000
research participants across four or ﬁve sub-Saharan African countries. For this
country, the recruitment sites were two big cities, each aiming to recruit 200 par-
ticipants: adults at the ﬁrst site and children at the second. The target sample size
was almost achieved at the ﬁrst site but, before the study commenced at the second
site, some members of (the public) raised the alarm that the government was
carelessly risking the health, safety and lives of citizens in the cause of an unproven
vaccine that could precipitate a public health disaster. The trial was immediately
suspended. A commentary on this case, and on the importance of trust, is provided
by Katharine Browne and Doris Schroeder at the end of this chapter. It highlights
differences between this case and a phase I Ebola vaccine trial in Canada in 2014.
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Area of Risk of Exploitation
Phase I clinical trials are trials in which the safety of a new treatment is tested in a
small group of individuals (often healthy volunteers) to evaluate safety and side
effects and to determine dosage. The chances of therapeutic outcomes for the
research participants are almost always zero. In this context, the risk of exploitation
of low- and middle-income country (LMIC) participants is particularly high, as, due
to low education levels, they are more likely to assume that they will beneﬁt
personally. For this reason, phase I clinical studies have previously been carried out
only in high-income countries. However, they are now increasingly also carried out
in LMICs, especially in accordance with community engagement procedures and
where the expected outcomes of the study mostly or exclusively beneﬁt LMICs.
The same applies, with limitations, to phase II clinical trials, whose main purpose is
to assess efﬁcacy. In phase I/II clinical trials in LMICs, it is therefore particularly
important to protect research participants.
Speciﬁc Case
This case study is about a phase I/II clinical trial (testing for safety and immuno-
genicity) of a candidate Ebola virus vaccine in a sub-Saharan African country in
2015.
In early 2015, a team of experts from the country’s Ministry of Public Health
evaluated the availability of facilities for Ebola vaccine trials in certain medical
centres and laboratories. The team included members of the country’s National
Ethics Committee (NEC). Equipment inventoried during this visit, in at least one of
the centres, was marked as a previous donation from the owner of the candidate
vaccine. After these visits, two urban medical centres were retained for the Ebola
vaccine study.
The visits occurred after the Ebola epidemic that had broken out in West Africa
towards the end of 2013 and that had been brought under reasonable control by
2015. The epidemic had severely affected three countries. However, the country of
the candidate vaccine trial had not registered any cases of the Ebola virus disease.
The study was designed as a randomized double-blinded trial in which half of
the research participants would receive the candidate vaccine and the other half a
placebo. The study was sponsored and funded by one of the biggest Northern
multinational pharmaceutical companies, globally well known and highly respec-
ted. The ﬁrst medical centre was to recruit 200 adult research participants and the
second 200 children. The protocol of the study, at least for the ﬁrst recruitment site,
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received ethics approbation from the NEC. Recruitment was nearing completion at
the ﬁrst site when, following complaints from some members of the public, the
study was suspended.
The suspension order was apparently made by word of mouth. The Minister of
Public Health who had initially announced the commencement of the study over the
radio did not announce its suspension through any public media. However, he did
write to the principal investigator (PI) at the local branch of the Northern diagnostic
laboratory to explain that the study had been suspended due to public protests and
that the trial involving children would now be withdrawn too. The general public,
as well as the research participants and their families and communities, knew little
about the study, let alone why it had been suspended, and therefore permitted
themselves the most fanciful speculation about it.1
Case Analysis
This case bristles with ethical problems and issues that go beyond any simple
identiﬁcation of instances of North-South “ethics dumping”. It involves subterfuges
to circumvent standard regulatory procedures and discretion bordering on secrecy –
approaches that would be inconceivable in high-income countries, or anywhere else
where there is sufﬁcient awareness of the stakes of biomedical research and the
ethics of clinical research, particularly that involving human research participants.
The risk of exploitation in this case is not limited to a single rubric such as “no
beneﬁt sharing” or “inadequate informed consent process”, but relates rather to the
exploitation of the general weaknesses and inadequacies of an entire system, par-
ticularly its lack of a credible and adequate research governance and regulatory
framework. This suggests double standards that would also be inconceivable in a
high-income country.
International regulatory texts are simple and clear on the procedural rules for the
ethically acceptable conduct of medical research, particularly clinical trials, with
human beings as research participants. The Declaration of Helsinki, for instance,
states:
The research protocol must be submitted for consideration, comment, guidance and
approval to the concerned research ethics committee before the study begins. This com-
mittee must be transparent in its functioning, must be independent of the researcher, the
sponsor and any other undue influence and must be duly qualiﬁed (WMA 2013: art. 23)
(emphasis added).
Regarding “post-trial provisions”, the declaration states:
In advance of a clinical trial, sponsors, researchers and host country governments should
make provisions for post-trial access for all participants who still need an intervention
1For popular concerns raised in such contexts, see Geissler and Pool (2006).
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identiﬁed as beneﬁcial in the trial. This information must also be disclosed to participants
during the informed consent process (WMA 2013: art. 34).
These minimal conditions were evidently not fulﬁlled for this trial. The members
of the ethics committee that approved the study were all appointees by decree of the
Minister of Public Health and functioned within a civil service system where
obedience to hierarchical superiors was regarded as a duty. It is the view of this
author that by assuming sponsorship of the clinical trial in this case, the Minister
virtually made it the duty of all within the Ministry of Public Health to help
facilitate its accomplishment. This would explain why some members of the ethics
committee were involved in prior site preparations for the trial, which was inap-
propriate for an ethics committee as it compromised ethical oversight of the study
and put the independence and transparency of the ethics committee in serious
doubt.
There is no doubt that all the members of the approving ethics committee (which
in fact acts as the national ethics committee) are highly qualiﬁed in their ﬁelds, but
this does not automatically make them experts in ethics review. The expertise
represented in the committee is roughly as follows: a haematologist, a
parasitologist/epidemiologist, a pneumological epidemiologist, a sociologist, a
demographer, an x-ray oncologist, a pathologist, a jurist, a parasitologist, a surgeon,
a microbiologist/pharmacist, a dental surgeon, an expert in the science of education,
a paediatrician, a civil society member, a traditional practitioner, an expert on
Islamic religion and two community members. This is a highly impressive com-
mittee for science review, perhaps, but not necessarily for ethics review, if no
research ethics training has been provided. And even if such training has been
provided, which usually happens by way of workshops or symposia, every research
ethics committee still needs an ethics expert, meaning someone whose main
business and concern as a member of the committee is ethics aspects of and ethics
issues in the protocol.
The study was suspended before the recruitment of children had begun at the
second site. The inclusion of children in a clinical study designed for testing safety
and immunogenicity is a big ethical issue for which, at best, no justiﬁcation was
available for this study. All over Africa, women and children, because of their
vulnerability, high rate of morbidity, easy availability, naivety and trustfulness, bear
a heavy burden of clinical research. A competent ethics committee would have
checked the burden of research participation against the beneﬁts for research par-
ticipants and their immediate communities, especially where children were
involved.
The whole study involved structures and procedures that, on the surface,
appeared to conform to ethics demands but, in reality, violated the principles of
research participant protection that are paramount in research ethics. The following
section analyses the case further, with speciﬁc reference to the informed consent
documentation.
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The Informed Consent Process
The potential research participant information for this study contained inadequacies
and issues that any qualiﬁed ethics committee should have noticed and raised with
the investigators for redress or amelioration before subject recruitment commenced.
Regarding the informed consent process, the Declaration of Helsinki states:
[E]ach potential subject must be adequately informed of the aims, methods, sources of
funding, any possible conflicts of interest, institutional afﬁliations of the researcher, the
anticipated beneﬁts and potential risks of the study and the discomfort it may entail,
post-study provisions and any other relevant aspects of the study (WMA 2013: art. 26)
(emphasis added).
An analysis of the information sheets given to the potential participants in this
clinical trial shows serious omissions and inappropriate or misleading language for
the context (see also below). Participants were not taken through any informed
consent process other than being approached individually by the study physicians
or their agents at the chosen site of the study, given the information sheets to take
home and asked to come back the next day to sign the informed consent form,
followed by procedural instructions, and payment to them of a sum of approxi-
mately US$20. Furthermore, there was no process of community engagement
beyond the media announcement by the Minister of Public Health emphasizing that
the study had been approved by the World Health Organization (WHO) and was
simultaneously taking place in many countries. In retrospect, the Minister’s
announcement could be judged an inducement which played down the potential
stakes and risks of the study by referring to the approval of the WHO and the fact
that other countries had accepted the trial.
Some of the issues and questions addressed in the ﬁve-page prospective par-
ticipants’ information sheet are quoted below, in italics. Each excerpt is followed by
my attempt to review and critique it in the way a competent and vigilant ethics
committee might have done.
Why is this clinical study being done?
This study is done to test a vaccine against Ebola to make sure that it is safe and that it
brings about a protective response. You can get Ebola by being in direct contact with the
blood or other body fluids of a person who is already sick with Ebola. People infected with
Ebola can have many different symptoms, like fever, severe headache, muscle pain,
weakness, feeling tired, diarrhoea, vomiting, stomach pain and unexplained bleeding or
bruising. Ebola disease can be very severe and is a life-threatening disease.
Only the ﬁrst sentence of the above response addresses the question asked. But it
is misleading and confusing to state that the study is being done “to test a vaccine
against Ebola” whereas the answer to a subsequent question below states that “there
are no vaccines or treatment against the Ebola virus”. The candidate vaccine ought
to be called and described accurately for what it is. The rest of the response is not
relevant to the question: it answers another question that has not been asked,
namely: what is Ebola and how does one get it?
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Who can take part in this study?
You can take part in this study if you are at least 18 years old, healthy, not taking part in
another study, have not been in a country affected by the Ebola epidemic (Sierra Leone,
Liberia and Guinea) and have not been in contact with someone who has Ebola in the last
3 weeks.
In the country of this study, the age of majority and consent is 21. Since clinical
studies need to conform to local laws and regulations, the age of participation here
should be 21, not 18; or else it should be explained that those below 21 would
require the proxy consent of their parent or legal guardian in addition to their own
assent.
Considering the issue of fairness in the recruitment of study participants, it may
be questionable to make the mere fact of having been to an Ebola country and even
of having been in contact with an Ebola patient – without, however, contracting the
disease – an exclusion criterion for the study.
Which vaccine will you get?
You will get the Ebola vaccine, either at the start of the study, or after 6 months into the
study. At the start of the study, half of the people in the study (about 1,500 people) will get
the Ebola vaccine and the rest of the people will get a placebo (dummy vaccine that looks
like a real vaccine but does not have active components in it). Neither you nor the study
doctor can choose or will know which vaccine you receive. This will be randomly decided
by a computer (like the flip of a coin). We will only tell you and the study doctor which
vaccine you received after 6 months into the study, or if there is an emergency.
This response repeatedly refers to an “Ebola vaccine”, even though it does not
yet exist. It also fails to explain in simple ordinary language such terms as “pla-
cebo”, “dummy vaccine” and “active components”, and to illustrate what may
count as an “emergency”. Informed consent processes must avoid jargon, especially
in LMIC settings.
What does this study involve?
The ﬁrst study visit, called a Screening visit, is to check if you can take part in the study.
The study doctor will ask you some questions, do a physical examination and take some
blood to test blood factors. If you are a woman who can get pregnant, the study doctor will
also ask for a pregnancy test. If the Screening shows that you can take part in the study, you
will be in the study for about 1 year. Half of the people to join the study will have extra
study procedures done. … if you are part of the group of people that does NOT need extra
procedures you will: visit the vaccination centre 4 times after the Screening on Day 0,
month 1, month 3 (phone call/home visits), month 6, month 9 (phone call/home visit) and
month 12. At Day 0 visit, you will be vaccinated. This is an injection in the muscle of your
upper arm. After vaccination, you need to stay at the vaccination centre for at least
30 minutes for observation. If you receive the dummy vaccine at the ﬁrst visit, you will be
vaccinated with the Ebola vaccine 6 months later.… During the entire study, we will check
if you have any serious medical conditions. You will not have blood taken during the rest of
the study.
First, here too the use of technical medical terms is problematic (“screening
visit”, “blood factors”, “extra study procedures”, “muscle of your upper arm”,
“serious medical conditions”). Second, this may make a good entry in the notebook
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of the investigator but will not necessarily be meaningful to a prospective subject
without prior verbal explanation. What, for instance, is a barely literate person to
make of “Day 0, month 1, month 3 (phone call/home visits)”? Would s/he not be
wondering how a day could be zero and if s/he would be required to telephone
someone or visit them at home?
What about pregnancy?
We do not know yet if the Ebola vaccine may have an effect on an unborn baby. That is why
you should not take part in this study if you are pregnant or trying to get pregnant. … You
will need to use birth control during the ﬁrst 7 months you take part in this study. Tell the
study doctor if you are pregnant during the ﬁrst 7 months of the study. The doctor will
follow you up until the delivery of the baby.
This explanation about pregnancy is not free of ambiguity. It is quite clear that I
should not take part in the study if I am pregnant or want to get pregnant. It is also
clear that, if I want to have sex during the seven months of the study, I should use
contraception. But telling me that I should inform the study doctor if I get pregnant
during the ﬁrst seven months of the study so that s/he can follow me up until the
delivery of my baby is rather confusing. A study participant might say: “Getting
pregnant and being followed up until delivery is what I want most. So why does the
informed consent documentation say that I should not take part in the study if I am
pregnant or want to get pregnant?” This paragraph crucially fails to explain that
contraception can sometimes fail because no method of contraception or birth
control is 100% effective except abstinence.
What beneﬁts can you expect?
You may not beneﬁt from the Ebola vaccine because we do not know yet if the vaccine will
be able to protect people against Ebola virus.
This is at best an incomplete response to the question. Of course you do not
know yet if the vaccine will be able to protect people against the Ebola virus; that is
the whole purpose of the trial test. But what happens if/when it does prove to be
able to protect people against the Ebola virus disease? How is article 34 on
“Post-Trial Provisions” of the Declaration of Helsinki going to be respected?
What side effects or risks can you expect?
There is a very small risk that you could have an allergic reaction after vaccination. …
That is why it is important that you stay at the vaccination centre for at least 30 minutes
after vaccination, where all medical tools are available to treat an allergic reaction.
To avoid misunderstanding among research participants with low literacy and
education levels, it would be better to rephrase this response in terms of the pos-
sibility, not how small the risk – “It is possible that you could have an allergic
reaction” – followed by an explanation of what an allergic reaction is.
Are there other vaccines or treatments?
So far, there are no vaccines or treatment against the Ebola virus.
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For clarity, the question should be “Are there other vaccines or treatments
against Ebola?” Also note the confusion if one compares this statement with earlier
mentions of a vaccine, for instance in “You will get the Ebola vaccine …” (see
above).
What happens if you leave the study?
If you leave the study we will keep and use the information and samples we collected before
you left the study. We will ask you to return to the vaccination centre one more time for a
safety follow-up.
The obvious follow-up questions not addressed here are: Why would you keep
and use the information and samples you collected even when I have decided to
leave the study? And why should I return to the vaccination centre again after I
have decided to leave? What safety follow-up are you talking about?
Who will be looking at the information from this study?
Your information will be protected in accordance with the most stringent applicable law.
When you sign/thumb print this consent form you agree that your information can be
viewed and used by site staff, [the pharmaceutical company], agencies and independent
ethics committee. … [the pharmaceutical company] may publish the results but your name
will not appear in any publication. If you withdraw consent to use your personal infor-
mation you will no longer be able to continue in the study.
The questions that need addressing here are: what is “the most stringent appli-
cable law” that will protect my information, and why should my name not appear in
any publication of the results in spite of my contribution to it? (See also the
supplementary report after this case study, which describes the pride with which
Canadian research participants in a phase I Ebola vaccine trial made their names
public.)
What happens if you get injured while taking part in this study?
If you are harmed by the vaccination in the study or by any of the study procedures, you
will be compensated. Your study doctor can give you information about how to obtain
compensation in case of injury. You will not be paid for taking part in this study but you
will be paid reasonable travel fees to attend to study visits at the vaccination centre.
This question needs a fuller and clearer answer. Compensation for study-related
injury should not vaguely be referred to the study doctor; it should be explained
clearly. “You will not be paid… but you will be paid…” is not a good formulation
in informed consent information and needs to be rephrased less ambiguously or
even misleadingly.
The informed consent form (certiﬁcate) states:
The study has been explained to me. I have read the information or have had the infor-
mation read to me. I have been given enough time to make a decision. I have had the
chance to ask questions and I am happy with the answers that I have been given. I have
been told that I can change my mind at any time and stop taking part in the study without
giving any reason. By signing/thumb printing this form I agree:
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1. To take part in the study
2. That my information is used as described in this form
3. That my blood samples are used as described in this form
Tick as appropriate (this decision will not affect your ability to take part in the study):
YES. My samples may also be used for future research (at the time of the study or after the
study is ﬁnished) not described in this form with prior approval of the Ethics Committee
NO. Do not use my samples for future research (at the time of the study or after the study is
ﬁnished) not described in this form.
The tickable options above are about something as important as the use of
samples for unknown future research. This ought to be discussed and justiﬁed in
information designed for the prospective participant. As formulated here, the sec-
tion in parentheses is not clear and is liable to be quite confusing: “at the time of the
study or after the study is ﬁnished” should perhaps be changed simply to “after this
study is ﬁnished”.
Talking to two of the potential research participants suggested that the main
motivations for participation were the incentives – the health care beneﬁts and the
money paid. Of course, there are limits to the conclusions one can draw from
talking to only two people, but the literature shows that ﬁnancial incentives and
access to health care are a major driver for enrolment in studies in LMICs
(Mfutso-Bengo et al. 2008; Mduluza et al. 2013). For this reason the case raises
concerns about undue inducements.
Conclusion
The regulation of human subject research and particularly of clinical research is
quite advanced around the globe, to the extent that we can talk about a regulatory
infrastructure, whose presence or absence in any given context should indicate a
priori whether or not research involving human subjects can ethically be conducted
within that context. Such regulatory infrastructure would include, in a
non-authoritarian and genuinely democratic context, a legal framework that respects
fundamental human rights, especially freedom of inquiry and expression, overseen
by well-constituted, qualiﬁed and genuinely independent ethics review committees.
The absence of such infrastructure or doubt about its genuineness, in spite of
appearances, delimits a no-go area for ethical research. The veriﬁable existence of
such an infrastructure should be a precondition for human subject research, espe-
cially in resource-destitute settings and particularly in the ﬁrst two phases of
investigation. Transparency must be part and parcel of any procedures where
publicly available regulations need to be followed. Systemic faults tend to render
compliance with good procedural rules and practices not only difﬁcult, but
impossible. It is not just difﬁcult, but impossible, to carry water in a straw basket for
any distance.
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Supplement to the Ebola Vaccine Trial Case – The
Importance of Trust
This is an excerpt from a Canadian newspaper article:
Hundreds of Nova Scotians are volunteering to be injected with an experimental vaccine
that might cause aches and fever – but could protect against the Ebola virus.
Within minutes of the Nov. 14 announcement that Halifax’s IWK Health Centre was
chosen to hold the clinical trial to test Canada’s Ebola vaccine, the phones started ringing
and e-mails began arriving from people who wanted to participate. A week later, the trial
team has heard from about 300 people – it only needs 40 healthy individuals, between 18
and 65, for this ﬁrst-phase trial (Taber 2014).
The phase I trial for the Canadian-developed Ebola vaccine (VSVDG-ZEBOV)
was conducted at the Izaak Walton Killam Health Centre in Halifax, Nova Scotia.
The trial involved 11 clinic visits over six months, each requiring a blood draw.
Participants received CAD 1,125 for their participation in the entire trial.
One of the authors of this supplement, Katharine Browne, is involved in a study
examining the factors that motivate healthy volunteers to participate in phase I
vaccine trials. The study involves a survey of the motivations of healthy volunteers
for the Canadian phase I Ebola vaccine trial, as well as a phase I trial for a PAL
adjuvant.2 The central hypotheses of the study are that:
1. The ﬁnancial incentive will be the dominant motivation that participants
identify.
2. Other motivations will include a desire to contribute to the development of a
vaccine, and a desire to help others.
3. The high-proﬁle nature of the Ebola vaccine trial will play a factor in participant
motivations.
Surprisingly, and contrary to the ﬁrst hypothesis, preliminary ﬁndings from the
study reveal that ﬁnancial incentives are neither the sole nor the main determinants
in motivating individuals to participate in vaccine trials. The ﬁndings do, however,
conﬁrm the second hypothesis: that participant motivations include desires to help
develop a new vaccine and to help others. One research participant explained to the
media that participating in the trial had been a life-changing experience for her
(CTVNews.ca Staff 2014). When asked about the ﬁnancial incentive provided for
participation, she said that she would put it towards her university studies. She also
noted that another research participant had donated the money he received for
participating to a children’s charity (CTVNews.ca Staff 2014). Concerning the third
hypothesis, the ﬁndings are unable to conﬁrm or deny that the high-proﬁle nature of
the Ebola vaccine trial contributed to trial participation.
2An adjuvant is an immune booster that can be added to a vaccine. PAL is the name of a particular
adjuvant.
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The study ﬁndings, along with the anecdotes from trial participants, support a
general trend away from the selﬁsh actor model that underlies classical economic
theory and that informs policies and practice, including payment for research
participants.
The Canadian experience of the phase I Ebola vaccine trial provides a
remarkable contrast to the almost identical study at the African site. One possible
explanation for the over-recruitment at the Canadian site compared with the public
outcry at the African site could be the extent to which the two trials differ in the
levels of trust between research participants and researchers. The suggestion here is
that there is a lack of trust in North-South collaborations and that this dramatically
affects the recruitment of research participants. Further research is required to
conﬁrm or deny this hypothesis. To enhance trust in such collaborations, we
re-emphasize Tangwa’s two main conjectures:
1. The veriﬁable existence of an infrastructure that respects fundamental human
rights should be a precondition formedical research involving human participants,
especially in LMICs and particularly in the ﬁrst two phases of investigation.
2. Transparency is essential when conducting trials in LMICs.
In addition, Tangwa’s analysis of the informed consent documentation reveals a
notable ignorance of local requirements (e.g. researchers seeming unaware of the local
age of consent). This is likely to contribute to distrust in North-South collaborations.
One could venture that the non-existence of a reliable governance structure and
non-transparency, combined with insensitivity to local requirements, have a major
impact on trust.
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Chapter 7
Hepatitis B Study with Gender Inequities
Olga Kubar
Abstract This case study is about a study entitled “Comparable randomized
double-blind investigation of safety and immunogenicity of vaccine against
Hepatitis B in healthy adult subjects” proposed in Russia with an international
sponsor. There were indications of elements of exploitation, which consisted of
inadequacies in the study’s design compared with its announced purpose, and the
indirect inclusion of women research subjects in the clinical trial without their in-
formed consent. On the basis of noncompliance with the applicable regulatory and
ethical requirements the study was not approved by the local ethics committee (LEC).
Keywords Clinical trial  Hepatitis B  Russia  Women  Exploitation
Unethical  Ethics committee
Area of Risk of Exploitation
Healthy volunteers in clinical trials contribute to medical progress without any
beneﬁts to themselves. In addition, this case is of interest with regard to gender
inequities in research.
Case Description
This case study is based on an evaluation undertaken by the local ethics committee
(LEC) of the research institute in Russia at the end of 2014. All documentation
required for a complete ethical review of the proposed study was submitted in
accordance with the national law (Russian Federation 2005), the LEC’s standard
operating procedure and international rules of good clinical practice. The proposed
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clinical trial was entitled: “Comparable randomized double-blind investigation of
safety and immunogenicity of vaccine against Hepatitis B in healthy adult subjects”.
The main purpose of the proposed clinical trial was to study the safety and
immunogenicity of a vaccine against hepatitis B in comparison with a vaccine
already marketed in Russia, with a view to its future registration in the country.
The study design envisaged two groups of participants made up of both men and
women. The ﬁrst group would be vaccinated by an investigational product (a
vaccine proposed by an external sponsor), and the second (control) group would be
given a well-known vaccine registered in the country. According to the protocol,
the female sexual partners of male participants would be indirectly involved. For
this group, the study assigned special requirements.
The requirements for these women, who were not legally and directly involved
in the clinical trial, included a prohibition on and prevention of pregnancy, through
the use of contraception, during the entire eight months the study lasted and for one
month afterwards, even if the actual participant – their sexual partner – withdrew
from the study.
Detailed information would be collected about any pregnancy and its outcome,
and any adverse events (or serious adverse events) would be included in the
database as part of the monitoring process.
The investigational product had been well investigated in a series of earlier
clinical trials (as is clear from the protocol, investigation brochure and references),
and already approved in the country of the sponsor and many other high-income
countries. It was available on the open market for adults and children above ten
years old. For this reason, the appropriate design of the proposed clinical trial in
Russia would have been for a phase III study. However, the protocol design was
equivalent to a phase I or II study.
Seventeen visits of the volunteer participants to the investigator centre were
planned during the eight months of the clinical trial and for one month after its
completion. Visit procedures involved a detailed physical examination and the
collection of blood and urine samples for a wide spectrum of tests. The participants
would come to the centre in the morning and spend a few hours there for obser-
vation. In addition, they would have to buy and use the requested products for
contraception.
As a rule, healthy volunteers participating in clinical trials cannot expect any
beneﬁts. In this case, an external (i.e. non-Russian) sponsor declared that beneﬁts
were planned, because the participants (volunteers) would be vaccinated against
hepatitis B, and would therefore be protected from this infection in the future.
Analysis
The case study shows ethical inadequacy at several levels.
The suggestion that the study would be beneﬁcial to participants is controversial.
Vaccination against hepatitis B is included in the national immunization calendar of
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the Russian Federation. This is done with domestically and internationally produced
vaccines that are registered and have been granted permission for use by approved
order (Russian Federation 2014). Vaccination against hepatitis B is freely available
to everybody, and obligatory for high-risk groups (newborns whose mothers are
HbsAg carriers, or hepatitis B patients in the third trimester of pregnancy).
Therefore there were no beneﬁts for participants taking part in the clinical trial.
The autonomy of the women who were indirectly involved in the study was not
respected. There was no information or conﬁrmation in any part of the protocol to
the effect that these women (indirect participants) should be appropriately informed
about the procedures, or that their informed consent should be obtained.
In addition, their indirect involvement in the clinical trial was not covered by
insurance, even in the case of pregnancy with a serious adverse event (a congenital
anomaly or birth defect), because theywere not included in the framework ofﬁnancial
contracts and insurance coverage for study participants. No other guarantee (medical,
ﬁnancial etc.) for these women was described in the protocol or any other study
documents. This violates Russia’s compulsory regulations on good clinical practice:
In research which does not connect with treatment (without any beneﬁts for potential
participants from a medical point of view) only subjects who personally give, write and date
the informed consent can be involved (Russian Federation 2005: item 4.8.13).
The situation for women indirectly involved in the clinical trial without consent
would also contradict the universal ethical principles of the Declaration of Helsinki,
October, 2013 regarding vulnerable groups and populations:
Article 22: “The protocol should include information … regarding provisions for treating
and/or compensating subjects who are harmed as a consequence of participation in the
research study”
Article 25: “Participation by individuals capable of giving informed consent as subjects in
medical research must be voluntary … no individual capable of giving informed consent
may be enrolled in a research study unless he or she freely agrees”
Article 26: “The potential subject must be informed of the right to refuse to participate in
the study or to withdraw consent to participate at any time without reprisal” (WMA 2013).
The requirement to carry out a pregnancy test and prevent pregnancy throughout
the study also violated the women’s reproductive rights and represented a direct
intervention in the family’s planning.
The study documentation required considerable attention to be devoted to the
registering and following up of information concerning cases of pregnancy or
outcomes in these women, without their informed consent. This meant that their
personal information could be used without their agreement. It also contradicted the
general norms guaranteeing the protection of personal data set by the Russian
Federation’s Federal Law on Information, Information Technologies and the
Protection of Information (Russian Federation 2006a).
In addition the Federal Law on Personal Data of 27 July 2006 (Russian
Federation 2006b) (updated 2015–2016), deﬁnes maintaining the conﬁdentiality of
information as an obligatory duty, and requires this information not be transferred
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to third parties without the direct consent of its owner. According to article 31 of the
Fundamentals Of The Legislation Of The Russian Federation On Health Protection
No. 5487-1 (2007), “information contained in the person’s medical documents shall
make up a medical secret.”
The situation is also in conflict with the rules of the Declaration of Helsinki,
under the heading “Privacy and Conﬁdentiality”: “Every precaution must be taken
to protect the privacy of research subjects and the conﬁdentiality of their personal
information” (WMA 2013: art. 24).
Two other areas of exploitation identiﬁed in this proposed clinical trial were the
unreasonable exploitation of private time and the ﬁnancial exploitation of
participants/volunteers. The study, as noted above, was very time-consuming for
participants and there was no compensation for the expenses of transport, contra-
ceptive products or the disruption of normal daily work and activities. This violates
the most recent version of the Declaration of Helsinki: “Appropriate compensation
and treatment for subjects who are harmed as a result of participating in research
must be ensured” (WMA 2013: art. 15).
This case also points to gender injustice. One could argue that one can detect
covert discrimination against vulnerable populations indirectly involved in the
study. A fundamental understanding of the gender aspects of research should be
guided by the spirit and letter of the Universal Declaration of Human Rights of
1948, which states that “the peoples of the United Nations have in the Charter
reafﬁrmed their faith in fundamental human rights, in the dignity and worth of the
human person and in the equal rights of men and women” (UN 1948: preamble).
The ethical conflicts raised by this case study suggest some general arguments
that women can be discriminated against through their limited access to partici-
pation in clinical trials and the violation of their reproductive rights. The risk of
exploitation is especially present when the golden rules of the protection of au-
tonomy, conﬁdentiality and human vulnerability are ignored. The moral force for
the realisation of ethical concepts in medical research through the correct process of
freely given and obtained informed consent is presented in the UNESCO Universal
Declaration on Bioethics and Human Rights (UNESCO 2005) and in many other
national and international documents, including the Convention on the Elimination
of All Forms of Discrimination against Women, adopted by the United Nations in
1979 (UN 1979).
In summary, the following are the ethical issues raised by this case study:
• gender inequity
• violation of reproductive rights
• inappropriate promises of beneﬁt
• lack of insurance
• conﬁdentiality not preserved
• unreasonable use of private time
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Outcome of the Application for Ethics Approval
All properly submitted application documents were reviewed according to the
established review procedure (the LEC’s standard operating procedure). On the
basis of detailed review, discussion took place at a meeting of the LEC with a
quorum of its members present. An independent consultant (a specialist in
bioethics) was invited to join the meeting after signing an agreement on conﬁ-
dentiality and conflict of interest. Decision-making took place after sufﬁcient time
had been allowed for discussion, and was reached by consensus in accordance with
the LEC’s standard operating procedure. On the basis of disapproving or unfa-
vourable opinions from all members of the LEC, the decision was made in the
negative, with detailed and clearly stated reasons provided to the applicant. The
clinical trial was not approved.
Lessons Learned and Recommendations
• The system of ethical review worked well in this case, as an unethical study was
not approved.
• The possibility of indirectly masking/silencing and blindly exploiting women
(pregnant or otherwise) in a study requires attention.
• Gender variety and an assessment of its influence on risk-beneﬁt ratios should
be an integral part of clinical trial planning.
• Clinical trials should exclude any opportunity for non-informed or non-agreed
interventions that will impact on the privacy of participants’ lives, especially in
the context of women’s reproductive rights.
• Unreasonable risks and burdens, including inadequate compensation and an
excessive time burden, must be avoided.
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Chapter 8
Healthy Volunteers in Clinical Studies
Klaus Michael Leisinger, Karin Monika Schmitt
and François Bompart
Abstract Patients participate in clinical trials for a variety of reasons, the ﬁrst of
which is often the prospect of direct health beneﬁts for themselves. Healthy vol-
unteers, by deﬁnition, cannot expect such beneﬁts. In resource-limited settings,
healthy volunteers are most often poor people with low literacy levels who might
not understand the risks they may be taking and are in no position to refuse ﬁnancial
incentives. For many of them, participation in clinical trials is a critical source of
income. An added complication is that some participants covertly enrol in several
studies simultaneously, in order to increase their income. This exposes the volun-
teers to medical risks (e.g. drug-drug interactions), and also potentially biases study
data. Our recommendations are that speciﬁc efforts are made to ensure proper
informed consent of this vulnerable population and that compulsory national
databases be established to ensure that healthy volunteers do not participate
simultaneously in several studies.
Keywords Clinical trials  Healthy volunteers  Resource-limited settings
Risk  Vulnerability  National databases
Area of Risk of Exploitation
In high-income countries, healthy volunteers are sometimes university students
with a good literacy level and reasonable living standards. In resource-limited
settings however (including in high income countries), healthy volunteers are most
often poor people with low literacy levels who may not understand the risks and are
in no position to refuse ﬁnancial incentives. For many of them, participation in
clinical trials is a critical source of income. As a result, even though they might sign
informed consent documentation, they are a highly vulnerable group that deserves
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the “speciﬁcally considered protection” recommended by the World Medical
Association’s Declaration of Helsinki:
Some groups and individuals are particularly vulnerable and may have an increased like-
lihood of being wronged or of incurring additional harm.
All vulnerable groups and individuals should receive speciﬁcally considered protection
(WMA 2013: art. 19).
The Problem
Informal discussions and a literature review conducted by the authors of this case
study have revealed little professional interest in or attention to ethical considera-
tions regarding healthy volunteers from low-income settings. There is very little
data published on the number of clinical studies using such volunteers, making it
difﬁcult to assess the scope of the issue. While most ﬁrst-in-human (phase I) clinical
trials seem to be performed in high-income countries to ensure the quality of these
critical studies, a very large number of studies in healthy volunteers are performed
in low- and middle-income countries (LMICs) (Ravinetto 2015:3), particularly
bioavailability and bioequivalence studies needed to compare originator and generic
medicines.
Clinical studies using healthy volunteers are performed by international as well
as local companies, often through contract research organizations (CROs). One of
the few papers available on healthy volunteers in LMICs shows how CROs in India
resort to “middlemen” to recruit poor participants, who have no understanding of
what the studies are about and who sometimes participate in studies without
informing their families. They basically “chose to participate in the trials due to
insufﬁcient income and unstable jobs” (Krishna and Prasad 2014).
Resource-poor settings are not limited to the LMICs. A few papers describe the
situation of healthy volunteers in the US who have become “professional volun-
teers” and for whom study participation is a way to earn a living (Edelblute and
Fisher 2015; Eliott and Abadie 2008). One can assume that many of the ethical
issues related to US “professional volunteers” are highly relevant to their coun-
terparts in LMICs. Many have developed tactics to conceal their involvement in
several studies at the same time and have become experts at manipulating screening
tests for enrolment in clinical trials, for instance by concealing their participation in
concomitant studies, medical conditions, concomitant medications or substance
abuse (Edelblute and Fisher 2015; Devine et al. 2013). These concealments expose
the volunteers to medical risks (e.g. drug-drug interactions) and also potentially bias
study data, for instance in terms of safety or pharmacokinetic proﬁles of the tested
drugs (Eliott and Abadie 2008).
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The Way Forward
We believe that speciﬁc efforts should be expanded to ensure that healthy volun-
teers are able to understand the key features of the studies (Phase I, II and III) they
are offered to participate in, and are therefore able to provide genuine informed
consent. This could be done by ensuring that documents are speciﬁcally designed
for a population with low scientiﬁc literacy levels. Establishing compulsory
national databases for healthy volunteers appears to be the best way to avoid some
of the risks related with participation in multiple studies, detailed above (Devine
et al. 2013; Resnik and McCann 2015). Some countries (e.g. France and Morocco)
have set up or are in the process of setting up national healthy volunteers’ databases
to ensure that a given individual’s involvement in clinical trials is recorded, that
sufﬁcient “wash-out periods” between trials are respected and that payments made
to volunteers are tracked so as not to exceed certain levels.
Setting up national databases will require changes in countries’ legislation that
can only result from the mobilization of key stakeholders, including pharmaceutical
companies. In addition to logistical issues that will have to be solved for such
systems to be effective, ethical concerns related to conﬁdentiality and data pro-
tection issues will have to be addressed. The EU-based pharma industry should
support initiatives to ensure that this neglected, highly vulnerable population ben-
eﬁts from the best possible safeguards.
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Chapter 9
An International Collaborative Genetic
Research Project Conducted in China
Yandong Zhao and Wenxia Zhang
Abstract In 1995, a research team from a renowned US university started col-
lecting blood samples from villagers living in Anhui province, China, with the
cooperation of local research institutes and the Chinese government. In 2000, the
US university team was accused of violating research ethics principles by not
adequately informing the participants about the research and not sharing beneﬁts
fairly. Subsequent investigations by American and Chinese media and authorities
showed that the US research institute, its research personnel and a pharmaceutical
company involved were beneﬁting substantially from the project, while the Chinese
research participants and the government were not. Three levels of exploitation can
be distinguished in this case:
• the exploitation of local individual citizens as human research participants
• the exploitation of the local scientiﬁc community in China
• the exploitation of the country’s national interest
In order to avoid such exploitation, high-income countries as well as low- and
middle-income countries should strengthen their institutional arrangements and
improve their cooperation mechanisms, in order to ensure that both sides beneﬁt
equally from international science and technology cooperation.
Keywords US genetic research team  China  Blood samples
Collaborative study  Exploitation
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Area of Risk of Exploitation
Genetic studies in urban and rural areas in Anhui province are the topic of this case
study. One of the reasons why the case shows a risk of exploitation is that Anhui is
not as economically advanced as its neighbouring provinces. For example, in 2015,
the GDP per capita in Anhui was CNY 35,997 (EUR 4,878) (Anhui 2016), far
lower than that in the more developed neighbouring provinces, such as Jiangsu at
CNY 87,995 (EUR 11,925) (Jiangsu 2016), Zhejiang at CNY 77644
(EUR 10,523) (Zhejiang 2016) and Hubei at CNY 50,520 (EUR 6,847) (Hubei
2016).
Background
Since the launch of reform and opening up in the 1970s, international science and
technology (S&T) cooperation has been an important means for lifting China’s
capability and level of S&T innovation. It has also been an indispensable part of
China’s S&T development. To promote international S&T cooperation, the Chinese
government has formulated a series of documents1 including the National Outline
of International Scientiﬁc and Technological Cooperation in the Tenth Five-year
Period; the Outline for the Implementation of International Scientiﬁc and
Technological Cooperation Programme in the Eleventh Five-year Period; and the
Special Programme on International Scientiﬁc and Technological Cooperation in
the Twelfth Five-year Period. The national special programme on international
S&T cooperation was also added to the system of national S&T programmes in
2001.
In pursuing international S&T cooperation, China has upheld the principles of
equality, mutual beneﬁt and common development. From cooperation based on
joint research projects in the earlier period to today’s all-round cooperation cov-
ering skilled professionals, scientiﬁc bases and projects, China’s international S&T
cooperation has grown and continues to grow in both breadth and depth. Through
years of development, China has emerged as one of the most important partners for
joint scientiﬁc research in the world, and has established cooperative relations on
S&T with more than a hundred countries and regions. Joint research efforts
involving Chinese and international scientiﬁc research professionals are growing
wider and deeper.
China’s share of global science and engineering publications has pulled within a percentage
point of those from the United States, according to the latest research statistics published by
the US National Science Foundation (NSF) (Witze 2016).
1These documents (and others referred to later) are not available in English and have therefore not
been included in the reference list.
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Of the 82 items in Top Ten News of Basic Research in China (later known as the
Top Ten Scientiﬁc Advances in China) between 2005 and 2012, 43 (52% of the
total) are about international cooperation projects, while papers based on interna-
tional cooperation account for 54% of the 100 key academic papers in the relevant
ﬁelds (Cheng et al. 2015).
Mr Jin Xiaoming, former director-general of the Department of International
Cooperation of China’s Ministry of Science and Technology, has pointed out that in
a world where globalization is the trend in S&T progress, an internationalization
strategy is the only way to build China into an innovative country. Without
internationalization or international cooperation, China will suffer immensely in its
pursuit of advanced S&T (Jin 2012).
For years, international S&T cooperation has played an important role in
facilitating China’s S&T progress, lifting the scientiﬁc research performance and
international influence of Chinese scientists, and producing many successful
examples of mutually beneﬁcial cooperation. However, it is undeniable that
problems of inequality and unfairness also exist in joint research projects, some of
which have undermined the interests of the Chinese public and of the scientiﬁc
community, and even China’s national interests.
A strong case in point is that scientiﬁc research institutions and personnel from
some high-income countries (HICs) have built on their advantages of capital and
project experience to make the most of the eagerness of Chinese scientists to make
their presence known in the international academic community, and have exploited
the flaws and loopholes in China’s existing laws and administration to engage in
unethical R&D activities in violation of international norms, scientiﬁc ethics and
even Chinese laws. This has included:
• conducting clinical experiments on human research participants in China which
are banned in HICs
• collecting samples in China for commercial purposes
• harvesting China’s biological resources and undercutting the intellectual prop-
erty rights of Chinese scientiﬁc research personnel
• conducting human experiments and/or collecting blood samples without pro-
viding sufﬁcient information to the participants
• exploiting information asymmetries to conceal information about the
experiments
• ignoring and violating the participants’ rights to know
These problems are particularly serious in ﬁelds that undertake research on
medical treatment, pharmacy, genetics, and environmental and air pollution, as well
as research projects with potential commercial interests. The “genetic harvest”
project conducted by the US University in collaboration with Chinese medical
research institutions on farmers in Anhui province in the 1990s is a typical case in
point.
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Speciﬁc Case and Analysis
On 20 December 2000, a Washington Post article titled “An isolated region’s
genetic mother lode” (Pomfret and Nelson 2000) disclosed that a Chinese American
researcher of a renowned US University had been collecting blood samples from
villagers living in the Dabie Mountains region of China’s Anhui province since
1995 with the ﬁnancial support of the National Institutes of Health (NIH) and
biopharmacy companies. The blood samples were transferred to the US university’s
genetic bank for research into asthma, diabetes, hypertension and other diseases.
Because of the value of these carefully selected blood samples to the research and
development of new drugs, the US team received a large amount of research
funding from international organizations. The report exposed the loss of China’s
genetic resources and triggered a stir both in China and worldwide.
The US university’s genetic harvest project, conducted in Anqing city in Anhui
province between 1994 and 1998, involved tens of thousands of farmers in eight
counties. The project, led by an associate professor at the US university as the
“chief scientist” conducted genetics studies on multiple diseases, including asthma,
high blood pressure, obesity, diabetes and osteoporosis, while the experiments on
asthma and hypertension were funded by the NIH (Pomfret and Nelson 2000;
Xiong and Wang 2001, 2002).
The principal investigator from the US team also collaborated with a US
pharmaceuticals company, and received its ﬁnancial support. The project had three
Chinese partners, Beijing Medical University, Anhui Medical University
(AMU) and Anqing Municipal Bureau of Public Health. The US-based principal
investigator started working with the AMU School of Public Health in 1993, and set
up the Anhui Meizhong Bio-medicine and Environmental Health Institute in
Anqing. The institute chose the Anqing Bureau of Public Health as its local partner,
and selected the population groups suitable for taking samples based on grass-roots
investigation. It collected blood samples through physical examination and acquired
DNA samples of the target group for research purposes. The joint research project,
which was conducted under the guise of free physical examinations for the farmers,
mobilized the local population with the help of the local government. Blood
samples were collected from farmers in the eight counties of Anqing city:
Zongyang, Huaining, Qianshan, Tongcheng, Taihu, Wangjiang, Susong and Yuexi.
Media reports and the complaints of research personnel from the US university
later exposed details of certain parts of the project that were suspected of com-
promising research ethics. The asthma project is an example: the approved number
of participants was 2,000, but 16,686 were recruited. The research personnel also
changed the amount of the ﬁnancial subsidies for each recruit for food, travel and
job leave allowances; this was intended to be USD 10 per day, but participants were
paid an actual amount of only CNY 10 to CNY 20 per day (USD 1.50 to USD 3).
In addition, the actual volume of each blood sample was much higher than
approved. And the bronchodilators used were also different from what had been
approved (Xiong and Wang 2002).
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According to the investigation by Chinese journalists, the collection of genetic
samples had not been sanctioned by the relevant ethics committee in China (Xiong
and Wang 2002). There were also serious breaches of the requirements to keep the
participants informed. Many farmers who participated in the physical examination
were not aware they were taking part in research. They were never shown or briefed
about the “letter of informed consent” , and did not sign or put their ﬁngerprints on
any such document. They did not even know which institution they had given their
blood samples to, and nobody told them about the real purpose and results of their
“physical examination” or the rights and beneﬁts they were entitled to as part of
their contribution to research. The asthma project was only one of the dozen human
genetic research projects conducted by the US team in China. Other projects also
involved the genetic screening of blood samples collected from Chinese farmers for
the purpose of establishing the genetic links behind diseases like hypertension,
diabetes, obesity and osteoporosis. Many of these projects were ﬁrst supported by
the US pharmaceutical company before NIH funds flowed in (Xiong et al. 2003).
In March 1999, the US University sent a team to China to ensure that the Anhui
research was ethically and scientiﬁcally sound. Five months later, regulators from
the US Department of Health and Human Services launched an investigation into
the US university’s genetic research in China. In March 2002, the department found
that the genetic project in China seriously violated the regulations in multiple
respects, including medical ethics, participant safety, and supervision and man-
agement (Yangcheng Evening News 2002). On 2 May 2003, the US university
published the investigation results of the US government, which stated that there
had been some procedural errors in supervision and record-keeping, but no par-
ticipant was found to have been harmed in any way, so the school would not be
penalized (HSPH 2003). Some biomedical experts and ethicists in China expressed
regret about these results. They insisted that the studies had apparently violated
basic research ethics, and called for a joint US-Chinese review of the experiments
(Pomfret and Nelson 2000).
In this international research cooperation on a “genetic harvest”, the actors and
participants included both international and Chinese research institutes and research
personnel, international companies, local government and the local residents who
participated in the study.
During this cooperation, the US university, from its commanding position as a
world-famous, authoritative international scientiﬁc research institute with ﬁrst-class
research personnel and advanced technologies, attracted the participation of
Chinese partners and sold them the idea of building partnerships and the oppor-
tunity for co-authorship with US research personnel in return for the provision of
genetic resources used for research purposes. As a result, they obtained access to a
valuable pool of research data resources.
In 2003, the Chinese Ministry of Health and the Chinese Administration of
Quality Supervision, Inspection and Quarantine jointly issued regulations limiting
the export of special medical articles involving human genetic resources. However,
most of the DNA samples the US team had collected in Anhui had already been
shipped to the US. The principal investigator himself admitted that for the asthma
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research alone, 16,400 DNA samples had been transferred to the US (Zhao and Cai
2013). In 2002 and 2003, he set up a biopharmaceutical company and a biophar-
maceutical research institute in China. Several Chinese research personnel who had
participated in the genetic project in Anhui became his partners.
The US pharmaceutical company became the ultimate beneﬁciary after sup-
plying research funds. As part of the agreement signed with the US university, they
obtained the genetic information of Anhui farmers and claimed that it owned the
relevant patents. In July 1995, the company announced that it was in possession of
a large collection of asthma genetic samples from China. Soon afterwards, a large
Swedish pharmaceutical company, invested USD 53 million in the pharmaceutical
company for research into respiratory disease. The company’s control of obesity
and diabetes genes from China attracted another commitment of USD 70 million
from a pharmaceutical giant. The stock price of the company soared from USD 4
per share, when it was listed in May 1995, to more than USD 100 per share in June
2000. Several of the company’s senior executives earned a net proﬁt of over
USD 10 million each through trade in stocks (Xiong et al. 2003).
In striking contrast, the research participants from China received very few
beneﬁts from the project. Chinese research institutes and research personnel did
gain the opportunity of working with renowned international research institutes,
access to research funds and the co-authorship rights to scientiﬁc papers published
in international academic journals – all of which appeal to most Chinese scientists –
but the local residents who participated in the studies received nothing but a free
meal and an insigniﬁcant sum of money in travel and job leave allowances. In the
words of a Chinese journalist, it was China’s national interests and the unprotected
Chinese farmers that were most harmed by the project, and it was the big US
companies, research institutes and research personnel that received the real beneﬁts
(Xiong et al. 2003).
Lessons Learned
This case illustrates the dilemma faced by China and other low- and middle-income
countries (LMICs) in conducting international S&T cooperation. On the one hand,
opening up and cooperation are an important means for LMICs to build their
research capability and achieve faster development. On the other hand, given dis-
advantages in their capacity for S&T innovation, including the ability to acquire
information, and the inadequacy of ethical review and relevant governance systems,
it is extremely difﬁcult for them to develop equal partnerships with HICs in S&T
cooperation.
Although the academic communities of HICs have established a relatively
mature system of ethical standards for scientiﬁc research, its research personnel,
once working outside their home countries and in a relatively loose regulatory
environment, can exploit the systemic loopholes and regulatory “vacuum” of a host
country, intentionally or otherwise, and seek improper beneﬁts through potentially
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illegal acts. In particular, in those research projects driven by commercial interests,
when capital uses its economic and technological advantages to exploit resources
and beneﬁts from LMICs in the guise of scientiﬁc research, those countries ﬁnd it
difﬁcult to resist. Different levels of exploitation might be found in this process,
including the exploitation of local individual citizens as human research partici-
pants, of the local scientiﬁc community and of local countries’ national interests.
What has happened in China is something many LMICs have probably expe-
rienced. Most of the cases of international institutions, companies and research
personnel exploiting China’s biological resources happened in the 1980s, the 1990s
and the beginning of the 21st century. This had a lot to do with China’s inadequate
management and regulatory system, the lack of substantive ethical review and
insufﬁcient awareness of the need to protect rights and interests during that period.
In recent years, the Chinese government and the scientiﬁc community have gained a
deeper understanding of this problem and have taken a series of positive measures.
In November 1998, the Chinese Ministry of Health established the Committee of
Ethical Review on Bio-medical Research Involving the Human Body. To regulate
international cooperation in genetics, China promulgated the Provisional Methods
for the Management of Human Genetic Resources in 1998, which clearly stipulated
that international cooperation on China’s genetic resources must be conducted on
the basis of equality and mutual beneﬁt, with a formal agreement or contract, the
approval of the Chinese government and informed consent in the collection of
samples.
In 2003, the Chinese Ministry of Health and the Chinese Administration of
Quality Supervision, Inspection and Quarantine jointly issued a notice which pre-
scribed that special medical articles involving human genetic resources were not to
be taken abroad without authorization. The Methods for the Ethical Review of
Human-involved Bio-medical Research (Provisional) were promulgated in 2007.
We ﬁnd that with the gradual improvement of relevant management rules and
regulatory systems in China, the number of cases involving the exploitation of
China’s resources for biological research purposes is diminishing. China has
strengthened the rules and regulations concerning intellectual property rights pro-
tection, generic resources protection and ethical review in international cooperation,
enhanced the relevant management and supervision, and closed the loopholes in the
administration of research.
At the same time, as China increasingly opens up to the world, its S&T coop-
eration with international partners is also widening and deepening, and more and
more overseas Chinese students are returning to China. All these factors have
greatly mitigated the problem of knowledge and information asymmetry, and have
enhanced public awareness of the need to protect rights and interests. As a result,
there are fewer cases of HICs using their R&D advantage to exploit China’s
resources through international cooperation.
In conducting international cooperation, LMICs can only reduce and prevent the
occurrence of such cases when they are clear about their own resource advantages,
build stronger awareness of the need to protect rights and interests, and improve the
relevant management systems. In particular, in terms of the protection and
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utilization of traditional local knowledge and the protection of rights and interests
related to biological resources generally, and genetic resources speciﬁcally, LMICs
need clear awareness of these issues, while the international community should also
give them more protection in this regard.
Recommendations
To reduce exploitation in international S&T cooperation and conduct international
cooperation truly on the basis of equality and mutual beneﬁt, we must strengthen
our efforts in the following respects:
• We need to foster a stronger awareness of mutually beneﬁcial cooperation in the
international community. Countries – big and small, rich and poor, developed
and developing – must all uphold the established principles of equality, mutual
beneﬁt and sharing in international S&T cooperation, and incorporate these
principles into the framework of research ethics and responsible research and
innovation.
• The research institutes and research personnel of HICs must abide strictly by the
relevant international norms and ethical standards, especially international
standards concerning the protection of human rights, and the participants’ right
to be informed, right to privacy and intellectual property rights. In this context,
the regulatory agencies of HICs should strengthen not only the management and
supervision of the irregularities happening in their own countries, but also the
institutional design, in order to ensure effective supervision of improper acts
committed by their research institutes and research personnel in research
cooperation with other countries.
• LMICs should strengthen the building of ethical standards, promote knowledge
of modern biotechnologies and enhance public awareness of the importance of
protecting genetic resources, germplasm resources and patents in order to avoid
falling into the trap of technological exploitation, manipulation and deprivation.
In particular, they should be alert to the so-called joint R&D activities of certain
agencies and the personnel of HICs who might exploit the disadvantages of
LMICs and regions – such as poverty, hunger and information asymmetry – in
order to use these as the experimental subjects for research and the utilization of
technologies without proper compensation.
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Chapter 10
The Use of Non-human Primates
in Research
Kate Chatﬁeld and David Morton
Abstract The use of non-human primates in biomedical research is a contentious
issue that raises serious ethical and practical concerns. In the European Union,
where regulations on their use are very tight, the number of non-human primates
used in research has been in decline over the past decade. However, this decline has
been paralleled by an increase in numbers used elsewhere in the world, with less
regard for some of the ethical issues (e.g. genetic manipulations). There is evidence
that researchers from high-income countries (HICs), where regulations on the use of
non-human primates are strict, may be tempted to conduct some of their experi-
ments in countries where regulation is less strict, through new collaborative efforts.
In collaborative ventures, equivalence in the application of ethical standards in
animal research, regardless of location, is necessary to avoid this exploitation.
Keywords Animal experimentation  Animal ethics  The three ‘Rs’
Non-human primates
Area of Risk of Exploitation
This case study applies both to academic researchers and to political entities sup-
porting such research. Many areas of research using animals cause public concern,
but none more so than those involving non-human primates. European Union
Directive 2010/63/EU (EU 2010) imposed several stringent conditions on their use
in research, including their acquisition, scientiﬁc reasons for their use, husbandry
and housing conditions, and record keeping, restricting the overall severity of the
procedures carried out, and care of the animals during an experiment. Non-human
primates are used in a number of research ﬁelds, including neurological research
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that involves advanced brain responses which can be tracked in various ways,
safety testing for novel medicines and new batches of vaccines, defence studies and
studies that may beneﬁt wild animals. While in most areas of research the animals
concerned might not suffer extremes of pain, in some they are caused signiﬁcant
mental distress.
Certain types of work envisage substantial human beneﬁts (e.g. defence strate-
gies and antidotes), and this may impel some researchers to seek collaboration
abroad to carry out work that might be limited or severely curtailed in their own
countries. They might also accept compromises in the acquisition of experimental
primates: for instance, wild-caught animals, often seen as local pests, could be used
instead of purpose-bred animals. Furthermore, the application of the “Three Rs” –
replacement, reduction and reﬁnement1 – is likely to be less stringent, particularly
regarding reﬁnement strategies in the housing and husbandry of the animals, and
even more so in the experimental design of studies (e.g. the implementation of
severity limits and humane endpoints).
Animal Research Worldwide
Animal experimentation is used for many biomedical research activities, including
pharmaceutical studies, basic scientiﬁc research, biotechnology and traditional
medicine research. We cannot determine the exact number of animals used
worldwide in research, but there is an estimate of between 50 million and
60 million animal procedures per year, with rats and mice by far the most com-
monly used species (Understanding Animal Research 2015).
It is estimated that non-human primates represent a very small proportion of the
total number of animals used in experiments: fewer than 1 in 1,000 in the EU and
approximately 3 in 1,000 in the US (SCHER 2009). Worldwide, however, the
number may be more than 100,000 each year.
The wide variety of non-human primate species used in research can be divided
into New World species such as marmosets (e.g. the common marmoset, Callithrix
jacchus), and Old World species such as the long-tailed or cynomolgus or
crab-eating macaque (Macaca fascicularis) and the rhesus macaque (Macaca
mulatta). In addition, baboons, another Old World primate of the genus Papio, are
occasionally used.
1The “Three Rs” are the underpinning requirements of most policies and regulations in animal
research:
! Replacement: Methods that avoid or replace the use of animals.
! Reduction: Methods that minimize the number of animals used per experiment.
! Reﬁnement: Methods that minimize suffering and improve welfare.
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Non-human primates are highly valued in biomedical research because of their
genetic similarity to humans,2 which means they can be especially useful for testing
the safety of new drugs and studying infectious diseases, and in neurophysiology,
where they can be trained to respond to external stimuli and their central nervous
system responses monitored or followed in some way.3 However, their similarity to
humans also raises speciﬁc ethical concerns about their use in scientiﬁc experiments
(SCHER 2009).
In the EU, animal experiments are governed by Directive 2010/63/EU (EU
2010) on the protection of animals used for scientiﬁc purposes, which required
member states to apply the provisions of the directive through their national leg-
islation from 1 January 2013. According to the directive, the use of non-human
primates demands special attention and certain requirements have to be met:
Due to their genetic proximity to human beings and to their highly developed social skills,
the use of non-human primates in scientiﬁc procedures raises speciﬁc ethical and practical
problems in terms of meeting their behavioural, environmental and social needs in a lab-
oratory environment. Furthermore, the use of non-human primates is of the greatest concern
to the public (EU 2010: art. 17).
Consequently, the use of non-human primates is strictly controlled and the
purposes for which they can be used require rigorous scientiﬁc justiﬁcation:
Therefore the use of non-human primates should be permitted only in those biomedical
areas essential for the beneﬁt of human beings, for which no other alternative replacement
methods are yet available. Their use should be permitted only for basic research, the
preservation of the respective non-human primate species or when the work, including
xenotransplantation, is carried out in relation to potentially life-threatening conditions in
humans or in relation to cases having a substantial impact on a person’s day-to-day
functioning, i.e. debilitating conditions (EU 2010: art. 17).
There are additional requirements on the provision of life histories and severity
monitoring that add further criteria to try to ensure that the science is of the
highest quality and that animal welfare is not avoidably compromised (EU 2010:
art. 30, 39).
With increased scrutiny and regulation, and in response to public opinion, there
has been a marked reduction in the number of non-human primates being used in
research. Figures show that approximately 6,000 were used in scientiﬁc procedures
in the EU in 2011, compared with almost 10,000 in 2008 (SCHEER 2016).
Furthermore, some institutions are no longer using primates, such as the Harvard
Medical School, which closed its afﬁliated primate facility in 2015. Others are
2For example, baboons have a 91% DNA similarity (see also Wong 2014).
3Safety testing of new drugs, substances and devices, especially those intended for human med-
icine and dentistry, accounts for approximately 67% of the non-human primates used in research.
Fundamental biological research accounts for a further 14% and the research and development of
medical and dental products and devices for humans for about 13% (SCHER 2009).
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reviewing their primate use: for instance, the US National Institutes of Health
announced recently that it would review all non-human primate research that it
funds (Cyranoski 2016).
In light of this trend, the European Commission’s Scientiﬁc Committee on
Health, Environmental and Emerging Risks (SCHEER) announced in June 2016
that it was seeking more information to update the EU directive on the use of
non-human primate research. In particular, it is seeking opinion on areas of research
and testing where non-human primates continue to be used, possibilities to replace
their use, and the potential implications for biomedical research, as well as the
question of whether the use of non-human primates should be banned altogether in
the EU (SCHEER 2016). In Europe, researchers say, the climate for such research is
growing colder (Cyranoski 2016).
While the decrease in the number of non-human primates used in the EU may be
welcomed and regarded as a beneﬁcial impact of Directive 2010/63/EU, there is
rising concern that this decrease has coincided with an increase in the use of
non-human primates elsewhere. There is also concern from some in the scientiﬁc
community that the opportunity to gain valuable insights into certain human dis-
eases will be lost.
Hau et al. (2014) describe how, due to political pressure and the introduction of
the new EU directive, biomedical research with non-human primates is increasingly
difﬁcult to carry out in Europe. Consequently, European scientists are seeking
collaboration with non-human primate centres outside of Europe (Hau et al. 2014).
This has also been noted by Cyranoski (2016), who explains that non-human
primate research increasingly faces “a tangle of regulatory hurdles, ﬁnancial con-
straints and bioethical opposition” (Cyranoski 2016:300). As a result, some
researchers have stopped trying to do such work in the West, and he quotes one
neuroscientist as saying that “red tape drove her to China” (Cyranoski 2016).
There is a long tradition of collaboration between European academic institu-
tions and those in the US and Canada, but the network of collaborating institutions
is becoming increasingly globalized (Macy 2011). This is highly positive in many
respects, but if animals are to be used in collaborative research, the attention to
ethical concerns, animal welfare and the quality of the research must be equivalent
among research partners around the globe4 (Bayne et al. 2015). However, regula-
tions, norms, practices and standards in animal research are not currently harmo-
nized, as is clearly illustrated by the following case.
4The EU have already taken steps towards this end. International projects that are supported by EU
funding, such as the Horizon 2020 funding programme, must ensure that all collaborators in the
project comply with EU laws in their project activities.
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Speciﬁc Case and Analysis
In 2013 a report in the British press alleged that an academic from a UK university
was bypassing British law in his research with wild-caught baboons in Nairobi
(Macrae 2013). A professor of movement neuroscience, part of a team investigating
methods to treat conditions affecting the brain such as stroke, spinal cord injury and
motor neurone disease, was accused of exploiting a cheap and plentiful source of
animals in Nairobi.
The accusation followed an undercover investigation by the British Union for
the Abolition of Vivisection (BUAV), which had covertly obtained photos and
video footage of the baboons at the relevant institute in Nairobi. BUAV contended
that the images revealed disturbing welfare standards and that UK researchers
should not accept lower standards when carrying out research at non-UK facilities.
The UK professor was quoted as saying that while animal welfare standards
were not as high in Nairobi as in the UK, they had improved greatly during his time
there, and that the institute was committed to making further improvements. In
addition, he accepted that the experiments would not be permitted in the UK, but
argued that it was better to capture wild baboons, who had lived for four or ﬁve
years in the wild, rather than breed them in captivity. Experiments on wild-caught
animals are not normally permitted in the UK, but he claimed that the reasons
behind the ban on using wild-caught primates in the UK did not apply to his
experiments in Africa.
In a subsequent article in the Kenyan press, the institute in Nairobi denied
reports that the facility was being used to conduct harmful research on baboons,
claiming that the studies were aimed at advancing medical research for the beneﬁt
of Kenya and the world. It added that out of Kenya’s 13 non-human primate
species, only the two most abundant species (baboons and African green monkeys,
another Old World primate) were being used for biomedical research and that, far
from being endangered, baboons were considered pests in the wild and those being
used in the experiments would otherwise have been killed (Kariuki 2014).
This story received signiﬁcant coverage in the British media, with celebrities
adding their voices to the protests (Nelson 2013). A petition was launched by the
students’ union at the UK university to persuade the university to end such
experiments and, following public pressure, the university decided to halt the
baboon experiments in 2014.
There are two immediate concerns that arise from this case: ﬁrst, that the
standards of animal welfare in Kenya may have been lower than the standards
required in the EU, and second, that the baboons had been taken out of the wild.
It is not possible to make judgements about the equivalence of standards of
animal care without all the facts of the case. However, it is perfectly clear that these
experiments would not have been permitted on wild-caught animals in the UK. Of
the 2,466 non-human primates used in experiments in the UK in 2014, none had
been taken from the wild (Home Ofﬁce 2015).
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It would appear that for many researchers concerns about the equivalence of
standards in animal research are fundamental. As Niemi (2011) points out, with an
unprecedented level of scrutiny of research possible via the internet, the negative
consequences of mere allegations of animal mistreatment are greater than any
theoretical advantage to be gained by conducting animal research in a less rigorous
environment. This sentiment is echoed by Ogden (2011), who maintains that
pharmaceutical and biotech companies do not want to be perceived as using out-
sourcing in order to bypass standards of humane care and use. Generally, it is
acknowledged that the pharmaceutical industry has a vested interest in the pro-
motion of high-quality animal care and facilities and high-quality research outputs
(Medina et al. 2015).
However, even for those with the best of intentions, there are challenges for
collaborative animal research that stem from a lack of consensus on what should be
considered best practice across different cultures. In addition, regulations on animal
research and welfare differ from country to country and are subject to change (Landi
2011).
In China, for example, there does not appear to be the same degree of public
opposition to the use of non-human primates in research, and many new non-human
primate research centres are being established. Some advertise themselves as
“primate-research hubs”, encouraging researchers to fly in and out and make use of
their extensive facilities (Cyranoski 2016).
In Africa, non-human primates are used in research in a number of countries
including Kenya, South Africa and Ethiopia. Some Old World primate species and
baboons are considered agricultural pests in many parts of Africa, and legislation
governing their use in research is generally lacking (Hau et al. 2014).
Most African countries lag behind high-income countries (HICs) in regard to the
existence or adequacy of national and/or institutional policies and guidelines on the
use of animals in research. While some African countries have been developing
ethical or legal frameworks aimed at safeguarding the welfare of animals used for
research, in most African countries there is a serious lack of information in the
public domain. Consequently, some researchers from (HICs) may be tempted to
export their research activities to collaborating African institutions where ethical
and legal frameworks on the use of animals may be less stringent (Nyika 2009).
In 2011, Kimwele, Matheka and Ferdowsian published results from their survey
of 39 highly ranked academic and research institutions in Kenya aiming to identify
those that used animals, their sources of animals, and the application of the Three
Rs. At that time, 28 (71.8%) institutions had no designated committee to review or
monitor protocols using animals. Only two of the institutions with an established
animal care and use committee referred to documented guidelines, and neither
documented the composition of their committees (Kimwele et al. 2011).
Across Africa as a whole, the absence of legal and ethical frameworks and
committees to review protocols that involve animals in research means that animal
protection could be severely compromised, as well as the validity of the scientiﬁc
outcome data. In addition, the lack of institutional animal ethics committees
86 K. Chatﬁeld and D. Morton
promotes the outsourcing of animal research to these unregulated institutions
(Nyika 2009).
This situation is compounded by the fact that most Western academic institu-
tions do not have much experience with local animal care and use regulations in
other countries (Macy 2011). Hence, a double ethics review, where the Western
committee also provides an ethics opinion, is not a solution.
Recommendations
• The overarching requirement for avoiding exploitation in animal research is a
global code of conduct for research involving animals. There are moves towards
this outcome, but it is currently far from resolved. In recent years there have
been attempts from different organizations to develop global frameworks. In
2012, the International Council for Laboratory Animal Science and the Council
for International Organizations of Medical Sciences updated their International
Guiding Principles for Biomedical Research Involving Animals (CIOMS and
ICLAS 2012). These principles incorporate the Three Rs and are intended to
serve as a framework of responsibility for all countries, including those with
emerging research programmes.
• In the absence of a global code of conduct, there will inevitably be variations in
standards, regulations, legislation, scientiﬁc integrity, data validity and humane
practices. In light of this concern, researchers from HICs engaging in collabo-
rative research have an obligation to ensure the application of the same stan-
dards that are upheld in their home nations and home institutions.
• For residents of the EU, this entails full compliance with Directive 2010/63/EU
(EU 2010) in a manner that is both transparent and auditable. Partner institu-
tions must therefore also be transparent and auditable in the application of
principles that are equivalent to those speciﬁed in the directive. This must be a
requirement even when local legislation and regulation are different or less
strict.
• In practice this may entail much closer collaboration with partners on the
ground, working together with local representatives to ensure equivalence in all
activities such as animal housing and care, as well as experimental procedures.
• European funders of research involving animal experimentation have a partic-
ular responsibility to ensure that full compliance with Directive 2010/63/EU is a
necessary condition for their support.
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Conclusion
Although non-human primates constitute a small proportion of the animals used in
research worldwide, their use raises particular ethical concerns. In the absence of a
global code of conduct for animal research, animals in countries where regulations
and legislation are less well formulated are at risk of exploitation in research. For
collaborative ventures, it is vital that institutions from HICs apply precisely the
same standards as are required in their home countries and institutions. This may
entail close working relationships with local partners to ensure equivalence in
standards and some investment to achieve that goal.
For non-human primates, the application of equivalent standards may result in a
reduction in the numbers used in collaborative biomedical research, but it will also
result in more rigorous science and improved welfare standards and a better
application of the Three Rs.
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Chapter 11
Human Food Trial of a Transgenic Fruit
Jaci van Niekerk and Rachel Wynberg
Abstract The research and development of any “new” agricultural crop created
using genetic modiﬁcation technologies, even if undertaken with the best of
intentions, is accompanied by novel human health, environmental, social, economic
and other risks. To date, much of the research that has accompanied the release of
genetically modiﬁed (GM) crops has focused on the environmental and health
impacts. Evidence has been inconclusive, however, with debates remaining highly
divided and contested, and each “camp” presenting evidence to support its position.
Keywords Genetic modiﬁcation  Human food trial  Nutritionism
The case presented here does not attempt to elucidate the various positions in the
debate, but rather concerns the research process of developing a GM
“vitamin-enriched” food for cultivation in a low- or middle-income country (LMIC).
It raises questions not only about the ethical complexities of participant involvement
in such trials, but also about the ethics of how Northern researchers and philanthropic
organizations determine research priorities without necessarily involving the affected
LMICs. The case relates to a proposed food trial involving students at a North
American university and a banana enrichedwith a vitaminA precursor, beta-carotene,
through genetic modiﬁcation. The ultimate goal of the study was to roll out the
transgenic banana to Uganda, a country where vitamin A deﬁciency was seen by the
researchers and funders involved as a major nutritional challenge.
This case brings up questions about exploitation risks to human participants, and
also fuels debates about potential impacts on hunger and nutrition in the intended
country of release. By highlighting differences between the concepts of food
security and food sovereignty (see table below for deﬁnitions), the case illuminates
two very different approaches to addressing poverty-induced hunger and malnu-
trition. Food security, supported by institutions such as the World Bank, the G8-led
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New Alliance for Food Security and Nutrition and large consumer companies, is
described by critics as “nutritionism”, and is “understood as a set of ideas and
practices that seek to end hunger not by directly addressing poverty, but by pri-
oritizing the delivery of individual molecular components of food to those lacking
them” (Patel et al. 2015:22). In contrast, food sovereignty aims to reduce malnu-
trition through an emphasis on diversiﬁcation and the importance of peoples and
countries deﬁning their own food and agricultural priorities, taking into consider-
ation local social, economic, ecological and cultural aspects. Food sovereignty is
supported by a growing movement supportive of farmers’ rights, women’s
empowerment and agroecological approaches to farming.
Food security Food sovereignty
According to the Food and Agriculture
Organization of the United Nations (FAO
2001), achieving food security requires:
• an abundance of food
• access to that food by everyone
• nutritional adequacy
• food safety
Food sovereignty is deﬁned as “the right of
peoples to healthy and culturally appropriate
food produced through ecologically sound and
sustainable methods, and their right to deﬁne
their own food and agriculture systems”
(Declaration of Nyéléni 2007)
Areas of Risk of Exploitation
This case raises two sets of issues relating to risk of exploitation.
Risks of Participating in the Food Trial
The ﬁrst set of risks pertained largely to the trial participants in the high-income
country (HIC) where the trials were planned. They related to:
• how and whether informed consent was obtained from female students invited
to participate in the study
• the potential vulnerability of the student participants, as they may have been
unduly incentivized to take part in the study by the USD 900 fee
• potential human health risks, especially given that this was one of the ﬁrst
human food trials of a transgenic plant product.
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Risks of Undermining Local Food Systems
The second set of risks pertained to the potential release of the transgenic fruit in
Uganda, in the context of pursuing “nutritionism” as a research priority. These
include:
• risks of undermining local food and cultural systems and imposing inappropriate
solutions
• risks of reducing banana agrobiodiversity
A Proposed Human Food Trial
In early 2014, an US university sent an email to all female students, wanting to
recruit 12 volunteers for a transgenic food trial. According to Leys (2014), par-
ticipants were requested to eat a diet provided by the researchers, which included
genetically modiﬁed bananas, for four days during each of three study periods.
They would have their blood drawn to test whether the fruit’s enhanced
beta-carotene content translated into higher vitamin A levels in their bodies (AGRA
Watch 2016; Gimenez et al. 2016). In return for their participation, the students
were offered USD 900. According to a local paper, The Des Moines Register, more
than 500 applications were received, from whom 12 volunteers were selected (Leys
2015).
The main aim of the study, funded by the Bill and Melinda Gates Foundation
(BMGF), was to assess the efﬁcacy of the banana for eventual roll-out in Uganda,
an East African country where bananas are a staple food. According to the lead
scientist at the US university, the transgenic banana included a gene taken from a
sweet variety of banana which naturally produces large amounts of beta-carotene.
Residents of Uganda use the less sweet cooking banana as a staple, hence the
selection of this type to be genetically modiﬁed by the researchers.
Members of non-governmental organizations heard about the proposed study
and, along with journalists at The Des Moines Register, demanded to know more
about it. Initially the lead researcher declined to share information about the study
design, claiming that disclosure would be detrimental to her chances of publication
(Leys 2014). She relented later, however, stating through a university spokesperson
that she had led a similar study ﬁve years previously, with six women eating
porridge made from corn also modiﬁed to produce high levels of beta-carotene (Li
et al. 2010).
The proposed food trial, and particularly the initial lack of transparency sur-
rounding it, gained a lot of attention on the US campus, prompting a coalition of
concerned students to protest. In collaboration with a number of non-governmental
organizations, the students delivered a 57,000-signature petition to the relevant
Agriculture and Life Sciences college and to the Gates Foundation’s headquarters
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in February 2016. The students questioned the transparency, risks, and generaliz-
ability of the trial, and maintained that prior informed consent had not been
obtained from the participants (AGRA Watch 2016). Another exploitation risk
hinged on the USD 900 fee, a relatively large sum of money, which could have
unduly incentivized students who were not ﬁnancially secure to take part in the
study.
Risks Related to Unknown Human Health Impacts
As this was the ﬁrst human feeding trial of a GM product that had not been tested
on animals, the students were being asked to consume a product of unknown safety
(Kruzic et al. 2016). Concerns were also expressed about the potential health risks
for women of childbearing age. A molecular biologist based at the Salk Institute for
Biological Studies commented:
Beta-carotene is chemically related to compounds that are known to cause birth defects and
other problems in humans at extremely low levels, and these toxic chemicals are possible –
if not likely – by-products of plants engineered to make large amounts of beta-carotene.
Since there is no required safety testing of the banana or any other genetically modiﬁed
organism, doing a feeding trial in people, especially women, should not be allowed (AGRA
Watch 2016).
Impacts on Local Food and Cultural Systems
Concerns were also raised about the social, economic and environmental impacts of
the proposed study. According to Eric Gimenez, executive director of the Institute
for Food and Development Policy, such questions
recognise that hunger and malnutrition are not just biological or technical challenges, they
are social problems rooted in poverty, inequality and a skewed distribution of resources.
Ending hunger can’t be reduced to simple gene transfers, and the socioeconomic and
agroecological impacts of GM go far beyond the single crops in which they are genetically
expressed (Gimenez et al. 2016).
Such concerns were linked to wider issues about the nutritionism approach
adopted through biofortiﬁcation.1 Proponents of biofortiﬁcation recommend its use,
1Biofortiﬁcation is the process by which the nutritional quality of food crops is improved through
agronomic practices, conventional plant breeding or modern biotechnology [genetic modiﬁcation].
Biofortiﬁcation differs from conventional fortiﬁcation in that biofortiﬁcation aims to increase
nutrient levels in crops during plant growth rather than through manual means during processing of
the crops (WHO 2016).
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especially in staple crops, to complement conventional fortiﬁcation2 activities,
particularly in targeting the undernourished in remote rural populations (Bouis et al.
2011; WHO 2016).
Critics of this approach maintain that malnutrition is best countered with a diet
based on a diverse variety of foods, and label biofortiﬁcation as “a strategy that aims
to concentrate more nutrients in few staple foods … [and] may contribute to further
simplifying diets already overly dependent on a few carbohydrate staples” (Johns
and Eyzaguirre 2007:3).
Such views have been supported by the much-studied example from the
Philippines and elsewhere of Golden Rice, also fortiﬁed with beta-carotene. Stone
and Glover (2017), for example, observe that the developers of Golden Rice have
yet to produce GM varieties that yield as well as existing varieties, and maintain
that the storage qualities of the biofortiﬁed rice remains unknown, as does the
probability of the beta-carotene being converted into vitamin A in the bodies of
severely undernourished children.
Threats to Banana Agrobiodiversity
Aside from questions about the efﬁcacy of the eventual banana product, concerns
were also expressed about the risks of undermining local food systems and reducing
banana agrobiodiversity. This is especially pertinent considering that East Africa is
regarded as a secondary centre of banana diversity (after India), with Uganda being
the largest producer and consumer in the region (Gold et al. 2002). If the GM
banana variety were to be adopted in Uganda, it would most likely be grown as a
monoculture, impacting food security through the erosion of genetic diversity.
A signiﬁcant body of research indicates that diverse plant communities preserve
genetic potential for the selection of desirable traits, and also withstand plant
pathogens better than monocrops (see e.g. Zhang et al. 2007; Cardinale et al. 2012).
Uganda is home to banana varieties that are already higher in beta-carotene than the
proposed GM variety. In addition, with the country situated in a fertile, tropical
zone, the cultivation of foods naturally rich in beta-carotene, such as sweet potatoes,
leafy vegetables and certain types of fruit, offers affordable, healthy, culturally
acceptable and locally produced ways of avoiding nutrient deﬁciency.
2Fortiﬁcation is the practice of deliberately increasing the content of an essential micronutrient, i.e.
vitamins and minerals (including trace elements), in a food, so as to improve the nutritional quality
of the food supply and provide a public health beneﬁt with minimal risk to health (WHO 2016).
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Lessons Learned
This case yields a number of valuable lessons across high-, middle- and low-income
country scenarios for:
• those involved in plant breeding
• development-related programmes that have LMICs as their focus, as well as
funders
• those serving on ethics committees
With regard to the trials conducted in a HIC, the case reveals the importance of
ensuring that trial participants make decisions based on a full set of information,
and also of examining the rationale behind such trials and fully exploring potential
risks to participants. It also suggests that debates about healthy volunteers extend
into the domain of agricultural research, a ﬁeld which is surprisingly undeveloped
in the realm of ethics.
With regard to the impacts of such research in LMICs, the case shows that
research driven from HICs and by philanthropic donors should be sensitive to local
peoples’ rights to self-determination of their food systems, and to alternative
approaches to addressing nutrient deﬁciencies. In the words of a concerned
Ugandan, “Just because the GM banana has been developed in Australia and is
being tested in the US does not make it super! Ugandans know what is super
because we have been eating home-grown GM-free bananas for centuries. This GM
banana is an insult to our food, to our culture, to us a nation, and we strongly
condemn it” (Leys 2015).
Recommendations
• Human food trials of GM products should be approached with caution. In the
absence of precedents, such trials need to be conducted transparently, with
participation based on informed decision-making and without being unduly
influenced by ﬁnancial incentives.
• The determination of R&D (Research & Development) priorities should be
carefully evaluated in terms of local needs, taking into account social, eco-
nomic, political and environmental implications. Research involving staple
crops should not have outcomes that violate a LMIC’s right to
self-determination or food sovereignty. Impacts on existing farming systems and
on agrobiodiversity need to be carefully considered. Technical solutions such as
biofortiﬁcation should not be introduced at the expense of existing, diverse
sources naturally rich in the nutritional substance perceived to be lacking.
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• Further research is needed to deepen understanding about ethics in agricultural
research. This should take cognizance of the need for extensive and inclusive
participation in determining research priorities, and should involve regular
review to assess the suitability and acceptability of different applications in view
of fast-changing technologies.
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Chapter 12
ICT and Mobile Data for Health Research
David Coles, Jane Wathuta and Pamela Andanda
Abstract Mobile cellular subscriptions had reached 87% of the world’s population
by 2011 (ITU 2011). Notably, Africa has “the fastest mobile phone growth rate in
the world and … a proliferation of social media users” (Mutula in Information
ethics in Africa: cross-cutting themes. African Centre of Excellence for Information
Ethics, Pretoria, pp 29–42, 2013:31). Mobile phones that can run software appli-
cations (apps) are increasingly used in health settings, for example, to improve
diagnosis and personalize health care (Mosa et al. in BMC Medical Informatics and
Decision Making 12(1):67, 2012). This fast-paced development saw the number of
“mHealth” apps reach 97,000 as of March 2013 (He et al. in AMIA Annual
Symposium Proceedings, pp 645–654, 2014).
Keywords Health research  ICT  mHealth  Mobile data  Mobile phones
Personal data
The application of mobile technologies (mobile phones or other remote monitoring
devices) for health-related purposes is termed “mHealth”: a mobile tool for
expanding access to health information and services around the world (K4Health
2014). According to the World Health Organization (WHO 2011:6) , mHealth is the
“medical and public health practice supported by mobile devices, such as mobile
phones, patient monitoring devices, personal digital assistants and other wireless
devices”. Although mHealth has come to signify the use of any mobile technology
to address health care challenges such as access, quality, affordability, matching of
resources and behavioural norms (Qiang et al. 2011), most mHealth interventions
use mobile phone technology, thanks to its versatility as an ICT tool (Leon and
Schneider 2012:7).
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With the pervasive growth in technology infrastructure, mHealth can reach
communities in ways that conventional health services and other communication
tools cannot. Mobile phones are described as potentially the most widespread
embedded surveillance tools, especially due to the use of location sensors and the
consequent possibility of documenting and quantifying habits, routines, and per-
sonal associations (Shilton 2009). This case study focuses on the potential ethical
issues associated with the use of mHealth apps in medical research and health care.
mHealth offers “attractive low-cost, real-time ways to assess disease, movement,
images, behaviour, social interactions, environmental toxins, metabolites” (Collins
2012:1). It has the power to bring the research lab to the patient and obtain real-time,
continuous biological, behavioural and environmental data (Collins 2012).
Mobile phones collect a wide range of personal information from their users,
with or without their knowledge, which raises novel and complex ethical and
practical challenges. Research teams (and clinicians) need to understand these
challenges so that, without rejecting mHealth and related mobile technological
advancements, they minimize any unintended harms (Carter et al. 2015). Wicklund
(2015) observes that clinical studies that utilize mHealth devices and platforms are
venturing into uncharted ethical territory.
Area of Risk of Exploitation
Software apps in the mHealth category can be used for collecting health-related data
on a large scale for biomedical research; the so-called “big data” (Park and
Jayaraman 2014; Hsieh et al. 2013). In general, however, mHealth raises concerns
regarding data security issues – from transmission of data to its local storage, and
“ownership” of what is otherwise considered conﬁdential patient data. This data is
easy to obtain, but difﬁcult or impossible to retract once shared. In addition to safety
and security risks, mobile sensing also disrupts social boundaries and challenges
distinctions between public and private (Shilton 2009). One of the key challenges of
using mHealth in low- and middle-income countries (LMICs) is how to ensure
workable approaches to privacy and security (Leon and Schneider 2012:19).
Carter et al. (2015) have identiﬁed a range of ethical issues raised by the use of
mobile phones for research and clinical purposes. These are:
• the protection of privacy
• minimizing third-party uses of data
• informing patients of complex risks when obtaining consent
• maximizing beneﬁts while minimizing the potential for disclosure to third
parties
• care in the communication of clinically relevant information
• the rigorous evaluation and regulation of mHealth products before widespread
use
In practical terms, the issues discussed below need to be considered carefully.
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Context-Based and Fully Informed Consent
Should Be Obtained
Researchers should seek and obtain informed consent before using mHealth tech-
nologies in research. Accordingly, participants must be informed about, and
understand the risks and beneﬁts of, mHealth technologies, and then make a free
and voluntary decision to participate or not. The risks associated with mHealth are
complex, and these need to be communicated and negotiated. If the study involves
the collection of data from interaction with identiﬁable third parties, it may be
necessary to obtain their informed consent as well. This in turn means that mHealth
participants will have to disclose their condition and/or mHealth participation
(Carter et al. 2015).
Only Necessary Data Should Be Collected
Compared with other health information systems, mHealth collects a much larger
amount and broader range of data about patient lifestyles and activities, over an
extended period (He et al. 2014). A potential danger to bear in mind in this regard is
that of collecting excessive amounts of raw data to maximize the information
extracted by the research team (Carter et al. 2015).
Any Tracking Should Be Proportionate
and the Correct Person Should Be Tracked
Continuous or intermittent recording and transmission of detailed information about
where a person is, and to some extent what they are doing, may breach privacy and
conﬁdentiality. There are risks of inadvertent insight into a participant’s behaviour
revealing information beyond the proﬁles that are scientiﬁcally justiﬁed and for
which data collection was employed. This also poses problems of informed consent,
as privacy may be violated in ways unforeseen by either investigators or partici-
pants. Text messages (SMS) can be read by persons other than the intended
recipient; messages can be forwarded and can remain on unsecured devices
indeﬁnitely. One result could be the unintended disclosure of a medical condition
(Labrique et al. 2013).
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Research Participants Should Know Exactly Which Data Is
Collected and Who Will or Could Have Access to It
This is a great challenge, especially in a global research environment that
increasingly requires the sharing of data in publicly available repositories. The case
of an alleged breach of smartphone users’ privacy by manufacturers of popular
smartphone apps for Apple and Android devices illustrates this risk. The manu-
facturers are alleged to have gathered information from personal address books on
the phones of Kenyan users, stored it on their own computers, and transmitted it
without the knowledge of its owners, all of which demonstrates how difﬁcult it is to
guarantee privacy when using smartphones (Mutula 2013; Wambugu 2012).
The security of data collected via mobile phones cannot be guaranteed either, in
part because no strict privacy regulations exist.1 Many mHealth apps do not use
encryption when transferring data, and even when they do, hackers and govern-
ments can still gain access. Potential violations of privacy include hacking of
personal data with the known likelihood of identity theft and ﬁnancial losses,
computer malware and virus programs, and malevolent apps planted by developers
who steal data for commercial or criminal purposes (He et al. 2014).
Incentives to Take Part in Research Should Be Proportionate
and not Result in Exploitation
Research involving mHealth apps often requires the participant to have a smart-
phone. If researchers speciﬁcally target those who do not already own newer
devices or other modes of mobile technology, the prospect of being given access to
such technology may unduly influence them to take part (Labrique et al. 2013:3).
Patients should not, however, be excluded from mHealth monitoring beneﬁts if they
cannot afford a device capable of supporting the app or connect with networks
capable of transmitting potentially large volumes of data. This requirement there-
fore needs very careful judgement.
1Companies like Apple and Google have to comply with the privacy regulations in each of the
countries where they collect data. Where little or no privacy regulation exists, the companies have
wide scope regarding what data they collect and how they use it. Interestingly, Apple announced
that with their new iOS10 operating system they would be introducing “differential privacy”,
which they claimed would enable them to collect much more personal user data while preserving
users’ privacy. This concept involves introducing numerical “noise” into the data collected in order
to de-identify it (see Brandom 2016). However, it is questionable whether data provided this way
will be suitable for research purposes (see Friedman and Schuster 2010).
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Speciﬁc Case and Analysis
The details of a case of HIV/AIDS tele-counselling in South Africa were obtained
from an interview with Cell-Life’s general manager, Peter Benjamin, conducted and
published in 2011 by Boyle (2011). Additional information is available in a report
that was prepared on the use of mobile technologies for the monitoring and eval-
uation of public sector community-based health services (Leon and Schneider
2012).2
Cell-Life, a non-proﬁt organization, entered into a contract with the South
African national Department of Health (DOH) for a big project. “Cell-Life started
in 2001 as a research collaboration between staff of the engineering faculty of the
University of Cape Town (UCT) and the Cape Peninsula University of Technology
(CPUT)” (Loudon and Rivett 2013). It became a not-for-proﬁt organization in 2006
(Loudon and Rivett 2013). In terms of the contract, the DOH set up a national
mHealth system that used cellphones for monitoring an HIV counselling and testing
(HCT) campaign.
Cell-Life used chat software called Mxit, which enabled users to send instant
messages over a cellphone system. To do this, users had to download a small app
that connected them to the Mxit server, enabling immediate communication with
anyone else on Mxit. The app sent SMS-type messages through GPRS,3 via which
messaging was effectively free.
Cell-Life created a website within Mxit where it provided all the usual HIV
content, information and interactive quizzes. An interesting feature that Cell-Life
included was linking Mxit to South Africa’s National AIDS Helpline, so that users
could text on Mxit and the message would go through to the computer screen of a
professional HIV counsellor at the National AIDS Helpline. The counsellor would
type a reply which would appear on the user’s cellphone screen.
Cell-Life was awarded additional contracts by the DOH for the design and
implementation of a mobile monitoring and reporting system for the national HIV
counselling and testing (HCT) campaign, and the national antiretroviral treatment
expansion programme (Cell-Life nd). These systems have been the subject of
research into how software applications for the monitoring and evaluation of
community-based care are used in a research and service delivery context (Leon
and Schneider 2012).
The data processed and transmitted through the software apps related to patients’
personal information, which was subsequently stored and monitored through the
system. The use of mobile phones in this process raises practical ethical issues, such
as concerns about the protection of information and privacy, and consent to the
potential use of such information for research purposes. As Labrique et al. (2013)
2See also Cell-Life (nd).
3“General Packet Radio Service (GPRS) is a packet oriented mobile data service on the 2G and 3G
cellular communication system’s global system for mobile communications (GSM)” (General
Packet Radio Service 2017).
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have observed, although mHealth apps ensure the availability of real-time data that
brings with it new and beneﬁcial strategies, the rapid adoption of these technologies
raises ethical issues that need careful consideration. Accordingly, existing standards
and practices have to be supplemented with new guidelines to ensure that patients
and vulnerable populations are adequately protected. The gap between technolog-
ical innovation and the development of ethical standards and guidance needs to be
reduced, so that researchers and other stakeholders have a reference framework for
assessing and mitigating the risks of mHealth research and data collection.
Recommendations
The following measures could help avert the possibility of exploitation in the
context of mHealth:
• Developers should determine when, where and how sensitive data are uploaded
and stored, to minimize the risk of privacy violations. In addition, they should
take steps, by using encryption and anonymization (Carter et al. 2015; He et al.
2014), to ensure that data collected by an mHealth app are not available to other
apps or programs installed on the phone or in third-party storage without
security and privacy guarantees (He et al. 2014).
• Participants should be able to control what they consent to and how their data
may be used and stored. The data should be deleted as soon as no longer needed
(Albrecht and Fangerau 2015).
• Appropriate regulation of mHealth devices and apps should be developed to
ensure their safety and effectiveness, including minimal privacy violations and
guarantees that they provide clinically accurate information. Albrecht and
Fangerau (2015), for instance, have recommended the transformation of the
fundamental principles of medical ethics in order to make them applicable to
mHealth.
• Proven innovations for the improvement of data protection and privacy should
be implemented by researchers as soon as possible after they become available.
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Chapter 13
Safety and Security Risks of CRISPR/Cas9
Johannes Rath
Abstract This case study looks into recent developments with regard to the
CRISPR/Cas9 and other novel genome editing technologies that are becoming
widely available thanks to their low costs and modest technological requirements.
Keywords Biosafety  Biosecurity  CRISPR/Cas9
Responsible research and innovation
Genome editing allows the speciﬁc modiﬁcation of a genome; genes are modiﬁed
within their respective location in the genome, making the changes often indis-
tinguishable from natural mutations. Developments of this technology such as the
use of gene drives, where speciﬁc genes are spread within populations, or the use of
viral vector systems, are enabling additional applications in environmental engi-
neering and disease treatment. There are substantial individual and societal beneﬁts
from applying genome editing; nonetheless the technology also poses signiﬁcant
risks to individuals, society as a whole and the environment.
The central focus of this case study is on the unresolved ethical issues related to
safety and security that pose both short-term and long-term challenges to interna-
tional research partnerships. As such, the case study focuses not on a single incident
but on the risks in the proliferation of a new and very powerful technology at a time
when accepted and tailored ethical and legal frameworks at the international,
national and local level are missing.
In the case study two areas of safety risks are mapped and existing governance
approaches described: ﬁrst, risks to humans, for example in relation to therapeutic
applications of genome editing; second, risks to the environment in relation to the
use of genome editing on animals, plants and microbes. In addition, two aspects of
security risks are also assessed: ﬁrst, the creation of harmful agents relevant in the
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bioweapons context; second, human enhancement in a military context and its
medium- and long-term implications for international security.
It is concluded that the rapid emergence of high-risk safety and security appli-
cations of genome editing challenge not only today’s safety and security risk
assessment but also existing governance tools. In addition, the absence of inter-
national standards of governance may result in safety- and security-sensitive
experiments being transferred to countries with less stringent oversight, which will
have serious implications for trust in international research.
Area of Risk of Exploitation
The key area of risk relates to the exploitation of international inconsistencies in
biosafety and biosecurity with regard to the governance of genome editing exper-
iments. These inconsistencies create an environment where risky experiments might
be carried out in countries with no legal framework (European Commission nd), or
in countries where, although legal frameworks exist, their implementation cannot be
achieved due to limited resources (Dickmann et al. 2015). This undercuts estab-
lished European standards of safety and security, while at the same time, due to the
nature of some of these experiments, potentially affecting safety and security in
Europe itself (Defensive Drives 2015).
Analysis
In everyday life, the terms “safety” and “security” are often used interchangeably.
Here “safety” denotes the protection of humans, animals, plants and the envi-
ronment from unintentional harm, whereas “security” relates to intentional harm
(e.g. in a military context). This case study on genome editing focuses on the safety
and security implications in four concrete experimental settings that have either
been used in laboratories already, or are well within the range of existing techno-
logical capacities. These experimental settings are:
• the use of genome editing in human inheritable disease, infectious disease and
cancer treatment and human enhancement
• the use of genome editing in creating novel pathogenic organisms
• the use of genome editing in environmental engineering and disease vector
eradication
• the use of genome editing in agriculture
The controversy surrounding the publication of a research paper applying gen-
ome editing technologies to human embryonic stem cells has brought to the
attention of the international scientiﬁc community the varying international
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governance approaches regarding such research. Since then a broad discussion has
emerged on how to use this technology in an ethically sound way (Cyranoski
2015:272; Lanphier and Urnov 2015:411; Callaway 2016:16).
Although many of these discussions focus on the moral status of a human
embryo and the permissiveness of human germ-line enhancement, it has become
generally accepted that a common ethical issue is whether or not genome editing
can be carried out safely and securely.
The safety aspect was highlighted very early on in the discussion as a critical
limitation that would need to be resolved before any application of genome editing
on humans or release into the environment could take place (Akbari et al. 2015).
The security aspect, on the other hand, only recently gained attention when leading
governmental ofﬁcials identiﬁed genome editing as a national security threat (Oye
et al. 2014).
Resolving the major safety and security concerns of genome editing is therefore
of general importance, not only as a prerequisite for a reasonable discussion of the
potential beneﬁts, but also to foster trust among stakeholders in international col-
laborative research.
Genome editing has huge potential in human inheritable disease treatment and
human enhancement. Research here relates to the treatment of various genetic
disorders, infectious diseases and cancer. Recent examples that are currently
undergoing safety testing in clinical trials are the use of somatic gene therapies
involving immune cell modiﬁcations to treat cancer (Reardon 2016),
CRISPR-based approaches to treating HIV (Reardon 2014) and the proof of prin-
ciple of genome editing in the treatment of heritable diseases such as Duchenne
muscular dystrophy (Mendell and Rodino-Klapac 2016). Key safety concerns in
this area have been the number of off-target changes, mosaicism and potential
epigenetic effects (Next-generation genome editing 2015). These are not new safety
concerns, but have also been encountered in other gene therapeutic approaches. The
existing step-wise approach applied in clinical studies should therefore be sufﬁ-
ciently robust to identify, assess and govern such risks.
There is a fluid relationship between genome editing as employed in heritable
disease treatment and its use for human enhancement (Ishii 2015; Cox et al. 2015).
Genetic human enhancement has substantial security implications. In certain
countries, approving the use of genome editing for this purpose (e.g. IQ and
physical endurance) would have far-reaching military and economic security
implications at the national and international level. These security risks need to be
included in risk beneﬁt assessments of human enhancement based on genome
editing.
Certain genome editing techniques open the possibility for the development of a
new class of infectious pathogenic organisms. A recent example has been the
creation of cancer models in mice, where the cancerous mutation was introduced
through genome editing using viral vectors – in essence transforming cancer into a
transmissible infectious disease (Chiou et al. 2015). This creates novel safety risks
that will need to be included in biosafety oversight schemes. In addition, such work
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has the potential to create new generations of biological and chemical weapons
which might not be detectable by current diagnostics.
The use of genome editing in environmental engineering has been discussed in
the context of pest control, with new ways to eradicate agricultural pests (Huang
et al. 2016; Leftwich et al. 2016), as well as that of disease eradication. For
example, gene drive systems are being developed to eradicate malaria (Gantza et al.
2015), and contemplated for the eradication of the Zika (Hegg 2016) arthropod
vector. Key safety concerns relate to the environmental harmfulness, controllability
and reversibility of such environmental interventions. Key security concerns relate
to their potential use as socio-economic and environmental weapons.
The use of gene drives in an environmental context creates novel risks for both
safety and security, which are not restricted by national boundaries. Current
national and international risk management approaches to biosafety and biosecurity
are incapable of mitigating these risks adequately.
The use of genome editing in agriculture for breeding purposes in plants and
animals (Sovová et al. 2016) creates unique and novel challenges to biosafety and
biosecurity. Key safety concerns relate to the outbreeding and spread of these new
varieties into natural populations, the detectability of these new variants (Breeding
Controls 2016) and challenges to established coexistence provisions (Ledford
2015).
Below are quotations from leading researchers that address some of the relevant
issues on biosafety and biosecurity (all quoted in Ledford 2015):
Leading Researchers Quotes
James Haber – on the issue of off-target
effects:
These enzymes will cut in places other than
the places you have designed them to cut, and
that has lots of implications.
Jennifer Doudna – on the biosafety and
biosecurity of an experiment creating a
human cancer model through a
CRISPR-engineered virus:
It seemed incredibly scary that you might
have students who were working with such a
thing. … It’s important for people to
appreciate what this technology can do.
George Church – on the safety risks of gene
drives in relation to the environment:
It has to have a fairly high pay-off, because it
has a risk of irreversibility – and unintended
or hard-to-calculate consequences for other
species.
Jennifer Kuzma – on the detectability of
genome-edited GMOs in nature:
With gene editing, there’s no longer the
ability to really track engineered products. It
will be hard to detect whether something has
been mutated conventionally or genetically
engineered.
Kenneth Oye – on governance: It is essential that national regulatory
authorities and international organizations get
on top of this — really get on top of it.
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Recommendations
There are four levels on which recommendations can be made to avoid the ex-
ploitation of safety and security weaknesses in genome editing in the future.
Technical Level
• Reduce off-target effects, mosaicism and epigenetic effects through further
research in higher ﬁdelity and better understanding of genome editing
technologies.
• Use safe virus systems or alternative less risky vector systems to transfer gen-
ome editing tools.
• Develop reversal gene drives in parallel that can undo the effects of gene drives.
• Provide technological assistance (e.g. detection capacities for modiﬁed organ-
isms) in implementing international obligations such as the Cartagena Protocol.
Containment Level
• Ensure adequate biosafety risk classiﬁcation and implementation of adequate
containment measures in biosafety-sensitive genome editing experiments.
• Develop “molecular containment” approaches when working with
genome-edited high-risk pathogens.
Governance and Oversight level
• Provide international guidance or amend existing guidance documents on bio-
safety and biosecurity to cover risks from genome editing.
• Map the status of existing biosafety and biosecurity legislation as well as its
practical implementation in countries carrying out genome editing experiments.
• Include stakeholders (e.g. funding institutions, research institutions, researchers)
in the responsible governance of research involving genome editing.
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International Standardization
• In case of gaps in legal oversight, develop international codes and guidelines for
safe and secure work in genome editing.
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Chapter 14
Seeking Retrospective Approval
for a Study in Resource-Constrained
Liberia
Jemee K. Tegli
Abstract The increase in the volume of health-related research in Africa has not
everywhere been accompanied by improvements in research oversight systems
related to biomedical and health services research, including the strengthening of
institutional review boards (IRBs) and national regulatory oversight institutions.
Critical to such oversight are not only competencies in ethics for the review of
clinical trials, but also competencies in diverse research methods, statistical anal-
yses and project implementation. In Liberia, there are recognized weaknesses in the
existing infrastructure and capacity to regulate and monitor clinical research based
on ethical institutional regulations and guidance for the protection of human re-
search participants. During the height of the Ebola virus disease (EVD) surge in
Liberia in 2014, there was a fragile national regulatory framework to oversee
research. Some researchers took undue advantage of this gap to conduct unethical
research.
Keywords Ebola Virus Disease  Liberia  Emergency research
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This case study is about an attempt to seek ethics approval after the study had already
been conducted. Trying to obtain retrospective approval of research undermines the
legitimacy of an Institutional Review Board (IRB) and the research review process
itself. If the level of risk that a research study on EVD survivors presents is only
determined after its completion, then the participants would have already been
exposed to harm and their autonomy compromised. The researcher in this case used
the cover of “emergency research” to avoid the review process – although emergency
J. K. Tegli (&)
PREVAIL OFFICE, 1st Floor, East Wing, JFK Medical Center, 21 Street, Sinkor,
Monrovia, Liberia
e-mail: tegli@ul-pireafrica.org
J. K. Tegli
UL-PIRE Africa Center, University of Liberia, Ground Floor, GD Bldg.,
Monrovia 100010, Liberia
© The Author(s) 2018
D. Schroeder et al. (eds.), Ethics Dumping, SpringerBriefs in Research
and Innovation Governance, https://doi.org/10.1007/978-3-319-64731-9_14
115
research regulations stipulate full disclosure of proposed research prior to imple-
mentation, and there are speciﬁed consenting processes (National Institute of
Medicine (2002)).
Area of Risk of Exploitation
An investigator breached the Declaration of Helsinki and other global ethical
guidelines by ignoring an ethical review oversight process that was fully functional
in Liberia. The investigator was provided with information about the country’s
ethical review process at meetings of the Ebola Response Incident Management
System, but chose to deploy the research team into targeted communities without
ethical approval, collecting data through focus group discussions, key informant
interviews and in-depth interviews. The data were analysed and submitted for
presentation and/or publication at national and international meetings.
The entire data collection process, involving sensitive topics centred on
Ebola-affected communities, was highly distressing. The consent process was
conducted at the discretion of the researcher and the study team (Pollock, 2012).
Providing so-called consent processes to participants in the frenzy of an epidemic
can lead to misconceptions on their part. Risk mitigation measures were not fully
assessed because guidance from an ethical institution was not explored or sought
prior to the conduct of the study.
The fundamental pillar of respect for persons was also ignored. This should be
the principle upon which each research participant makes an informed choice about
whether or not to participate in the research, and thus accepts the potential risks and
burdens of participation (Jasanoff, 1993). Thorough explanation to participants
about the availability of the research ethics review board to address concerns
regarding their rights or wellbeing, and providing contact information, are critical
elements of the consent process. Whether consent is sought verbally or in writing,
reference must be made to an ethics review board that reviewed and approved the
research study. Ignoring one of the major pillars of ethical research – namely, ethics
review – opens up a range of risks for exploitation (Martinson et al., 2005).
Background
Whatever the context, the need for the regulation of research is clear. In March
2014, the Ebola epidemic hit Liberia very hard. With Guinea and Sierra Leone also
affected, the death toll in Liberia as of May 2016 stood at 4,810, with 10,678
infected. At the peak of the epidemic in October 2014, researchers and institutions
were pouring into the country to conduct all forms of research, ranging from social
science, anthropological and clinical studies.
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As a result of the health emergency, the ethical research institutions were
overwhelmed with questions from many investigators and institutions seeking
information about the application process. The ethical boards were approached by
several potential investigators in and outside of Liberia for information and guid-
ance about the review process in the country. In spite of the availability of this
platform, some researchers proceeded to conduct their research studies in
November 2014 without prior review and approval by the relevant IRB. They
circumvented the process under the pretext of the emergency and collected data
from human participants in an unethical manner.
A particular case came to light in December 2014, when the IRB denied a
researcher employed by an international UN public health agency retrospective
ethical approval. Such an attempt to obtain retrospective approval of research
undermines the legitimacy of the IRB and the research review process itself. If the
level of risk that a research study on Ebola virus disease (EVD) survivors presents
is determined only after its completion, then the participants would have already
been exposed to harm and their autonomy compromised. This researcher used the
cover of “emergency research” to avoid the review process – although emergency
research regulations stipulate full disclosure of proposed research prior to imple-
mentation, and there are speciﬁed consenting processes.
Details of the Case
In early December 2014, the University of Liberia-Paciﬁc Institute for Research and
Evaluation IRB received an application from a researcher working for an interna-
tional UN public health agency seeking approval for medical anthropological
research on survivors of EVD in Monrovia. The focus of the study was on gathering
information on the economic well-being of EVD survivors in Liberia. The objective
was to assess the psychosocial situation and the impact of stigma and discrimination
on the lives of survivors.
The research, which took place at the height of the EVD surge from November
to December 2014, involved several EVD-affected communities in urban and
peri-urban Monrovia. Most were from semi-literate and illiterate populations and
had already been traumatized by the surge in EVD deaths. This study therefore had
the potential to inflict distress on these participants: for example, it is traumatizing
for EVD survivors to recount their experiences or circumstances, because these
involve very recent catastrophic events in their lives.
The IRB convened and expedited the review process, given the importance of
conducting the proposed research in a timely manner during the EVD outbreak. At
the time, the IRB was not aware that the research had already been completed when
the application was submitted for review. The researcher had left Liberia and was
not present at the meeting, but was represented by a less experienced Liberian
research assistant (RA).
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During the IRB meeting, the RA was asked a question about the intended
timetable for commencing the study. To the board’s surprise, they were told that the
data for the study had already been collected and analyzed. The role and respon-
sibilities of this junior researcher in the implementation of the study were unclear
and apparently minimal. The research team was only seeking approval from the
IRB in order to disseminate the research results.
The IRB chair immediately called the meeting off and told the RA that the
incident undermined best practices in the ethical conduct of health research.
The RA was instructed to report the ﬁndings of the IRB to the principal investi-
gator: namely that research had been conducted unethically, research review and
approval regulations had been contravened, and the autonomy of the EVD survivors
who were research participants had been breached.
Reasons for IRB Decision and Conclusion
A retrospective IRB approval of a research project – that is, after participants may
already have been exposed to unnecessary harm or violation of their rights – would
be unethical. Conducting a research study without IRB oversight violates both
ethical principles and IRB procedures. In this context, the decision takes a stance on
public policy that aims at increasing compliance with IRB requirements.
Without ethics approval, it is impossible to have the results of a study published
in a reputable journal. One must assume that this is why the researcher tried to
obtain retrospective approval. While the decision the IRB reached was emphatic, it
was preceded by a short discussion on whether granting approval retrospectively,
and thereby allowing publication of the research results, may contribute to the
public good (Tansey et al., 2010). However, the IRB decided ﬁrmly in the negative,
partly because the research had been undertaken on a highly vulnerable group of
illiterate and uneducated Liberians who would have little knowledge of the consent
process.
The Liberian IRB therefore made a clear decision to uphold the autonomy of
both the IRB and the research participants by refusing to approve a study
retrospectively.
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Chapter 15
Legal and Ethical Issues of Justice: Global
and Local Perspectives on Compensation
for Serious Adverse Events in Clinical
Trials
Yali Cong
Abstract A 78-year-old Chinese woman joined a clinical trial sponsored by a
pharmaceutical company. Unfortunately a serious adverse event (SAE) occurred.
The sponsor paid for the cost of the medical care arising from the SAE, but refused
the family’s request for compensation. The family then sued the company and the
hospital in Beijing. Although the SAE was related to a complication of lower
extremity angiography and not the drug itself, it was a direct consequence of
participating in the trial. According to Good Clinical Practice, a set of regulations
promulgated under Chinese law, “the sponsor should provide insurance to those
human subjects who participate in clinical trials, cover the cost of treatment and the
corresponding economic compensation for the occurrence of the harm or death
associated with the trial” (SFDA in Good clinical practice. State Food and Drug
Administration,2003: art. 43). The court ordered the trial sponsor to provide a
translation of the company’s insurance policy, so that the court could understand
the amount of compensation available to the patient under the policy, but the
sponsor never surrendered either the documentation or a translation. Consensus was
never reached about the amount of compensation due to the patient through
negotiation with the hospital, the company and the family. The litigation ended after
nine hearings and ﬁve long years. This chapter provides an ethical analysis of the
case relative to at least three areas of risk of exploitation when a major, international
pharmaceutical company sponsors clinical research in a country with an immature
legal system and where research participants have limited resources.
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Areas of Risk of Exploitation
There are at least three ways in which this case illustrates the risk of exploitation.
The principle of justice requires that the beneﬁts and burdens of research be
distributed fairly. This means that participants who are injured during the research
should be compensated fairly for their injuries. The present case demonstrates the
main risk of exploitation during the process of an individual research participant’s
litigation. Although individuals may be compensated, litigation is costly and
time-consuming. Studies have found that approximately 50% of the sums recovered
from tort lawsuits in high-income countries (HICs) do not reach the injured parties
but instead go to attorney fee payments and other costs. Legal barriers such as the
assumption of risk, contributory negligence and government immunity may dis-
courage litigation by injured research participants or preclude recovery in whole or
part (Resnik et al. 2014).
Second, this case illustrates the risk of exploitation due to the considerable
variation in regulations across various countries, which results in inconsistent
compensation for the victim of a serious adverse event (SAE). Regarding the
payout amount for compensation, trial sponsors might approach the amount dif-
ferently for human research participants who suffer the same SAEs in different
countries. This suggests that the values of justice may not be fulﬁlled, as there
should be no double standards in the compensation for SAEs. While there is no data
publicly available about variations in payment for SAEs, this case raises the sus-
picion that equal and just compensation in global studies is not being achieved, or at
least not in all cases. Exploitation occurs when different patients suffer the same
harm or injury, but do not receive equal compensation (or at least compensation
adjusted to amounts based on average incomes in the countries concerned).
The third risk of exploitation derives from the inequality in access to resources
for litigation between individual research participants and pharma sponsors. In this
case the company exploited its position of litigatory strength. It did not cooperate
with the local court, in that, for example, it did not supply either the original of the
insurance contract or a translation into Chinese. In addition to being a failure to
comply with the court’s request, this delayed the legal process.
Background
Xarelto® (rivaroxaban) or BAY 59-7939 is an oral tablet (factor Xa inhibitor),
taken once a day, intended for prophylaxis of deep vein thrombosis (DVT) and the
prevention of atrial ﬁbrillation, cardiac thromboembolism and cerebral infarction.
The company’s application “On the BAY 59-7939 international multi-centre phase
III clinical trial” was submitted to China’s State Food and Drug Administration
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(SFDA) in October 2005 and approved in February 2006. The institutional review
board (IRB) of a hospital approved the trial based on the application. Being a global
clinical trial, the hospital was invited as the leading centre. The trial sponsor signed
a contract with the hospital.
The Case
A 78-year-old woman came to hospital for knee replacement surgery. During her
index hospitalization in 2006, she was invited to join this clinical trial. Her daughter
was with her at the time of recruitment, and they both agreed to her participation.
The knee replacement surgery was conducted on 24 October 2006. In accordance
with the protocol, she took the daily tablet, intended for prophylaxis of DVT and
the prevention of atrial ﬁbrillation, cardiac thromboembolism and cerebral infarc-
tion. She was enrolled from 23 October to 6 November 2006. The research protocol
required the patient to undertake double lower-limb vein angiography in order to
test for thrombus formation. An SAE occurred after venous angiography. The
patient suffered chest tightness, shortness of breath, palpitations, cough, sweating, a
very weak pulse, blood pressure dropping to 60/40 mm HG and shock. The patient
regained consciousness three hours after resuscitation. The hospital’s principal
investigator judged this complication to be an SAE and completed the SAE report
form on 15 February 2007. The SAE was also reported to the China State Food and
Drug Administration on the same day.
The total expenses of the medical treatment caused by the SAE were
CNY 3296.17 (approximately USD 420 in 2006), all of which the trial sponsor
paid. Considering the patient’s suffering and the adverse effect on her recovery of
knee function, she and her family desired compensation for the limitations the SAE
had imposed on her life. The patient and her family knew that the sponsor had
compensation insurance for the study. The investigator reminded the patient of this,
and they found relevant information in the informed consent form.
In the section entitled “Patient Notice”, the consent form read, “if a subject
involved in this trial is injured during the study, the insurance company will pay
correspondingly”. Based on the consent form, and the study investigator’s expla-
nation, the patient knew that the trial sponsor had purchased global insurance for
this multi-centre clinical trial. When the patient and her family requested com-
pensation from the hospital and the pharmaceutical company, the company refused.
Despite extensive discussions, the three parties could not reach consensus. After
failure to agree on a compensation amount, the sponsor and the hospital were
summoned to the Beijing Chaoyang Court by the plaintiff in 2008.
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Procedure for Compensation Claim in China
Usually in China, if a plaintiff is injured and claims compensation, the court will
require the plaintiff to consult with a third party to evaluate the nature and degree of
the injury. Based on this evaluation, the court can then make a judgement about the
seriousness of the injury, and determine an amount of compensation. In this case,
the children did not want to expose their elderly mother to the pressure of visiting
the evaluation centre and having to wait a long time for a result that she might not
be satisﬁed with anyway, so they decided to spare their elderly mother this ordeal.
The family did not ﬁle a suit as a lawsuit based on infringement of rights or as a suit
of tort, but ﬁled as a “dispute of contract”.
The Source of Disagreement
The sponsor argued that there was an agreement between themselves and the
hospital to carry out the trial of a new drug, and hence a contractual relationship
between the company and the hospital, but there was no contractual relationship
between the company and the patient plaintiff. In contrast, the plaintiff argued that
the hospital had clearly informed the patient (research participant) that the hospital
was only a representative of the trial sponsor, and further that the research partic-
ipant had been informed that the company had entrusted/endorsed the hospital to
sign the contract with trial participants. On these grounds, the plaintiff declared that
a contractual relationship existed between the plaintiff and the company. The
Chaoyang Court ultimately accepted the plaintiff’s claim as a dispute of contract.
Having accepted the suit, the court requested the parties to provide the relevant
documents. It repeatedly requested the company to provide a copy of the insurance
contract, and explained this requirement to the company, but the company resisted
and did not submit the insurance contract. The court also asked the hospital for the
insurance contract, but the hospital responded that it had been unaware that it
should request that documentation. Similarly, the hospital ethics committee had not
required conﬁrmation of an insurance contract at the time the protocol was
approved. The hospital argued that it had signed a clinical trial contract with the
company, which had declared that it had purchased special insurance to cover
economic loss by the subjects participating in the study, including any harm caused
by the drugs. The third page of the participant information sheet for the study
stated: “Adverse drug reactions related to angiography include angiography reac-
tion, such as skin reaction; some will imply allergic reaction, such as anaphylactic
shock”. Thus an adverse event from the double lower-limb vein angiography was
included.
The plaintiff then requested the hospital ethics committee to seek help from the
SFDA, but the committee were informed that the SFDA did not have this document
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either. In short, no one but the company had access to a clear description of the
amount of compensation during the earlier stages of the case.
Later in the court process, the pharma company provided Chaoyang Court with
certiﬁcation of insurance purchased from a German provider, certifying that the
company purchased insurance effective from January 1, 2002, which covered the
study overseas and participants from all countries. Each person’s maximum
insurance was approximately 500,000 Euro. (Chao Min Chu Zi 2009).
The court asked the company to provide a Chinese version of the insurance
contract, but the company refused. After several requests, the court, the plaintiff and
her family were informed that it would take a long time to prepare such a translation
and that it would be too expensive (estimated cost CNY 20,000, approximately
USD 3,000 at that time).
This meant that the available documentation – namely, the consent form and
insurance contract – included no clear description of the exact amount of com-
pensation, nor how to compensate for different situations, types of injury, different
countries, etc. When the plaintiff claimed EUR 150,000 compensation, the com-
pany argued that there was no reasonable basis for such a claim.
Though no speciﬁc criteria were provided about the amount of compensation,
the civil judgement included a clause referring to the insurance company’s view
that where the company was responsible for the compensation of subjects, the
insurer should provide the compensation based on the requirements of the local
laws where the injury occurred (Chao Min Chu Zi 2009). The pharmaceutical
company requested a non-public hearing for the appeal, which made information
unavailable. The plaintiff explained that she was persisting with her appeal as she
suspected that there was an unfair clause in the insurance contract and that there
was an unequal description of compensation for HICs and LMICs.
After ﬁve years, the lower court’s judgement was issued in February 2013. The
Beijing Chaoyao Court determined that according to the Chinese Good Clinical
Practice regulations, the company should compensate the plaintiff with
EUR 50,000. However, the plaintiff did not accept this, and appealed to the Beijing
Second Middle Level Court. That court rejected the appeal.
In summary, between 2009 and 2011, nine hearings were held. The ﬁnal con-
clusion came out in February 2013. The entire process of litigation and appeal
lasted for ﬁve years. Compensation of EUR 50,000 euros was paid directly by the
company, not by the insurance company. This suggested that the process of SAE
compensation was dealt with internally within the company, rather than through a
formal procedure that involved the insurance company.
Due to the SAE and consequent extended hospitalization, the patient was placed
on strict bed rest, even though rehabilitation from the original knee replacement
surgery would have required her to move. Her dream had been to travel abroad after
the surgery, but participating in the trial delayed her rehabilitation from the surgery.
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Update
It was reported from Berlin on 4 May 2015, that the company’s once-daily oral
anticoagulant BAY 59-7939 (rivaroxaban) had been approved by China’s State
Food and Drug Administration for the prevention of stroke and systemic embolism
in adult patients with non-valvular atrial ﬁbrillation with one or more risk factors
(Bayer 2015). Additionally, the administration has approved BAY 59-7939 for the
treatment of DVT and the reduction of the risk of recurrent DVT and pulmonary
embolism following acute DVT in adults. Since 2009, BAY 59-7939 has been
available in China for the prevention of venous thromboembolism in adult patients
undergoing elective hip or knee replacement surgery.
Lessons Learned & Recommendations
• Though the capacity for human research participant protection and ethics review
have been improved in China in recent years, this case shows that some matters
may have been neglected, especially access to the insurance contract for com-
pensation. In this case, all three stakeholders should strengthen their sense of
responsibility and learn this lesson: the hospital’s ethics review committee did
not fulﬁl its responsibility to request the company to provide the insurance
contract. The SFDA needs to develop a working system which ensures that the
pharmaceutical company sponsoring a trial prepares and submits to the ethics
review committee relevant documents such as the insurance policy as a
requirement.
• While both the local Chinese Good Clinical Practice regulations and the
Guideline for Good Clinical Practice of the International Council for
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
(ICH 1996) have provisions about compensation, it is hard for an individual
research participant to negotiate and reach consensus with individual companies.
For example, article 43 of the Chinese GCP (SFDA 2003) addresses compen-
sation, but clearly places the responsibility on the shoulders of the sponsor.
• The prolonged processes involved in the interpretation and application of the
law also contribute to potential harm and exploitation of trial participants and
their families. In this case, the lawsuit started in 2008 when the plaintiff was
79 years old and ended when she was 85. Her dreams of travel after the knee
replacement surgery were shattered.
• Bringing a legal case always involves costs for the plaintiff, which have to be
advanced at least until the court reaches its ﬁnding or insurance is paid. It is
often impossible for vulnerable populations in research to provide fees to
lawyers and courts. (This case was an exception.)
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• Within China, as this case illustrates, an academic dialogue is needed on the
nature of the relationship between individual human research participants and a
trial sponsor. During medical treatment, patients and doctors form a ﬁduciary
relationship, as well as a contractual relationship. There is academic discussion
of the doctor-patient relationship. However, there is not yet an academic dis-
cussion about the nature of the relationship between research participant and
trial sponsor.
• This case calls into question whether compensation for injury should be a set
amount, an amount based on an individual’s economic situation, or an amount
based on a country’s economic situation. Regarding the amount of compensa-
tion to an individual research participant with an SAE during a global clinical
trial, ethicists need to address the ethical challenge of a double standard.
• One ﬁnal lesson relates to the exploitation of a less mature legal system. China,
like many other middle-income countries, lacks lawyers and legal teams who are
able to provide support in litigation with a pharmaceutical giant.
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Other Resources
These open access casebooks may be useful to the reader:
Barrett DH, Ortmann LW, Dawson A, Saenz C, Reis A, Bolan G (2016) Public
health ethics: cases spanning the globe. Springer International Publishing. http://
www.springer.com/us/book/9783319238463
Cash R, Wikler D, Saxena A, Capron A (2009) Casebook on ethical issues in
international research. World Health Organization, Geneva. http://www.who.int/
rpc/publications/ethics_casebook/en
UNESCO (2011) Casebook on beneﬁt and harm. Bioethics core curriculum.
Casebook series no. 2. UNESCO, Paris. http://unesdoc.unesco.org/images/0019/
001923/192370e.pdf
UNESCO (2011) Casebook on human dignity and human rights. Bioethics core
curriculum. Casebook series no. 1. UNESCO, Paris. http://unesdoc.unesco.org/
images/0019/001923/192371e.pdf
The following high-calibre Ph.D. thesis contains a range of excellent case
studies:
Ravinetto R (2016) Methodological and ethical challenges in non-commercial
North-South collaborative clinical trials. Leuven University Press, Leuven
Table 1 shows how the case studies selected for this book align with the ethical
issues identiﬁed by the Horizon 2020 programme of the European Commission.
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Table 1 Ethics dumping cases organized according to Horizon 2020 ethical issues checklists
Ethical issue Subcategory Chapter
Human embryos and
foetuses
None identiﬁed in our
research
Humans Volunteers for social science research 2
Persons unable to give consent,
including minors
6
Vulnerable groups 2, 3, 4, 5, 6, 8, 9
Patients 15
Healthy volunteers in medical studies 4, 5, 6, 7, 8
Human cells and tissues 4
Personal data 12
Animals 10
Third countries: Not applicable, as all cases in this report involve third countries
Environment, health
and safety
Environment 11, 13
Health and safety 11, 13
Dual use 13
Misuse 12, 13
http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/ethics/h2020_hi_ethics-self-
assess_en.pdf
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